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Regulation of gene expression is a complicated process, subject to different mechanisms 
operating at different levels.  At the genomewide level, work in this thesis describes the 
use of chromatin immunoprecipitation and next-generation sequencing to interrogate the 
coincident and allele-specific binding of the proteins CTCF, cohesin, ATRX and 
MeCP2.  Identifying regions co-binding these proteins helps generate a model to 
understand how these proteins influence gene expression, particularly at imprinted loci.  
Using these tools we are able to understand more about the proteins that participate in 
the genomic landscape around imprinted loci and drive this unusual mode of gene 
regulation.  These loci act as models for studying DNA binding proteins and their roles 
in transcription.   
 
At the level of the individual locus, mechanisms of gene regulation were investigated 
using imprinted retrogenes as a model.  Retrogenes are transcriptionally active 
intronless genes located within an intron of a ‘host’ gene.  The role of epigenetic factors 
influencing gene transcription were investigated at the H13/Mcts2 locus. Expression of 
an intronic retrogene can cause premature termination of a ‘host’ transcript.  Our 
hypothesis is that this premature termination can be caused by transcription of the 
retrogene interfering with host gene transcription.  We have designed a construct based 
on this locus, which allows us to regulate the expression through the retrogene to study 
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1.1. - Gene Expression 
Gene expression is the process through which the information encoded in DNA is 
transcribed into RNA, before being translated into protein.  Regions of DNA to be 
transcribed are marked by DNA binding proteins, which bind to specific regulatory 
sequences, and attract RNA polymerase, an enzyme that synthesises a strand of pre-
RNA from the DNA template.  As the RNA strand is being produced introns (and in 
some cases exons) are spliced out and the 5’ (leading) end of the strand is capped.  Once 
the stop codon of the gene has been transcribed the RNA strand is cleaved and a poly 
(A) tail is added in a process known as polyadenylation, to the 3’ (trailing) end of the 
strand [1].  These modifications result in mature RNA, which is then exported from the 
nucleus to the cytoplasm, where it is translated into a protein.  The expression of a 
particular gene can be regulated at any of these stages on the way from DNA to protein.  
 
Not all RNA is translated into protein, roughly 98% of all transcripts in humans encode 
non-coding-RNA (ncRNA) [2].  There are many different types of non-coding RNA, 
thought to be involved in a wide range of processes in the cell.  They include the 
classical RNAs like transfer RNA (tRNA), messenger RNA (mRNA) and ribosomal 
RNA (rRNA), as well as many newly discovered and less well-defined RNAs like 
microRNA (miRNA), small nuclear RNA (snRNA) and small nucleolar RNA 
(snoRNA).  miRNAs are single stranded RNAs of about 22 nucleotides (nts) in length, 
generated from transcripts containing a local hairpin structure.  They regulate 
transcription by binding to complimentary (but not completely complementary) regions 
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of mRNA transcripts, repressing their translation or regulating their degradation [3] [4].  
miRNAs are involved in a wide range of developmental processes in both mammals and 
plants [2].  Short interfering RNAs (siRNAs) are similar to miRNAs, but they target 
messenger RNA to which they are completely complimentary, targeting them for 
degradation in the process known as RNA interference (RNAi) [5].  snRNAS are a 
small group of ncRNAs involved in splicing.  snRNAs U1, U2, U4, U5 and U6 interact 
with over 200 proteins to form the spliceosome, and are responsible for splice-site and 
branch-site recognition, which are important for the removal of introns from the pre-
mRNA [3] [6].  snoRNAs are between 60 and 300 nts in length, and tend to originate 
from the introns of protein coding or non-coding genes.  They act to guide site-specific 
modification of other RNAs [5], and some snoRNAs have been shown to display tissue 
specific expression [2].  Long non-coding RNAs (lncRNA) are any RNAs over 100 nts 
in length, which are typically involved in imprinting and X-chromosome inactivation 
[7].  For example the lncRNA Xist (X inactive specific transcript) is essential for the 
silencing of the inactive X chromosome, through the recruitment of epigenetic factors 
associated with silencing to the inactive chromosome [8].  Piwi interacting RNAs 
(piRNAs) tend to be around 26 to 31 nucleotides in length, and are associated with the 
Piwi protein, which is involved in gametogenesis.  They have been shown to regulate 
DNA methylation in germ cells in mice [9].  Enhancer RNA (eRNA) is thought to act as 
a scaffold to regulate the local chromatin architecture around their transcription start 
site, aiding expression through the gene [10]. 
 
1.2. – Imprinting 
Diploid organisms have two copies of each autosomal chromosome, one inherited from 
each parent.  Most genes are expressed from both parental alleles (biallelic expression).  
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However there are some genes that are only expressed from either the maternal or 
paternal allele (monoallelic expression, see Figure 1.1).  These are known as imprinted 





Figure 1.1 – Summary of biallelic vs monoallelic expression from a gene.  GAPDH is 
an example of biallelically expressed gene, which is the case for most genes, it is 
expressed from both parental alleles.  H19 is an example of a monoallelically expressed 
gene, it is only expressed from the maternal allele and not the paternal allele. 
 
The concept of imprinting was first described in 1984 by two independent studies 
published around the same time (McGrath, 1984 [12] and Surani, 1984 [13]).   These 
groups both used pronuclear injection to generate murine embryos containing either two 
copies of the paternal genome (androgenetic) or the maternal genome (gynogenetic).  
Embryos containing both a maternal and a paternal copy of the genome, but generated 
through pronuclear injection were used as controls.  The androgenetic and gynogenetic 
embryos failed to develop to full term.  The androgenetic embryos developed to the 6-8 
somite stage and showed extensive developmental impairment, while the trophoblast 
and extra-embryonic tissues were similar to controls but somewhat overgrown.  The 
gynogenetic embryos appeared normal (they developed to the 25 somite stage) although 
smaller than controls, but with impaired development of the trophoblast.  This is 
summarised in Figure 1.2.  These experiments show that it is not the DNA sequence 
alone that is important for mammalian development.  They illustrated that these 





genome is necessary for proper development of the extra-embryonic tissues and the 
maternal genome for the development of the embryo, and that both are required for 
normal embryonic development. 
 
 
Figure 1.2 – The non-equivalence of the maternal and paternal genome, demonstrated 
through the generation of androgenetic and gynogenetic embryos (adapted from Surani, 
1986 [14]). 
 
Evidence for the non-equivalence of the parental genomes has also come from 
phenotypes observed during the breeding of reciprocal and Robertsonian translocation 
mice, at the MRC mouse breeding centre at Harwell [15] [16]. A Robertsonian 
translocation is a chromosomal abnormality in which two acrocentric chromosomes 
(where the chromosome arms are of different lengths) become joined by a common 
centromere [17].  For example intercrossing mice heterozygous for the Robertsonian 
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translocation Rb(11.13)4Bnr produced litters containing mice disomic for chromosome 
11 or 13 (where both copies of the chromosome are inherited from one parent).  While 
mice with disomy 13 develop normally, mice with disomy 11 show a size difference 
depending on which parent they inherit their two copies of chromosome 11 from.  Mice 
with paternal chromosome 11 were much larger than their littermates, while those with 
maternal chromosome 11 were much smaller.  Intercrosses with mice heterozygous for 
T(2;11)30H (the reciprocal translocation) showed that only the proximal region of 
chromosome 11 was involved.  In this case, offspring with a maternal duplication or 
paternal deficiency of the proximal region of chromosome 11 were small at birth, 
having a similar phenotype to mice with maternal disomy 11.  No offspring with a 
maternal deficiency or a paternal duplication of the proximal region of chromosome 11 
were found, implying that these are lethal [18].  These translocation studies 
complemented the nuclear transfer experiments and lead to the identification of many 
imprinted genes. 
 
The fact that both copies of an imprinted gene can be identical suggests the existence of 
another mechanism through which the two alleles can be differentiated, so that only one 
is expressed while the other is silenced.  This mechanism must be heritable, as it must 
be maintained through mitosis throughout the life of the organism [19].  There is now a 
large body of work proposing that this mechanism is cytosine methylation, a type of 
epigenetic mark (reviewed by Ferguson-Smith, 2011 [17]).   
 
A difference in the DNA methylation state between the two alleles of a gene can cause 
them to be expressed differently, making them imprinted.  The region of DNA 
containing this difference in methylation is known as a differentially methylated region 
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(DMR), and this can be established either in the germline (a gDMR), or later in 
development in a somatic line.  A DMR that has been experimentally shown to control 
the regulation of an imprinted gene in its vicinity is called an imprinting control region 
(ICR).  The imprinted regions in mice are summarised in Table 1.1.
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Gene/Cluster Location  Methylated 
Allele 
Gene Allele expressed 
From 
 P Gpr1 1qC2 P 
ZDBF2 P 
Sfmbt2 2A1 M  P 
 P Mcts2 2H1 M 
H13 M 






Gnas 2qH4 M 




















































Rasgrf1 9qE3.1 P 
A19 P 




DDC  P 
Grb10 11qA1 M 
Cobl M 






Anti-Rtl1 microRNAs M 
Rian snoRNAs M 
Dlk1 12qF1 P 











Igf2r 17qA1 M 
SLC22A3 M 
Impact 18A2 M  M 
 M 
Xlr4b M 
Xlr3b XqA7.3 M 
Xlr4c M 
 P Xist XqD M 
Tsix M 
 
Table 1.1 – Table of imprinted regions in mice (taken from the MRC Harwell 
Imprinting website [20], and the catalogue of imprinted genes [21] and Prickett, 2013 
[22]) 
 
The Ifg2-H19 locus is a classic example of an imprinted gene locus and is an excellent 
model from which to understand genomic imprinting and to test mechanisms of gene 
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regulation at other imprinted loci.  At this locus the DMR is located at H19 and is 
paternally methylated, meaning H19 is only expressed from the un-methylated maternal 
allele.  The promoter of Igf2 is un-methylated on both alleles, nevertheless Igf2 is 
imprinted; it is only expressed from the maternal allele [23].  This is due to the DMR at 
H19.  On the un-methylated maternal allele, CTCF (an insulator protein that 
preferentially binds to un-methylated regions) binds to the DMR, blocking the 
interaction of an enhancer located downstream of H19 with Igf2.  On the paternal allele 
CTCF cannot bind due to the methylation at the DMR, allowing the interaction of the 






Figure 1.3 – Imprinted expression of H19 and Igf2.  The H19 promoter is methylated 
(black circles) on the paternal allele, and un-methylated (white circles) on the maternal 
allele, where H19 is expressed.  The Igf2 promoter is un-methylated on both alleles, but 
Igf2 is only expressed from the paternal allele, as CTCF (grey oval) bound at the DMR 
of H19 blocks the interaction between Igf2 and its enhancer (black oval).  The boxes 
represent the promoter of the gene, and not the entire gene. 
 
There is evidence to suggest that CTCF binding to the maternally un-methylated DMR 
during development acts to protect the DMR from gaining methylation.  RNA 
interference (RNAi) was used to knock down the levels of CTCF in the mouse oocyte.  
Of the five founder females generated the three showing the greatest reduction in CTCF 
mRNA and protein were hypermethylated at the H19 DMR, compared to the non-










experiments show that CTCF is required during development to maintain the 
hypomethylated status of the maternal H19 DMR.  
 
1.3. - Mechanisms of Gene Expression 
Some genes only need to be expressed for short periods of time; for a defined stage of 
development or in response to changes in their environment for example.  As expression 
from such a gene is essential during these periods but can be detrimental at other times, 
the cell has devised a number of ways to regulate gene expression, and expression from 
a gene can be controlled through several of these mechanisms.   
 
1.3.1. - Regulatory Elements 
These are sequences of DNA that can alter transcription through a gene.  Promoters are 
usually located at the transcription start site (TSS) of the gene and directly activate 
transcription by allowing the binding of transcription factors and RNA polymerase II.  
Many genes also require cis-regulatory elements, which can be located up to 1Mb away 
from the TSS (either upstream or downstream), and can be located within introns of 
neighbouring genes [26].  Enhancers are a type of cis-regulatory element that act to 
stimulate transcription by recruiting tissue-specific transcription factors (TFs), RNA 
polymerase II and other cofactors involved in transcriptional activation [27].  
Repressors are a type of cis-regulatory element that recruit proteins that decrease the 
expression of a gene or inactivate it [28].  The final type of cis-regulatory element are 
insulators, which recruit proteins that isolate regions of DNA or regulatory elements 
from each other [28].  For example, if located between the TSS of a gene and an 
enhancer, an insulator can block the activity of the enhancer so that it has no effect on 
expression from the gene. 
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Topologically associating domains (TADs) can act as insulators to restrict interactions 
betweens genes, promoters and enhancers [29].  TADs are regions of about 100kb, 
where the genes they contain form more interactions with each other, than they do with 
genes in neighbouring TADs [30].  The boundaries between TADs are usually 
associated with binding sites for the insulator protein CTCF, and appear to stop the 
spread of heterochromatin between TADs [30].  TADs are conserved across species and 
cell types providing support of the important role they play in the regulation of 
transcription.  There is evidence that disruption of the boundaries between TADs can 
cause misregulation of genes and can lead to disease [29].  Liebenberg syndrome is an 
autosomal dominant disorder where an individuals arms exhibit morphological 
characteristics of their legs.  This is due to the deletion of a boundary element, which 
usually protects PITX1 (a gene involved in hindlimb development) from the activity of 
a neighbouring enhancer element.  When the boundary is removed the enhancer can 
activate expression from PITX1 [29].  Disruptions to the TAD boundaries flanking 
EPHA4 (a receptor tyrosine kinase) can lead to brachydactyly (short digits) or 
syndactyly (the fusing together of digits) depending on which boundary is disrupted, 
despite EPHA4 having no involvement with limb development.  A disruption to the 
TAD boundary on the telomeric side of EPHA4 allows limb enhancers to interact with 
PAX3 (which is usually located in a neighbouring TAD), causing it to be incorrectly 
expressed and resulting in brachydactyly.  A disruption to the TAD boundary on the 
centromeric side of EPHA4 allows the limb enhancers to interact with WNT6 (usually 
located in a neighbouring TAD), again causing it to be incorrectly expressed, resulting 
in syndactyly [31] [29].  There is also evidence that disruption of TAD boundaries can 
play a role in the progression of cancer [29].      
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1.3.2. – DNA Methylation 
DNA methylation is the addition of a methyl group to the 5’ position of a cytosine 
residue (Figure 1.4).  This mainly occurs when the cytosine is located next to a guanine 
in the DNA sequence of mammals, known as a CpG dinucleotide, but can occur on a 
cytosine not located next to a guanine.  CpG dinucleotides occur throughout the 
genome, but are also clustered in regions known as CpG islands [32].  CpG islands are 
defined as regions of at least 200bp with a CG content of over 50% and with an 
observed-to-expected CpG ratio of over 0.6 (for most of the genome the number of CpG 
dinucleotides is much lower than 0.6 times what would be statistically expected) [33].  
Isolated CpG dinucleotides tend to be methylated, whereas those located in CpG islands 
tend to be un-methylated [32].  CpG islands are associated with about 70% of 
mammalian genes including most housekeeping genes and a large proportion of tissue 
specific genes [34], usually at or near the promoter.  Most cytosines in a CpG island are 
un-methylated unless the gene is silenced, in which case they can be methylated on both 
alleles.  However, allele-specific methylation is a special case of gene regulation where 
































Methylation of a cytosine located next to an adenosine, cytosine or thymine is known as 
non-CpG methylation.  Non-CpG methylation occurs most commonly at CpA 
dinucleotides, less commonly at CpT dinucleotides and infrequently at CpC 
dinucleotides [35].  The distribution and abundance of non-CpG methylation varies 
across the genome and different cell types, but is more abundant in pluripotent cells 
than in most differentiated cells (high levels of non-CpG methylation have found in 
brain tissue) [36].  For example about 25% of methylated cytosines in human ES cells 
are located in non-CpG dinucleotides, compared to less than 1% in human fibroblasts 
[37].  There is evidence that non-CpG methylation at promoters is associated with 
reduced gene expression.  Non-CpG methylation at the promoter of the B29 gene in 
human B cells inhibits the binding of the early B cell factor transcription factor, causing 
a reduction in the activity of the promoter [38].  Similarly the presence of non-CpG 
methylation in the promoter of the syt11 gene (human synaptotagmin XI, which has 
been associated with the development of schizophrenia) blocks the binding of Sp family 
proteins, reducing the activity of the promoter, and expression through the gene [39].  
The expression of PGC-1α (which is involved in mitochondrial function) has also been 
shown to be influenced by non-CpG methylation in the skeletal muscle of patients with 
Type II Diabetes Mellitus.  Again non-CpG methylation at the promoter of PGC-1α 
leads to a decrease in expression of the gene.  However, this methylation can be altered 
in response to other factors in the cell, as TNF-α and free fatty acids can induce non-
CpG methylation [40].  Non-CpG methylation may also play a role in the regulation of 
imprinted genes, as it is present on the repressed allele of several imprinted genes, 
including Peg13, Sgce, Grb10 and Kcnq1ot1, in adult mouse frontal cortex [41].  
However, more research is needed to elucidate the role non-CpG methylation plays in 
the regulation of gene expression.     
 31 
 
1.3.2.1. – Mechanisms of DNA Methylation 
Although DNA methylation is a stable mark, in the sense that it is maintained during 
fertilisation and cell division, it is also dynamic; the methylation status can be altered 
when required (for example during germ cell development).  The addition of a methyl 
group is catalysed by a family of DNA methyltransferases (Dnmts) (see Table 1.2 for 
more detail).  Dnmt3a and Dnmt3b are the de novo Dnmts as they can establish new 
patterns of methylation on DNA strands.  Dnmt1 is the maintenance Dnmt as it 
maintains current patterns of methylation during DNA replication by copying the 
methylation pattern from the parental strand to the new daughter strand.  It also has the 
ability to repair DNA methylation [42].  The activity of Dnmt3a and Dnmt3b can be 
modulated by association with another family member; Dnmt3l, which lacks a catalytic 
domain and therefore acts as a cofactor.   
 
Dnmt3l is expressed during development and is required for the establishment of 
genomic imprinting [43].  Bourc’his et al demonstrated that disrupting both copies of 
the Dnmt3l allele in mice resulted in sterility.  It was found that heterozygous progeny 
of homozygous mothers failed to develop past 9.5 days postcoitum (dpc), due to 
abnormalities in the extraembryonic tissues.  In addition, bisulphite genomic sequencing 
of the embryo DNA showed that the maternally imprinted genes Snrpn and Peg1, were 
un-methylated on both alleles.  H19, a paternally imprinted gene, showed the expected 
allele-specific methylation [43].  These results show that Dnmt3l is required for the 




 Function Reference 
Maintenance of methylation during 
replication 
Moore, 2013 [42] 
Essential for the survival of foetal mitotic 
neuroblasts 
Role in organ development  
Cellular differentiation 
Fan et al, 2001 
Dnmt1 
Genomic stability 
Establishing intestinal epithelial crypts after 
birth 
Elliott et al, 2015 [44] 
Establishment of new sites of methylation Bourc’his, 2001 [43] Dnmt3a 
Methylation of CpT, CpA and CpC sites 
(cytosine-phosphate-thymine / adenosine / 
cytosine respectively) 
Uysal, 2015 [45] 
Establishment of new sites of methylation Bourc’his, 2001 [43] Dnmt3b 
Methylation at repeated DNA sequences in 
the pericentric satellite regions of 
chromosomes 
Okano, 1999 [46] 
Establishment of genomic imprinting  Bourc’his, 2001 [43] Dnmt3l 
Essential for fertility Bourc’his, 2004 [47] 
 
Table 1.2 – Dnmt family members and their role in methylation. 
 
1.3.2.2. – Mechanisms of DNA Demethylation 
In order for DNA methylation to be a dynamic mark it must also be possible to remove 
the methyl group from the cytosine.  Demethylation can occur either passively, through 
the inhibition or repression of Dnmt1 during replication, or actively.  No direct DNA 
demethylases have been identified, which suggests that methyl groups are removed 
indirectly.  This is thought to occur through the base excision repair pathway, which can 
remove a methylated cytosine and replace it with an unmodified cytosine.  There are 
two ways the base excision repair pathway can be triggered.  Firstly, methylated 
cytosine can be deaminated by activation-induced cytidine deaminase (AID) or 
apolipoprotein B mRNA-editing enzyme complex (APOBEC) to form thymine, which 
is recognised as being a mismatched base and removed by thymine DNA glycosylase 
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(TDG), a member of the base excision repair pathway [42].  Alternatively, a family of 
hydroxylases have recently been implicated in this indirect demethylation pathway.  
The Tet (ten eleven translocation) proteins, in the presence of their cofactors Fe2+ and 2-
oxoglutarate, can oxidise methylated cytosine through a series of intermediates to form 
5-carboxy-cytosine (see Figure 1.5) [48] [49].  5-carboxy-cytosine can then be removed 
by TDG [42], as above.    
 
 
Figure 1.5 – Mechanism of active demethylation.  Methylated cytosine is oxidised by 
Tet enzymes to generate 5-hydroxymethyl-cytosine (5hmC), which is further oxidised 
to form 5-formyl-cytosine (5fC).  This in turn is oxidised to form 5-carboxy-cytosine 
(5caC), which is recognised by TDG (thymine DNA glycosylase), a component of the 
base excision repair pathway, and the base is cleaved from the phosphate backbone and 
replaced with cytosine. 
 
In mammals genomewide demethylation takes place early in the development of the 
germline.  By the time mature sperm and oocytes have developed, the level of 
methylation in the genome will have risen to the levels seen in somatic cells.  This wave 
of rapid demethylation of the genome (complete by embryonic day 14) followed by a 
slower re-methylation, allows the removal of any acquired epigenetic modifications, 
and the correct resetting of methylation patterns.  The expression of Dnmts corresponds 
to the changing methylation patterns in these germ cells [50] (see Figure 1.6).  There is 
little or no expression of any of the Dnmts while the genome undergoes demethylation.  
However, as the expression of the Dnmts increases, methylation of the genome also 
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Figure 1.6 – The changing levels of DNA methylation and expression of DNA 
methyltransferases during mammalian germ cell development.  The blue line represents 
methylation of paternally imprinted genes and the red line represents methylation of 
maternally imprinted genes.  Methylation of non-imprinted genes closely follows the 
methylation of imprinted genes.  The expression of the Dnmts is shown.  
Developmental stages - PGC = primordial germ cell, Oog = oogonia, PL = preleptotene, 
L = leptotene, Z = zygotene, P = pachytene, NG = non-growing oocyte, MII = 
metaphase II oocyte (reproduced from Lucifero, 2007 [51]). 
 
1.3.2.3. – Non-methyl Cytosine Modifications 
There is evidence that the intermediates generated during the demethylation of 
methylated cytosines could be viewed as cytosine modifications in their own right.  
5hmC is the most common of these modifications, occurring at varying levels in 
different tissue types, and being most abundant in brain.  In the cortex of the human 
brain 5hmC occurs at about 1% of all cytosine residues, or at 20-25% of all 5mC bases 
[52].  5hmC tends to be located at promoters or within gene bodies, and has been 
associated with gene activity [52], but this localisation varies across cell types.  In ES 
cells 5hmC tends to be localised to enhancers, but in neurons it is located within the 
gene bodies of genes required for the functioning of the neuron.  5hmC seems to be 
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associated with active genes [53].  Levels of 5hmC have been shown to be high in 
pluripotent cell types [53], and reduced in cancer cells compared to their normal 
neighbours [52].  5fC and 5caC are present at much lower levels, about 10-1000 fold 
lower than the levels of 5hmC, across all cell types.  5fC is present at distal regulatory 
elements, preferentially at poised enhancers or the promoters of poised genes [53].  It is 
thought that these three modifications could play a role in gene regulation.  
 
These modifications can affect the activity of certain restriction enzymes, and so 
restriction digests can be used to determine the presence of modified cytosines in a 
sequence.  MspI can digest 5C, 5mC and 5hmC, but not 5fC or 5caC [49].  MspI and 
HpaII (its isoschizomer) can be used to determine the presence of 5hmC in a defined 
sequence.  These two restriction enzymes have differing sensitivities to the 
glycosylation of 5hmC, so treating the sample with β-glucosyltransferase (βGT) inhibits 
the activity of MspI, but not HpaII.  To determine the abundance of 5hmC the sample is 
treated with βGT and then digested with either MspI or HpaII, amplified using PCR, 
and then the results are compared [54].  Alternatively after the sample has been treated 
with βGT it can be digested with AbaSI (which recognises glycosylated 5hmC, but not 
other cytosine modifications), which digests the DNA about 11-13nts or 9-11nts away 
from the 3’ end of the glycosylated 5hmC.  The DNA fragments are then sequenced and 
mapped back to the genome to determine the location of 5hmC [55].  MspJI and 
PvuRtsI can also be used to discriminate between 5mC and 5hmC, as they will only 
digest 5hmC or glycosylated 5hmC, and not 5mC [56]. 
 
There are several methods available for the genomewide detection of these 
modifications, and they all utilise bisulphite conversion.  Sodium bisulphite can be used 
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to deaminate cytosine generating a uracil base.  The presence of a methyl group on a 
cytosine protects it from this deamination.  When the sodium bisulphite treated DNA is 
then amplified in a PCR reaction, the uracil (from the deaminated cytosine) is amplified 
as a thymine, while the methylated cytosines are amplified as cytosine.  Any cytosines 
in the resulting sequence show the presence of methylated cytosines in the original 
sequence [57].  The bisulphite treated sample can then be used for pyrosequencing 
(where the region of interest is amplified through PCR [58]) or whole genome 
sequencing (BS-Seq).  This protocol has formed the basis of the sequencing methods 
used to detect 5hmC, 5fC and 5acC.  Tet-assisted Bisulphite Sequencing (TAB-Seq) 
and Oxidative Bisulphite Sequencing (oxBS-Seq) can differentiate between 5mC and 
5hmC [59], which are both detected by BS-Seq.  In TAB-Seq βGT is used to add a 
glucose group onto 5hmC, to generate β-glucosyl-5-hydroxymethylcytosine (5gmC), 
which protects the 5hmC from oxidation by TET.  The sample is then treated with TET, 
which oxidises all the 5mC to 5caC, before being treated with sodium bisulphite, which 
converts all the cytosines and 5caC to uracil or 5caU but leaves the 5gmC.  When the 
sample is sequenced the cytosines in the sequence will show the location of 5hmC in 
the original sequence [60]. In oxBS-Seq potassium perruthenate is used to oxidise 
5hmC to form 5fC, which upon treatment with sodium bisulphite is deaminated to form 
uracil.  In this experiment only 5mC is protected from deamination by sodium 
bisulphite and so when the sample is sequenced the cytosines show the location of 5mC.  
To determine the location of 5hmC BS-Seq (which detects both 5mC and 5hmC) must 
be performed and the results compared to those generated from the oxBS-Seq [61].  
5caC can be detected through Chemical Modification-assisted Bisulphite Sequencing 
(CAB-Seq), which uses 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
(EDC) to attach an amine group to 5caC, protecting it against deamination by sodium 
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bisulphite. In the resulting sequence cytosines mark the location of either 5mC, 5hmC 
or 5caC.  To determine the location of 5caC only these results must be compared BS-
Seq where 5mC and 5hmC are read as cytosines and 5caC is read as a thymine [62].  
Reduced Bisulphite Sequencing (redBS-Seq) can be used to detect 5fC.  Sodium 
borohydride is used to reduce 5fC to 5hmC, before bisulphite treatment and sequencing.  
5hmC protects the cytosines from deamination by sodium bisulphite and so any 
cytosines in the resulting sequence show the presence of 5mC, 5hmC or 5fC.  To 
determine the location of 5fC in the original sequence the redBS-Seq results are 
compared to BS-Seq, where only 5mC and 5hmC are read as cytosines, and 5fC is read 
as a thymine [63].  
 
1.3.3. - DNA Binding Proteins 
There are many different families of proteins that can bind to DNA and affect 
expression of a gene. 
 
The transcription factors are a family of DNA binding proteins involved in gene 
transcription.  These bind to specific sequence motifs in the promoter or enhancer of the 
gene and act to recruit RNA polymerase to the TSS [64] [65].   
 
There are only three forms of RNA polymerase, making it a very small family of DNA 
binding proteins, but as they transcribe DNA into RNA they are an important one [66].   
 
Histones are another important group.  These are proteins around which DNA is coiled 
to form chromatin, allowing the whole genome to be packed into the small space of the 
nucleus.  Gene expression can be regulated through this coiling, with tightly coiled 
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chromatin (heterochromatin) repressing expression, and more open chromatin 
(euchromatin) allowing expression of genes within these regions [67].   
 
1.3.3.1. – Methylation Sensitive Binding Proteins 
The methyl-CpG-Binding Domain (MBD) family bind preferentially to methylated 
DNA, except for MBD3 which has a similar binding affinity for both methylated and 
unmethylated CpG dinucleotides and MBD5 and MBD6 which bind unmethylated 
cytosine [68] [69] [70].  The MBD folds to create a wedge shaped structure, which 
recognises methylated CpG dinucleotides [68].  Apart from this domain there is little 
structural similarity between family members, although MBD2 and MBD3 do have very 
similar DNA sequences [68], and several family members, including MeCP2 which I 
shall discuss further in section 1.3.3.6., contain a transcriptional repressor domain 
(TRD) [70].  These proteins play an important role in methylation dependant gene 
regulation [69], and have been implicated in neurogenetic disorders and various cancers 
[70].   
 
MBD proteins play an important role in transcriptional regulation as they link 
methylation marks to histone modifications, which can alter the chromatin landscape 
around certain genes to influence their expression [70].  Therefore any disruption to 
their normal functioning can have wide-ranging implications.  Most of the MBD 
proteins have been associated with neurological disorders.  Mutations in MeCP2 play a 
role in the development of Rett syndrome [71], which will be described in more detail 
in section 1.3.3.6.  Missense mutations in MBD4, and mutations in the MBD of MBD4 
have been implicated in the development of autism spectrum disorders [70] [72].  SNP 
mutations and single base insertions in MBD5 and MBD6 have also been implicated in 
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the development of autism spectrum disorders [70], possibly through the disregulation 
of the development and proliferation of neural cells due to the altered function of these 
proteins [72].         
 
Mutations in MBD proteins, as well as their overexpression or inhibition have been 
associated with multiple cancer types [70] [72].  For example overexpression of MBD2 
has been associated with the hypermethylation of the promoter of GSTP1, a well-
studied tumour suppressor gene, in prostate cancer [70].  Knockdown of MBD2 has 
been shown to remove the repression of several tumour suppressor genes like p16INK4a 
and p14ARF, increasing the possibility of developing cancer [70].  Frameshift mutations 
in MBD4 have been associated with the development of colorectal, gastrointestinal, 
pancreatic and endometrial cancers [70].  
 
1.3.3.2. – Non-methylation Sensitive Binding Proteins 
Just as there is a family of proteins that recognise and bind to methylated CpG 
dinucleotides, there is also a family of proteins that preferentially bind to unmethylated 
CpG dinucleotides.  These proteins contain a 35-42 amino acid zinc finger CxxC 
domain (ZF-CxxC) [73], which recognises unmethylated CpG dinucleotides and 
therefore CpG islands.  Proteins containing this domain are involved in the regulation of 
chromatin modifications and DNA methylation, which suggests that they could play a 
role in defining the chromatin environment of CpG islands [74].  For example CxxC 
finger protein 1 (CFP1) forms part of a methyltransferase complex with SETD1, which 
is responsible for the methylation of lysine 4 of histone H3 (H3K4me3) [75].  This mark 
is usually associated with the activation or poising of genes, and has been shown to 
block the activity of Dnmt3L, protecting the region it marks from de novo methylation 
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[76].  Regions containing large quantities of unmethylated CpG dinucleotides, like CpG 
islands, are sufficient to recruit CFP1 [77] leading to the deposition of the H3K4me3 
mark, to block de novo methylation and maintain a chromatin state allowing the 
initiation of transcription [75]. 
  
KDM2A is a lysine demethylase containing a ZF-CxxC domain, which acts to remove 
the methyl groups from lysine 36 on histone H3 over the CpG islands where KDM2A 
binds [74].  The function of the H3K26me2 is poorly defined, but studies in yeast imply 
that it could play a role in the recruitment of EAF3, which is part of the RPD3S histone 
deacetylase complex, to repress transcription [75].  Therefore removing this mark from 
CpG islands could act to create a chromatin environment that permits initiation of 
transcription.       
 
In sections 1.3.3.3 – 6. I will discuss further the four DNA binding proteins that are 
relevant to this thesis. 
 
1.3.3.3. – CTCF 
CTCF is an 11-zinc finger CCCTC DNA binding protein that is highly conserved across 
all vertebrates.  The function of the zinc fingers is to bind CTCF to DNA [78].  It has a 
consensus binding sequence (as the binding site varies slightly in length and sequence 
between tissues) of about 11-15bp; this sequence is bound by 4-5 central zinc fingers.  
Variations at the 12 bp of the consensus binding sequence can alter the methylation of 
the binding site, altering CTCF binding [79].  CTCF forms transcriptional boundaries 
and has been extensively studied in the context of imprinted genes [11], as it binds 
preferentially to un-methylated regions of the genome.  It plays an important role at the 
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imprinted Igf2-H19 locus, binding to the un-methylated DMR on the maternal allele to 
regulate the expression of Igf2 by blocking its interaction with the enhancer (for more 
detail refer back to section 1.2 and Figure 1.3).  CTCF also plays a key role at the β-
globin locus.  In humans and mice this locus is flanked by CTCF sites, which were 
thought to insulate it from the surrounding chromatin [80].  However, chromosome 
conformation capture (3C) experiments have shown that these CTCF sites interact with 
each other, forming large loops of DNA in erythroid progenitor cells (Figure 1.7).  One 
of these loops contains the locus control region (LCR), main regulatory elements and 
the genes [80], bringing these elements into close enough proximity to allow 


















































Figure 1.7 – Overview of the β-globin locus and its interactions with CTCF.  A- 
Diagram of the β-globin locus in humans. B – Chromatin loop formation at the β-globin 
locus.  HS5 and 3’HS1 are insulator elements, which CTCF binds to.  ε is expressed in 
the embryo, Gγ and Aγ are expressed in the foetus, and δ β are expressed in adults. 
Adapted from (Kim, 2012 [81]).  
 
CTCF plays a role in the formation of chromatin loops in other regions of the genome, 
forming and stabilising interactions between distant regions of the chromosome [82], 
and regulating the expression of genes located in these regions.  CTCF has been shown 
to co-localise with cohesin during the formation of these loops [78]. 
 
1.3.3.4. – Cohesin 
The cohesin complex is made of four core subunits; SMC1α, SMC3, Rad21 and 
SA1/SA2, which form a ring (Figure 1.8).  It is involved in many chromosomal 
processes including double-strand break repair, condensation (the reorganisation of 
extended chromatin chains into compact chromosomes during meiosis and mitosis) and 
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gene expression, as well as its traditional role in maintaining the attachment of sister 
chromatids during mitosis [83].  The cohesin ring opens to embrace the two chromatids 
and hold them together [84].  This ability to hold sister chromatids together is also 
essential for homologous recombination for the repair of double-stranded DNA breaks 
in G2 (the second growth phase of the cell cycle, where the cell prepares for cell 
division).  By bringing the sister chromatids together the intact chromatid can be used as 
a reference for the repair of the broken one [85].    
 
Cohesin binding sites have been found at the promoters of active mammalian genes 
[86], implying a role for cohesin in gene expression.  3C experiments have shown that 
cohesin is also involved in stabilising or forming long-range interactions between its 
binding sites [86].  Cohesin can also act to regulate gene expression during interphase, 








Figure 1.8 – Diagram of the structure of cohesin.  Adapted from (Mehta, 2013 [89]) 
Smc1 and Smc3 are long antiparallel coiled-coil structures that heterodimerise at one 
end.  The other ends are joined by Rad21 to close the ring.  SA1/SA2 interacts with the 
ring through Rad21 [84]. 
 
As cohesin is involved in several essential processes in the cell, mutations in this 
complex lead to at least three diseases in humans, known collectively as the 





Breakage syndrome [90]. Cornelia de Lange syndrome (CdLS) is an autosomal 
dominant disease affecting 1 in 10,000 individuals [83], while the other cohesinopathies 
are recessive and much rarer.  Mutations in cohesin and its interacting proteins are also 
implicated in several cancers [90].   
 
CdLS and the other cohesinopathies are characterised by craniofacial and limb 
deformities, developmental abnormalities and mental retardation [91] [83].   65% of 
CdLS cases are caused by mutations in NIPBL, whose product forms a heterodimer with 
MAU2 which is involved in loading cohesin onto chromatin.  Mutations in the SMC 
subunits of cohesin account for around 7% of CdLS cases (5% are due to SMC1α and 1-
2% to SMC3).  Around 5% of cases are caused by mutations in HDAC8, causing a loss 
of HDAC8 activity [83].  HDAC8 is a SMC3 deacetylase, which is essential for the 
deacetylation of SMC3 after sister chromatid cohesion so that it can be re-loaded onto 
chromatin for the next cycle.  Acetylated cohesin is loaded onto chromatin at a reduced 
rate negatively affecting transcription [89]. 
 
1.3.3.5. – ATRX 
The ATRX (alpha-thalassemia/mental retardation, X-linked) gene is located on the X 
chromosome.  It consists of 36 exons, spanning about 300kb, in humans.  At least two 
alternatively spliced transcripts are generated from the gene differing at their 5’ ends, 
and producing slightly different proteins.  A shorter transcript, which retains intron 11 
and then terminates, produces a truncated version of the protein, known as ATRXt [92].  
ATRX is involved in many different cellular processes, and as such generating a knock-
out mouse has proved difficult.  A traditional knock-out of ATRX is lethal, and so 
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conditional knock-outs, where ATRX is knocked-out in a particular tissue, must be used 
[93] [94].   
  
ATRX is a member of the SW12/SNF family of proteins, which are involved in 
chromatin remodelling.  ATRX has been shown to be involved with gene silencing.  It 
interacts with death domain-associated protein (DAXX) to deposit H3.3.  H3.3 is a 
histone, which is essential for mammalian development; it is usually associated with 
transcription in which case it is recruited to gene rich regions by histone regulator A 
(HIRA).  However ATRX and DAXX act to deposit H3.3 at telomeres, pericentric 
heterochromatin and at the methylated allele of a DMR [95].  In the latter case this 
causes gene silencing by blocking the recruitment of the necessary transcriptional 









Figure 1.9 – Schematic of ATRX mediated recruitment of H3.3 to DMRs.  A and B – 
ATRX recruits DAXX to the methylated allele of a DMR.  DAXX deposits the histone 
variant H3.3 onto chromatin at the DMR, to repress transcription through the allele.  C – 
ATRX is unable to bind to the un-methylated allele of a DMR, therefore DAXX and 
H3.3 cannot be recruited allowing transcription to occur through the allele.  Modified 















ATRX contains a plant homeodomain zinc finger (PHD, a chromatin interaction motif), 
which due to its similarity with a region found in the Dnmts has been designated the 
ATRX-Dnmt3-Dnmt3l domain (ADD), and an ATPase/helicase domain [96].  The 
SW12/SNF family of proteins use their ATPase/helicase domains to slide histones 
along the chromatin, remodel them or remove them completely [97]. 
Mutations in the ATRX gene are associated with alpha-thalassemia/mental retardation, 
X-linked syndrome, and a range of phenotypically similar syndromes including 
Carpenter-Waziri syndrome, Holmes-Gang Syndrome, Juberg-Marsidi Syndrome and 
Smith-Fineman-Myers Syndrome [92], which are predominately found in males.  As 
well as alpha-thalassemia, symptoms also include mental retardation, facial, skeletal and 
urogenital abnormalities [97].  113 different disease associated mutations have been 
identified in the ATRX gene so far.  The mutations tend to be missense mutations, and 
cluster in the ADD domain (about 50%) and the ATPase/helicase domain (about 30%) 
[92]. 
 
1.3.3.6. – MeCP2 
MeCP2 (Methyl CpG Binding Protein 2) binds to methylated CpG dinucleotides located 
within 11bp of a run of at least four adenine/thymine nucleotides [98], and can act to 
recruit the helicase domain of ATRX to heterochromatic foci in a DNA dependent 
manner [71].  MeCP2 is located on the X chromosome and mutations in this gene are 
associated with Rett Syndrome, a neurodevelopmental disorder [71].  Rett syndrome 
occurs in about 1 in 10, 000 female births.  Development proceeds normally until 6 to 
12 months of age when symptoms start to appear and there is a loss of learned skills, 
like speech and controlled movement.  Other symptoms include social withdrawal, 
 47 
respiratory problems, deceleration of head growth, intellectual impairment, and seizures 
[99] [100] [101].   
 
MeCP2 contains three functional domains; MBD at the N-terminus, a nuclear 
localisation sequence and a TRD.  There are currently 1,013 documented mutations 
spread through these three domains [102].  The eight most frequent mutations are C to T 
conversions.  All types of mutation can be found throughout the gene, with frameshift 
mutations tending to cluster in the C-terminal domain and the TRD, and missense 
mutations in the MBD [103].  
 
1.3.4. - Histones 
The basic unit of chromatin is the nucleosome.  DNA is wrapped around an octamer of 
four core histones, with two copies of each histone present.  These core histones are 
H2A, H2B, H3 and H4.  About 147bp of DNA is wrapped around each octamer and 
together these comprise a nucleosome [67].  The region of DNA between each 
nucleosome is termed the linker region and can range between 10bp and 100bp in 





Figure 1.10 – Diagram of a nucleosome.  About 147bp of DNA is wrapped around an 
octamer comprising of two copies of each of the following histones; H2A, H2B, H3 and 
H4. 
 
Histones are essential for the correct folding of the DNA into chromosomes.  The 
histone genes are located in three main clusters in humans: HIST1 consists of 55 genes 
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on chromosome 6, HIST2 contains six genes and is located on chromosome 1 and 
HIST3 containing three genes on chromosome 1.  There is a lot of redundancy amongst 
the histone genes, for example there are 14 genes that encode the same H4 protein 
[105].  As well as there being multiple copies of each gene there are also variants of all 
of the histone proteins except for histone 4.  There are 11 variants of histone 1, with six 
of these being tissue-specific.  For example H1t and H1T2 are only expressed in the 
testis [106].   
 
There are at least 19 variants of histone H2A, encoded by 26 genes [107].  Only about 
four of these have been studied in detail; H2A.X, H2A.Z, macroHA and H2ABBD 
[108].  H2A.X is the most commonly occurring variant [109], and is essential for DNA 
repair and recombination [108].  H2A.Z is another important variant being essential for 
embryogenesis as it plays a role in establishing pluripotency [110], as well as playing 
roles in transcription and suppression of antisense RNA [109].  macroH2A is involved 
in X chromosome inactivation and repression of transcription [108] [109], while 
H2ABBD (H2A Barr-body-deficient) plays a role in spermatogenesis [109].  16 distinct 
variants of histone H2B have been identified [111], but very little is known about their 
functions.  Three of the variants (H2B.1, H2B.W and subH2B) are all involved in 
spermatogenesis [109].  There are six histone H3 variants; centromeric H3 (or cenH3), 
H3.1, H3.1t (also known as H3.4), H3.2, H3.3 and H3.3C, encoded by a total of 18 
genes [107].  These variants have specific roles, for example H3.3 is enriched at 
transcriptionally active genes and regulatory elements [112], cenH3 is essential for 




1.3.4.1. – Histone Modifications 
The N-terminal tail of each histone extends out from the nucleosome, and can be 
modified in a variety of ways.  Each histone can be subject to different modifications at 
the same time.  The different combinations of modifications are known as the ‘histone 
code’, which can be ‘read’ by other proteins to affect transcription [114].  
 
One of the most common modifications is methylation, which mainly occurs on lysine 
and arginine residues of the tail.  Lysines can be mono-, di- or tri-methylated, whereas 
arginine residues can only be mono- or di-methylated. S-adenosylmethionine (SAM) is 
used as the methyl donor for both lysine and arginine.  Histone lysine 
methyltransferases (HKMT’s) are responsible for the addition of a methyl group to 
lysines, and are specific for a particular residue in the histone tail [115].  Protein 
arginine methyltransferases (PRMT’s) [67] are responsible for the addition of a methyl 
group to arginine residues.  They come in two forms; the type I and the type II 
enzymes[115].  As with CpG methylation, histone methylation is also a dynamic mark 
and methyl groups can be removed from the histone.  
 
Acetylation is another common histone modification.  Acetyl groups can be added to 
lysine residues through the activity of histone acetlytransferases (HATs), which use 
acetyl Co-A as a donor.  There are two major classes of HATs, those acetylating free 
histones (type-B HATs), and those acetylating bound histones (type-A HATs) [115].  
The addition of an acetyl group to lysine neutralises its positive charge, and can weaken 
the interaction between the histone and the DNA, allowing transcription [67].  
Conversely, histone deacetylases (HDACs) remove acetyl groups from lysine residues, 
stabilising the interaction between the histone and the DNA, and repressing 
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transcription.  There are four classes of HDACs.  Class I and II HDACs are most 
closely related to yeast scRpd3 and scHdaI respectively, class III HDACs are 
homologous to yeast scSir2, and there is only one class IV HDAC, HDAC11 [115]. 
 
Phosphorylation can occur on serine, threonine and tyrosine residues of a histone tail.  
This mark is also dynamic, with kinases transferring a phosphate group from ATP [115] 
onto the histone tail, and phosphatases removing this group [67].  The addition of a 
negative charge to the histone could act to further weaken the interaction between the 
histone and the DNA, promoting transcription through the region [114].   
 
Other histone modifications include deimination (the conversion of an arginine to a 
citrulline), β-N-acetylglucosamine (the addition of β-N-acetylglucosamine to a serine or 
threonine residue), ADP ribosylation (both mono- and poly- ADP ribosylation of 
gluamtate and arginine residues), ubiquitylation (on lysine residues) and sumoylation 
(on lysine residues).  All of these marks are reversible [115]. 
1.3.4.2. – Reading the Histone Code 
The histone code is complex and dynamic.  ‘Writer’ proteins place the modifications on 
the histone tails (HKMT’s, PRMT’s, HAT’s and kinases), while ‘eraser’s’ remove these 
modifications (HDAC’s, and phosphatases).  A third group of proteins, the ‘readers’, 
interpret these modifications to influence transcription through the underlying DNA.  
Each ‘reader’ tends to recognise specific modifications.  In general methylated residues 
are recognized by proteins containing chromodomains, tudor domains, PHD fingers, 
MBT domains, Ankyrin repeats, PWWP domains, HEAT domains or WD40 domains 
[116].  Acetylated residues are recognized by proteins containing bromodomains, a 
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small domain containing a 4-helix-bundle fold and a hydrophobic binding pocket [116] 
[117].  Phosphorylated resiudes are recognized by proteins containing 14-3-3, BRCT, 
and BIR domains [116].   
 
Histone modifications play a role in regulating gene transcription.  Individual 
modifications tend to be associated with either activating or repressing transcription.  As 
multiple modifications can occur on the same nucleosome it is possible for a bivalent 
state to occur, where the region contains both activating and repressive marks and is 
considered to be poised for future activation [110].   
 
Examples of common histone modifications and their functions are listed in the table 













Modification Function Reference 
H2A.Zub1 Repression or poising. Santoro, 2015 [110] 
acH2A.Z Activation or poising. Santoro, 2015 [110] 
H2BK5ac Activation. Santoro, 2015 [110] 
H2BK5me1 Elongation of transcription. Santoro, 2015 [110] 
H3K9me2 Repression. Campos, 2009 
[118], Zhou, 2011 
[119] 
H3K9me3 Repression. Santoro, 2015 [110], 
Zhou, 2011 [119] 
H3K4me3 Activation or poising. Campos, 2009 
[118], Santoro, 2015 
[110], Zhou, 2011 
[119] 
H3K27me3 Repression or poising.  It is associated with 
Polycomb repression. 
Campos, 2009 
[118], Santoro, 2015 
[110], Zhou, 2011 
[119] 
H3K27ac Activation. Zhou, 2011 [119] 
H3K36me3 Activation (when located in gene bodies). Campos, 2009 
[118], Zhou, 2011 
[119] 
H3K79me2 Activation (when located in gene bodies). Zhou, 2011 [119] 
H4K20me3 Repression. Campos, 2009 [118] 
Table 1.3 – Table of common histone modifications and their associated functions.  
Nomenclature of histone modifications – the first part specifies which histone the 
modification is on, the middle part specifies the location on the histone tail, and the 
final part specifies the type of modification.  For example H3K9me3 means that lysine 
9 on histone H3 is tri-methylated. 
 
1.3.5. – Chromatin Architecture 
The bound state of chromatin can affect gene expression.  The bound state of a given 
region of DNA can vary by cell type and by phase of development.  Generally, actively 
expressed genes are in regions of euchromatin, and repressed genes are in regions of 
heterochromatin.  Euchromatin is less tightly coiled than heterochromatin, making the 
DNA more accessible for the transcriptional machinery [120].   
 
Regions of DNA can interact with each other across quite large areas; for example the 
enhancer of Sonic Hedgehog (SHH) is located 1Mb away from the gene [121].  This 
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interaction occurs through looping of the DNA, which allows these two regions to 
localise together so they can interact.  These loops are dynamic [122], and are usually 
associated with cohesin [123], which acts to hold both regions of DNA together to 
‘close’ the loop, bringing the genes and regulatory elements located within it 
sufficiently close to interact. 
 
CTCF recruits cohesin to its binding sites by interacting directly with its SA2 subunit.  
This stabilises long-range interactions between CTCF sites [84].  Although CTCF and 
cohesin work together to form chromatin loops to regulate long-range chromatin 
interactions, they play different roles.  Experiments in which their binding was 
disrupted in human cell lines showed that both cohesin and CTCF are responsible for 
local chromatin interactions, but CTCF also plays a role in silencing interactions 
between different loops [124]. 
 
Cohesin has also been shown to interact with the Mediator Complex (see section 1.3.6.) 
to form loops to regulate the expression of lineage specific genes [125].  The Mediator 
Complex interacts with cohesin through NIPBL, which is involved in the loading of 
cohesin onto DNA [65]. 
 
The development of Hi-C, which allows the interactions between all genomic regions to 
be determined [126], has shown that the genome is portioned into discrete 
compartments approximately 500-900Kb in length [122].  These are known as 
topologically associated domains (TADs), and they are conserved across mammals and 
cell types.  Loci within a TAD more frequently form contacts with each other than they 
do with loci in other TADs [127].  Cohesin and CTCF are enriched at TAD borders 
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[126] [128], which could help to explain why most interactions are within TADs rather 
than across them.  The genes within a TAD tend to be co-ordinately regulated.  CTCF 
mediated chromatin loops have also been implicated in maintaining TAD structure 
[128].   
 
1.3.6. – RNA polymerase II and the Mediator Complex 
A variety of proteins can bind to the gene or its regulatory regions to mediate its 
expression.  TFs bind to the promoter or enhancer of a gene and recruit RNA 
polymerase II to the TSS, through the Mediator Complex.  The mammalian Mediator 
Complex consists of 26 subunits, which can be exchanged, making it a dynamic 
complex.  Different TFs bind to different subunits, allowing for the binding of multiple 
TFs at the same time [64].  The Mediator Complex then recruits RNA polymerase II 
through an interaction between the C-terminal domain (CTD) of the RPBI subunit (the 
largest subunit) of RNA polymerase II [64] [65]. This forms the basis of the Pre-
Initiation Complex (PIC) along with TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH 
[125], and transcription is initiated.  
 
At many genes RNA polymerase pauses in its transcription between 30 and 50 
nucleotides downstream of the TSS [65]. The Mediator Complex plays a role in this 
pausing, but the mechanism through which it acts is still unclear [64].  RNA polymerase 
pausing can also be due to the nucleosome occupancy of the chromatin, or the 
methylation state of the DNA.  This pausing can affect exon and intron inclusion in the 
transcript, which will be discussed further in section 1.3.8.  Differential inclusion of 
exons is just one of the ways of generating such a large diversity of transcripts (about 
200, 000) from the relatively small number of genes (about 20, 000) found in humans.  
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1.3.7. – Alternative Promoters 
One way to increase transcript diversity from genes is through the use of alternative 
promoters, producing transcripts that vary in their 5’ end.  For example Grb10 (growth-
factor receptor bound protein 10), an imprinted signal adaptor protein contains four 
promoters.  Grb10 is expressed from the maternal methylated allele in most mouse 
tissues except for a subset of neurons, where it is expressed from the un-methylated 
paternal allele.  Maternal transcripts always originate from the major promoter of the 
gene.  Paternal transcripts originate from one of three minor promoters located 
downstream of the major promoter [129].  In this example the use of alternative 
promoters is being used to control tissue-specific expression of the gene. 
 
1.3.8. – Alternative Splicing 
It is estimated that around 95% of multiexonic human genes are subject to alternative 
splicing of the pre-mRNA [130] making this an important mechanism to consider when 
investigating the regulation of gene expression.  Alternative splicing is the mechanism 
through which multiple different mRNA transcripts can be generated from a single gene 
[131].  There are five types of alternative splicing; exon skipping, the use of alternative 
5’ splice sites, the use of alternative 3’ slice sites, intron retention and mutually 
exclusive splicing.  Exon skipping is responsible for 38% of alternative splicing events 
conserved between mice and humans.  The use of alternative 5’ and 3’ splice sites 
account for 18% and 8% respectively.  In this case all exons are represented in the RNA 
transcript but only part of the sequence may be retained for one or more of them 
depending on which 5’ or 3’ splice site in the exon is used.  Intron retention accounts 
for 3% of splicing events and occurs when an intron that is normally removed from the 
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transcript is retained.  The final 33% of splicing events are more complex cases, and 
include mutually exclusive exon inclusion, where the presence of one exon in the 
transcript inhibits the inclusion of another [132].   
 
Pausing of the RNA polymerase can lead to alternative splicing.  RNA polymerase 
pausing can be caused by nucleosome occupancy of the chromatin, or by methylation of 
the DNA sequence.  Exons tend to have a higher nucleosome occupancy than introns, 
and both exons and introns have specific histone modifications.  RNA polymerase 
pauses before histones at exons, regulating the inclusion rate of particular exons in the 
RNA strand.  Splicing factors can be recruited to the growing RNA strand while 
transcription is occurring, and a slowing of the rate of transcription can give these 
factors more time to recognise splice sites [133].  On average, exons have a higher level 
of DNA methylation than introns, which suggests that methylation status could 
influence alternative splicing [131].  CTCF and MeCP2 are both involved in translating 
these methylation marks.  At the CD45 locus, CTCF binding at the un-methylated 
boundary between the intron and the alternatively spliced exon (ASE) (exon 5) leads to 
RNA polymerase pausing and inclusion of exon 5 into the transcribing RNA [134].  
MeCP2 has been found to bind to methylated boundaries between introns and ASEs, 
leading to the inclusion of the ASE.  This is thought to be due to both the pausing of the 
RNA polymerase caused by the presence of MeCP2 on the DNA, and the recruitment of 
HDACs to deactylate the histones in the associated ASE (by MeCP2) [135]. 
 
The regulation of alternative splicing is complicated and involves many different 
factors.  Further work is needed to investigate how all these factors work together to 
ensure the correct splicing of the gene.  
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1.3.9. - Alternative Polyadenylation 
All fully processed eukaryotic mRNA’s have a 3’ poly (A) tail, a region of the mRNA 
consisting only of adenines [66].  The addition of a poly (A) tail is specified by three 
sequence elements (Figure 1.11); the upstream sequence element (USE), consensus 
polyadenylation signal (PAS) and the downstream sequence element (DSE) [136].  
Although these sequences are traditionally associated with the 3’ end of the gene, they 
can be located throughout the gene body, and each gene can contain multiple 
polyadenylation sites.  About 54% of human genes and 32% of mouse genes take 
advantage of these alternative polyadenylation sites to generate different transcripts 




Figure 1.11 – Diagram of the consensus sequence elements required for polyadenylation 
in mammals.  USE = the U-rich upstream sequence element.  DSE = the G/U- or U-rich 
downstream sequence element. nts = nucleotides.  The arrow shows where cleavage 
occurs.  Adapted from (Proudfoot, 2011 [136]). 
 
The polyadenylation site consists of a consensus polyadenylation signal (PAS) located 
between two Uracil-rich regions.  The PAS consensus sequence is AAUAAA, but this 
motif can vary slightly.  It is located between 0-20 nucleotides downstream of the USE.  
15-30 nucleotides downstream of the PAS is a CA dinucleotide, where cleavage of the 
RNA strand occurs.  0-20 nucleotides downstream of this is the G/U- or U-region 
known as the DSE.  Cleavage and polyadenylation specificity factor (CPSF) and 
cleavage stimulatory factor (CstF) recognise the AAUAAA and DSE and act to cleave 
the RNA strand between these two elements at the CA dinucleotide [136].   
USE DSE AAUAAA CA 
0-20nts 0-20nts 15-30nts 
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1.3.10. – Transcriptional Interference 
Transcriptional interference occurs when one transcriptional process or RNA 
polymerase complex has a repressive effect on a second transcriptional process [138].  
This usually occurs between two genes where their promoters are either convergent, 
located in tandem or are in an overlapping divergent configuration (Figure 1.12).  There 
are five mechanisms through which this can occur; promoter competition, the sitting 













Figure 1.12 – Different promoter arrangements important for transcriptional 
interference.  A – Convergent promoters.  B – Tandem promoters.  C – Overlapping 
divergent promoters.  Adapted from (Shearwin, 2005 [139]). 
 
Promoter competition occurs where the binding of an RNA polymerase complex to one 
promoter inhibits RNA polymerase binding at the second promoter (Figure 1.13 A).  








The sitting duck mechanism occurs where one of the two promoters is ‘stronger’ 
(quicker to transition from the open RNA polymerase complex to the more closely 
associated elongating RNA polymerase complex) than the other.  The RNA polymerase 
complex originating from the ‘strong’ promoter can hit and knock the transcription-
initiating complex from the second ‘slower’ promoter (Figure 1.13 B).  This can occur 
at both convergent and tandem promoters.   
 
Occlusion occurs where transcription from the first promoter across the second 
promoter transiently blocks transcription from the second promoter (Figure 1.13 C).  
This can occur at promoters located convergently or tandemly to each other. 
 
Collisions between converging elongation complexes can result in one or both of the 
elongation complexes being dislodged from the DNA, leading to premature termination 
of the transcript (Figure 1.13 D).   
 
So far the road block mechanism has only been seen where the DNA-bound Lac 
repressor acts to block the progress of RNA polymerase initiating upstream of the 
bound Lac repressor (Figure 1.13 E).  In theory this could occur where an open RNA 
polymerase is so tightly bound to the promoter that it can act as an immovable road 
block rather than a sitting duck, but this has not been confirmed [139].  These 

















Figure 1.13 – Mechanisms of transcriptional interference.  A – Promoter competition.  
B – Sitting duck mechanism.  C – Occlusion.  D – Collision.  E – Road block.  Adapted 
from (Shearwin, 2005 [139]). 
 
Some promoters are capable of initiating transcription in both the sense and antisense 
directions, ie they are bidirectional [140] [141].  Initiation rates have been shown to be 
roughly equal for both orientations, but transcription in the antisense orientation tends 
to drop off as RNA polymerase II moves further away from the promoter resulting in 
the generation of more sense than antisense transcripts [141].  However there are still a 
large number of genes where the antisense transcript plays an important role, for 
example Tsix, the antisense transcript of Xist, protects the active X chromosome from 










promoters means that several mechanisms of transcriptional interference may be acting 
on any promoter pair at a given time.   
 
Imprinted retrogenes are an interesting case for investigating these models of 
transcriptional interference.  Retrogenes are generated from the retrotransposition of an 
mRNA molecule into the genome [142].  In some cases the mRNA molecule is 
incorporated into an intron of a ‘host’ gene, and it is this type of retrogene that we are 
interested in studying.  They tend to be monoexonic and retain their function and 
activity [143].  Imprinted retrogenes (which are situated in the intron of a non-imprinted 
gene) are good models for examining gene regulation; although the two alleles share an 
identical environment and are subject to the same influences, the retrogene is only 
expressed from one allele and not the other.  Therefore, this must be due to epigenetic 
factors operating in cis.  The methylated CpG dinucleotides at the promoter of the 
repressed allele act to both block the binding of transcription factors and recruit 
methylation binding proteins, which also act to inhibit the binding of transcription 
factors to the gene [42].  CpG methylation can also act to alter the density of the 
chromatin over the region in which it occurs, through the activity of histone modifying 
enzymes.  Dnmt1 and Dnmt3a have been shown to bind to a histone methyltransferase, 
and Dnmt1 and Dnmt3b can bind to histone deactetylases, recruiting them to regions of 
DNA methylation.  The addition of methyl groups and the removal of acetyl groups at 
the histone tails increases the binding affinity of the histone for the DNA, leading to 
tighter binding blocking access of transcription factors to the gene [42].  MeCP2 can 
also recruit histone deacetylases to regions of methylated CpG dinucleotides to the same 
effect [42], and has been shown to recruit histone methyltransferases to reinforce the 
repression of the gene [144].   
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DNA methylation is not constant across a locus, not all of the CpG dinucleotides in a 
region classified as methylated are actually methylated, and the ones that actually are 
can vary between cells and tissue types.  The imprinted locus Gnas, which includes the 
imprinted transcripts Gnas, Gnasxl, Exon 1A, Nesp and Nespas, is an example of a 
region where the methylation status varies across the locus.  It contains three DMR’s, 
one which is unmethylated on the maternal allele and methylated on the paternal allele, 
and two which are methylated on the maternal allele and unmethylated on the paternal 
allele [145]. 
 
The work presented in this thesis makes use of the H13/Mcts2 locus as a model of a 
host/imprinted retrogene pair. 
 
1.4. – The H13/Mcts2 locus 
Mcts2 is an imprinted retrogene, located within intron four of H13, its host gene, on 
chromosome 2.  The promoter of Mcts2 is methylated on the maternal allele, and so 
Mcts2 is silenced, and H13 is transcribed using a down-stream poly (A) site.  However 
on the paternal allele, the promoter is un-methylated and Mcts2 is expressed.  The 
expression of Mcts2 coincides with the premature termination of the H13 transcript (see 
Figure 1.14), through the use of an alternative upstream poly (A) site. 
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Figure 1.14 – A summary of the transcripts generated from the H13 locus.  The black 
boxes represent the exons included in each transcript, while the lines joining them 
represent the introns excluded.  In the case of H13d and e parts of intron 3 are retained 
in the transcript.  The transcripts generated from the maternal allele are shown in the red 
box, and the transcripts generated from the paternal allele are shown in the blue box.  
The location of Mcts2 in intron 4 is shown, as are the locations of the CpG islands 
associated with this locus (reproduced from Wood, 2008 [146]). 
 
There are several internal poly (A) sites in the H13 locus, generating at least five 
different transcripts.  There are three transcripts (H13a, b and c) generated from the 
maternal allele utilising downstream poly (A) sites, and two transcripts (H13d and e) 
generated from the paternal allele utilising up-stream poly (A) sites (Figure 1.14) [146].  
The fact that H13d and e are only generated when Mcts2 is expressed suggests that 
transcription from an internal site could be responsible for premature termination of the 
host transcript.  It is unclear whether this premature termination is caused by the 
transcription of the retrogene or by the binding of a methylation sensitive 
polyadenylation factor to the DMR.  For example, this could be a factor that binds in the 
presence of methylation and inhibits the use of upstream poly (A) sites, dissociating in 
the absence of methylation to allow the use of both upstream and downstream poly (A) 
sites (with upstream sites being used preferentially in the case of H13).  Alternatively, 
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such a factor could bind only in the absence of methylation, promoting the use of 
upstream poly (A) sites, and therefore when the DMR is methylated there is no binding 
and only downstream poly (A) sites are used. 
 
1.5. – Project Aims 
The aim of this project is to further our understanding of the mechanisms of gene 
regulation at imprinted loci, using a model locus (the H13/Mcts2 locus) to explore some 
of these mechanisms in more detail.  This is being investigated using a variety of 
different experimental and bioinformatics approaches.  Experimental approaches are 
being used to demonstrate that intragenic promoters affect host gene transcript 
polyadenylation; through the deletion of the intragenic promoter and the relocation of 
the intragenic promoter into a new host gene.  The significance of epigenetic 
mechanisms in alternative polyadenylation and premature termination of a transcript is 
being determined through the use of siRNA’s to alter histone methylation marks, and to 
investigate if this mechanism occurs at other loci in the genome, in addition to the 
H13/Mcts2 locus.  Experimental and bioinformatics approaches are being used to 
discriminate between the models of transcriptional interference by an internal promoter 
and differential binding across the CpG island of the internal promoter.  The work in 
this thesis investigates the affect of intragenic promoters on host gene transcription, and 
aims to discriminate between the models of transcriptional interference and differential 
binding across the CpG island of the internal promoter.  
 
I was involved in the previous studies from Professor Oakey’s laboratory, which used a 
ChIP-Seq approach to map genomewide the locations of CTCF and cohesin binding 
[22].  ATRX and MeCP2 have been shown to bind with CTCF and cohesin at two 
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individual loci in the genome, the H19 ICR and the Gtl2/Dlk1 imprinted region [147].  
In chapter three I will describe the use of ChIP-Seq to identify the binding sites of 
ATRX and MeCP2.  By combining these with the existing data for CTCF and cohesin it 
will be possible to investigate the interaction of these four proteins in a genomewide 
manner.  Identifying regions which co-bind these proteins will help to generate a model 
to inform our understanding of how these proteins influence gene expression, 
particularly at other imprinted loci located across the genome.  
 
In chapter four I will focus on an individual locus, H13/Mcts2, and investigate its 
specific mechanisms of gene regulation.  Expression of Mcts2 is associated with altered 
transcription through H13, where the use of poly (A) sites upstream of Mcts2, leads to 
premature termination of the H13 transcript.  We hypothesise that this premature 
termination is caused by transcription of the retrogene interfering with host gene 
transcription.  I will describe the design of two series of DNA constructs based on this 
locus.  The first will allow expression through the retrogene to be regulated, allowing 
the direct consequences of Mcts2 expression to be examined in detail.  The second 
inserts Mcts2 into Fam13c, a large poly-exonic gene similar in structure to H13.  This 
will enable us to investigate whether the presence of Mcts2 can enforce the same 
phenotype, premature transcript polyadenylation, on Fam13c as it does at H13.  These 
studies will provide a mechanistic component to our whole genome analyses, allowing 
us to better understand the role of DMRs and propose specific mechanisms through 







Materials and Methods 
 
2.1. - Source of Mouse Tissue 
Tissue was generated from crosses between mice from two inbred subspecies: Mus 
musculus castaneus and C57BL/6 mice.  These mice were housed at the Biological 
Services Unit at King’s College London according to the United Kingdom Home Office 
Breeding Licence.  Colonies were managed with help from Dr Adam Prickett, Dr 
Michael Cowley and Matthew Shannon.  The mice were fed on expanded breeder pellet 
R&M No 3 (Special Diets Services, Essex, UK), and kept in a 12 hour dark/light cycle 
with 30 minutes dawn/dusk lighting, an ambient temperature of 21°C ± 2°C and at a 
humidity of 50% ±10%.   
 
2.2. - Cell Culture 
Cell lines were sourced from the American Type Culture Collection (ATCC).  All cell 
lines used were cultured at 37°C in a 5% CO2 atmosphere.  All reagents were heated to 
37°C before use.  Cells were cultured in tissue culture rated vessels and passaged when 
they reached 80% confluency, as determined by visual inspection.  To passage the 
3T3’s the medium was aspirated, and the cells were washed twice with PBS.  The cells 
were incubated in 0.05% trypsin in EDTA (Gibco®, Life TechnologiesTM, cat number 
25300-054) at 37°C until they detached from the flask.  10mls of medium was added to 
the flask to inactivate the trypsin.  The cells were transferred via 10ml stripette to a 
50ml falcon tube, and centrifuged at 1,000RPM for 5 minutes at room temperature.  The 
medium was removed and the cells were resuspended in fresh medium and transferred 
to a new flask.  To passage the Neuro2a and HEK 293 cells the medium was removed 
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and replaced with 10mls of fresh medium.  The medium was washed over the back of 
the flask (over the surface where the cells have attached) to detach them from the flask.  
The detached cells and medium were transferred to a 50ml falcon tube, and centrifuged 
at 1,000RPM for 5 minutes at room temperature.  The medium was removed and the 
cells were resuspended in fresh medium and transferred to a new flask.  All three of the 
cell lines were split at a range of concentrations from 1 in 10 to 1 in 20, depending on 
their growth rate. 
 
BxJ and JxB Embryonic Stem (ES) cells were kindly donated by Dr Robert Feil (Institut 
de Génétique Moléculaire de Montpellier).  These cells were grown on 0.1% gelatin 
coated plates.  Plates were coated with an excess of ESGRO Complete Gelatin Solution 
(Millipore, cat number SF008) for at least 30 minutes at room temperature.  The excess 
was removed.  The medium (Merck Millipore, cat number SF001-500P) was aliquoted 
into 50ml falcon tubes, to which 25µl of GSK3 β Inhibitor and 5 µl of LIF (Millipore, 
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Table 2.1 – Table detailing the type of medium used for each cell line.  FBS was filter 
sterilised before being added to the medium.  All the components of the medium for the 
cell lines were from Life Technologies.  Gibco® MEM Non-Essential Amino Acids (cat 
number 11140-035).  Penicillin and streptomycin (cat number 15140-122). DMEM.  
The medium for the ES cells was from Millipore.  ESGRO Complete PLUS Clonal 
Grade Medium (cat number SF001-500P).  The GSK3 β Inhibitor was supplied with 
this medium.  
  
 
2.3. – Chapter 3 
 
 
2.3.1. – Chromatin Extraction from Tissues 
 
This protocol was used to determine the allele-specific binding of CTCF and cohesin 
(as represented by Rad21) in postnatal day 21 mouse brain tissue [22]. 
Chromatin was extracted from p21 BxC and CxB inter-cross mouse brain tissue.  The 
tissue was first cut into small pieces with a sterile scalpel and then homogenized in 1ml 
of PBS pH8, using a Dounce homogeniser (Fisher).  The homogenised tissue was then 
centrifuged at 7,000RPM for 5 minutes at 4°C.  The supernatant was removed, the 
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nuclei were resuspended in 1ml PBS and then subjected to centrifugation at 7,000RPM 
for 3 minutes at 4°C.  The nuclei were washed in PBS three more times.  After the 
fourth wash the nuclei were resuspended in 1ml 5mM DTBP to cross-link the proteins 
to the chromatin.  The nuclei were incubated on ice for 30 minutes, before being washed 
twice in PBS (as previously).  The reaction was stopped by adding 1ml quench buffer 
(1M Tris HCL pH8, 5M sodium chloride and H2O) to the nuclei.  The nuclei were then 
washed twice in PBS (as previously).  The nuclei were then cross-linked with 1% 
formaldehyde in PBS, and incubated on ice for 10 minutes.  The nuclei were washed 
three times in PBS (as previously but for 4 minutes instead of 3).  The nuclei were 
resuspended in 1ml lysis buffer (0.1M PMSF, Protease inhibitor, 1M Tris HCl pH8, 
10% SDS, 0.5M EDTA, H20), and then sonicated to break up the chromatin into 
roughly 500bp fragments (at 40AMP, 1 minute on, 1 minute off, repeated for 15 
minutes).  A small sample of the chromatin was incubated overnight at 65°C with 5M 
sodium chloride and H20 to de-cross-link it so that it could be run on a gel to check the 
efficiency of the sonication.  The concentration of the rest of the chromatin was 
measured and it was stored at -80°C. 
 
2.3.2. – Chromatin Immunoprecipitation - Method 1 
Chromatin (to a final concentration of 0.08µg/µl) was added to 80µl agarose beads 
(Millipore, cat number 16-156 for Protein A beads and cat number 16-266 for Protein G 
beads), EDTA-free protease inhibitor (to a final concentration of 1x) (Roche, cat 
number 04693132001) and dilution buffer.  Samples were rotated at 4°C for 2 hrs.  
Each sample was applied to a Corning® Costar® Spin-X® centrifuge tube (Sigma 
Aldrich, cat number CLS8160-96EA) and centrifuged at 7,000g at 4°C for 2 minutes.  
This centrifugation step was repeated as needed, until the entire sample passed through 
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the column.  200µl was aliquoted into each tube.  140µl of dilution buffer was added to 
the tubes for the antibodies, and 200µl was added to the tube for the input sample.  The 
input was then stored at 4°C until the phenol extraction stage later in the protocol.  The 
antibodies were added to the appropriate tubes (20µg of ATRX; Insight Biotechnology, 
cat number sc-15408, 4µg of IgG; Millipore, cat number 06-371, and 7µg of MeCP2; 
ABCAM, cat number AB2828).  The samples were rotated at 4°C overnight. 
 
20µg of yeast tRNA, and 60µl agarose beads were added to each sample, and the 
samples rotated at 4°C for 2 hours.  The samples were centrifuged at 7,000g at 4°C for 2 
minutes, before being transferred to Corning® Costar® Spin-X® centrifuge tubes.  The 
samples were centrifuged at 7,000g at 4°C for 2 minutes, and the flow-through 
discarded.  600µl of wash buffer 1 was added to the beads (in the same centrifuge 
tubes), and the samples were rotated at 4°C for 10 minutes.  The samples were 
centrifuged at 7,000g at 4°C for 2 minutes, and the flow-through discarded.  600µl of 
wash buffer 2 was added to the beads (in the same centrifuge tubes), and the samples 
were rotated at 4°C for 10 minutes.  The samples were centrifuged at 7,000g at 4°C for 
2 minutes, and the flow-through discarded.  600µl of wash buffer 3 was added to the 
beads (in the same centrifuge tubes), and the samples were rotated at 4°C for 10 
minutes.  The samples were centrifuged at 7,000g at 4°C for 2 minutes, and the flow-
through discarded.  The beads were resuspended in 400µl of ddH2O and moved to a 2ml 
microcentrifuge tube.  The input sample was processed from this point on.  16µl of 5M 
sodium chloride was added to each sample, and incubated at 65°C overnight.   
 
2µl proteinase K (Roche, cat number 03115887001) and 1µl RNAse A was added to 
each sample and incubated at 45°C for 2 hrs.  Phase lock tubes (VWR, cat number 713-
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2533) were prepared by centrifuging them at 13,000g at 4°C for 1 minute.  One volume 
of phenol:chloroform was added to the DNA in a phase lock tube and inverted to mix 
the solution.  The solution was then centrifuged at 13,000RPM at 4°C for 10 minutes.  
The top aqueous layer was removed and transferred to a fresh microfuge tube.  1/10th 
volume of 5M sodium chloride, three times the volume of 100% ethanol and 1ul of 
glycogen were added to each tube.  The sample was then incubated at -20°C for 30 
minutes before being centrifuged at 13,000RPM at 4°C for 20 minutes.  The supernatant 
was removed and the pellet was washed in 70% ethanol.  The tube was centrifuged at 
13,000RPM at 4°C for 10 minutes, and the ethanol wash was then removed.  The pellet 
was left to dry before the DNA was resuspended in 21µl ddH20.  The concentration was 
measured on the Qubit®, before being stored at 4°C. 
 
2.3.3. - Chromatin Immunoprecipitation - Method 2 
The EZ-ChIPTM kit (Millipore, cat number 17-371). 
4.5µl of Protease Inhibitor Cocktail II was added to 900µl dilution buffer (for each IP) 
and stored on ice.  900µl of the prepared dilution buffer was added to 100µl of sheared, 
cross-linked chromatin.  60µl of protein G agarose beads were added, and the samples 
were incubated for 1 hour at 4°C, rotating.  The samples were centrifuged at 5,000g for 
1 minute to pellet the beads.  10µl of the supernatant was removed and saved as the 
Input at 4°C until the elution step on the following day.  The remaining supernatant was 
moved to a fresh microfuge tube, and the appropriate antibodies were added (20µg of 
ATRX; Insight Biotechnology, cat number sc-15408, 4µg of IgG; Millipore, cat number 
06-371, and 7µg of MeCP2; Abcam, cat number ab2828).  Samples were incubated 
overnight at 4°C.   
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60µl of protein G agarose beads were added to each sample, and incubated for 1 hour at 
4°C, rotating.  Samples were centrifuged at 5,000g for 1 minute and the supernatant was 
removed.  The beads were resuspended in 1ml of cold Low Salt Immune Complex 
Wash Buffer, and incubated for 5 minutes, rotating.  Samples were centrifuged at 
5,000g for 1 minute and the supernatant was removed.  The beads were resuspended in 
1ml of cold High Salt Immune Complex Wash Buffer, and incubated for 5 minutes, 
rotating.  Samples were centrifuged at 5,000g for 1 minute and the supernatant was 
removed.  The beads were resuspended in 1ml of cold LiCl Immune Complex Wash 
Buffer, and incubated for 5 minutes, rotating.  Samples were centrifuged at 5,000g for 1 
minute and the supernatant was removed.  The beads were resuspended in 1ml of cold 
TE Buffer, and incubated for 5 minutes, rotating.  Samples were centrifuged at 5,000g 
for 1 minute and the supernatant was removed.  This wash in TE buffer was repeated 
again.       
 
Elution of protein/DNA complexes: 
For each tube 200µl of elution buffer was prepared; 10µl 20% SDS, 20µl 1M NaHCO3 
(warmed to room temperature) and 170µl sterile, distilled H2O.  200µl was added to the 
Input and left at room temperature.  For sample tubes 100µl elution buffer was added 
and mixed by flicking.  Sample tubes were incubated for 15 minutes at room 
temperature, and centrifuged at 5,000g for 1 minute.  The supernatant was moved to a 
fresh tube.  100µl of elution buffer was added to the beads, and the beads were 
resuspended by flicking the tube.  The tubes were incubated for 15 minutes at room 
temperature, and centrifuged at 5,000g for 1 minute.  The supernatant was pooled with 
the previous eluted DNA. 
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Reverse the cross-links of the protein/DNA complexes to free the DNA: 
 8µl of 5M NaCl was added to each tube, and samples were incubated overnight at 
65°C.  1µl of RNase A was added to each tube, and samples were incubated for 30 
minutes at 37°C.  4µl of 0.5M EDTA, 8µl 1M Tris-HCl and 1µl Proteinase K was 
added to each tube, and incubated for 1-2 hours at 45°C. 
 
DNA purification using spin columns: 
1ml of Bind Reagent A was added to each 200µl DNA sample tube, and mixed well.  
600µl of sample/Bind Reagent A was transferred to a spin filter in a collection tube, and 
centrifuged at 10, 000g for 30 seconds.  The liquid was discarded and the sample/Bind 
Reagent A was again centrifuged at 10, 000g for 30 seconds, and the liquid discarded.  
500µl of Wash Reagent B was added to the spin filter, and centrifuged at 10, 000g for 
30 seconds.  The liquid was discarded and the spin filter was centrifuged at 10, 000g for 
30 seconds.  The spin filter was transferred to a fresh collection tube and 50µl of 
Elution Buffer C was added to the centre of the spin filter membrane.  The spin filter 
was centrifuged at 10, 000g for 30 seconds.  The eluted DNA was stored at -20°C. 
 
2.3.4. - Chromatin Immunoprecipitation – Method 3 
To prepare the Dynabeads/antibody: 
50µl of Dynabeads Protein A magnetic beads (Life TechnologiesTM, 10001D) were 
aliquoted into each tube and 1ml of filter sterilised 5mg/ml PBS/BSA was added.  The 
tubes were placed in a magnetic rack (Ambion®, AM10055), and the PBS/BSA 
solution was removed.  The beads were washed in this way three more times.  The 
beads were resuspended in the appropriate antibodies (20µg of ATRX; Insight 
Biotechnology, cat number sc-15408, 4µg of IgG; Millipore, cat number 06-371, and 
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7µg of MeCP2; Abcam, cat number ab2828) and up to 300µl of PBS/BSA was added. 
The tubes were incubated, rotating, at 4°C for 3-4 hours.  The beads were then washed 
four times in 1ml of PBS/BSA, before being resuspended in 300µl of PBS/BSA.   
 
To prepare the Dynabeads for pre-clearing: 
50µl of Dynabeads Protein A magnetic beads (Life TechnologiesTM, 10001D) were 
aliquoted into each tube and 1ml of filter sterilised 5mg/ml PBS/BSA was added.  The 
tubes were placed in a magnetic rack, and the PBS/BSA solution was removed.  The 
beads were washed in this way three more times.  The beads were resuspended in 300ul 
of PBS/BSA and incubated, rotating, at 4°C for 3-4 hours. 
 
To prepare the chromatin: 
Neuro2a cells/ JxB and BxJ ES cells were incubated with 0.05% trypsin (Gibco®, Life 
TechnologiesTM, cat number 25300-054) at 37°C until they detached from the flask.  
10mls of DMEM (with 10% Fetal Bovine Serum and Penicillin and Streptomycin) was 
added to the flask to inactivate the trypsin.  The cells were transferred to a 50ml falcon 
tube, and centrifuged at 1,000RPM for 5 minutes.  The medium was removed and 
10mls of PBS was added.  The cells were centrifuged at 1,000RPM for 5 minutes.  The 
PBS wash was repeated once more.  The cell pellet was resuspended in 30mls PBS and 
the cells were counted.  20 million cells were used for each ChIP reaction.  EGS (Pierce, 
cat number 21565, made up fresh) was added to each reaction to a final concentration of 
2mM, and the cells were incubated at room temperature for 45 minutes on a roller.  
Formaldehyde solution was added to each reaction to a final concentration of 1%, and 
the cells were incubated at room temperature for 20 minutes.  1/8 volume of 1M glycine 
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was added to each reaction to quench the formaldehyde.  The cells were centrifuged at 
1,000RPM for 5 minutes.  The cells were washed twice with 20ml 4°C PBS. 
 
The cells were resuspended in 10ml of lysis buffer 1 (see appendix) and rocked at 4°C 
for 10 minutes.  They were centrifuged at 2,000RPM at 4°C for 2 minutes. The cells 
were resuspended in 10ml of lysis buffer 2 (see appendix) and rocked at 4°C for 10 
minutes.  They were centrifuged at 2,500RPM at 4°C for 2 minutes.  The cells were 
resuspended in 3ml of lysis buffer 3 (see appendix).  The cells were aliquoted into 
1.5ml microfuge tubes (1ml into each tube).  The chromatin was sonicated to break up 
the chromatin into roughly 500bp fragments (at 40AMP, 1 minute on, 1 minute off, 
repeated for 15 minutes).  After sonication add 1/10 the volume of 10% Triton-X 100 to 
each tube, and centrifuged at 14,000 RPM at 4°C for 10 minutes.  The lysate was 
transferred to a 15ml falcon tube and the volume adjusted to 3ml.  50µl of the lysate 
from each sample was saved overnight at -20°C as an input sample.  50µl was saved to 
assess the sonication efficiency. 
 
300µl of the pre-clearing beads were added to 3ml of chromatin.  The chromatin/bead 
mix was incubated, rotating, at 4°C for 1 hour.  The samples were applied to a magnet 
and the chromatin was removed to fresh 5ml tubes.  The washed antibody bound beads 
were added, and the samples were incubated, rotating, at 4°C overnight. 
 
The beads were moved to a 1.5ml microfuge tube.  1ml of wash buffer was added and 
the samples incubated, rotating, at 4°C for 5 minutes.  The samples were placed in a 
magnetic rack and the supernatant was removed.  The wash was repeated four times.  
The samples were then washed once in 1ml cold PBS (with protease inhibitors).  All of 
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the five washes in wash buffer and the PBS wash were carried out in the cold room (at 
4°C) with ice-cold solutions.  After the PBS was removed from the beads they were 
resuspended in 250µl elution buffer, and incubated, rotating, at room temperature for 15 
minutes.  The samples were placed in a magnetic rack and the supernatant was removed 
to a fresh 1.5ml microfuge tube.  A further 250µl elution buffer was added to the beads, 
and they were incubated, rotating, at room temperature for 15 minutes.  The samples 
were placed in a magnetic rack and the supernatant was added to that from the previous 
round of elution.  20ul of 5M sodium chloride was added to the samples and they were 
incubated at 65°C for 4 hours.  The frozen input was thawed and 450µl of elution 
buffer, and 20µl 5M sodium chloride was added.  The input samples were also 
incubated at 65°C for 4 hours. 
 
20ul of 1M Tris pH6.5, 10ul of 0.5M EDTA, 2ul of 10mg/ml Proteinase K and 1ul of 
glycogen were added to each sample.  The samples were then incubated at 45°C for 1 
hour.  A phenol extraction and ethanol precipitation was then performed to clean the 
extracted DNA.  Phase lock tubes (VWR, cat number 713-2533) were prepared by 
centrifuging them at 13,000g at 4°C for 1 minute.  One volume of phenol:chloroform 
was added to the DNA in a phase lock tube and inverted to mix the solution.  The 
solution was then centrifuged at 13,000RPM at 4°C for 10 minutes.  The top aqueous 
layer was removed and transferred to a fresh microfuge tube.  50ul of 5M sodium 
chloride, 1,500ul of 100% ethanol and 1ul of glycogen were added to each tube.  The 
solution was then incubated at -20°C for 30 minutes before being centrifuged at 20,000g 
at 4°C for 10 minutes.  The supernatant was removed and the pellet was washed in 70% 
ethanol.  The tube was centrifuged at 20,000g at 4°C for 5 minutes, and the ethanol 
wash was then removed.  The pellet was left to dry before the DNA was resuspended in 
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21µl ddH20.  The concentration was measured on the Qubit®, before being stored at 
4°C. 
 
2.3.5. - Quantitative Real-Time PCR 
To check the efficiency of the ChIP qPCR was performed using Custom Plus 
TaqMan™ RNA Assays (Applied Biosystems) or primers used in conjunction with the 
Roche Universal Probe Library (Roche).  For more details see appendix 7.2. 
 
 
3µl of the ChIP sample was used as the template in a PCR reaction with 0.5µl primers 
and probe (at a 10mM concentration), 5µl 2x TaqMan™ Gene Expression Master Mix 
(Applied Biosystems, cat number 4369016) and 1.5µl distilled H2O. 
 
The PCR was performed and analysed on a 7900HT real time PCR system (Applied 
Biosystems).  The DNA was quantified against a standard curve and normalized as a 
percentage of the input. 
 
2.3.6. - Library Preparation for ChIP-Sequencing 
To check the fragment size of the ChIP samples 2µl of sample was run on a HS D1000 
ScreenTape on the Agilent 2200 Tapestation.  As the fragment size of the samples was 
quite large a Covaris E-220 ultrasonicator was used to shear the DNA, as per 
manufacturer’s instructions, to fragments of about 500bp in size.  Samples were 
sonicated with a duty cycle of 5%, a Peak Incident Power of 105 with 200 cycles per 
burst for 65 seconds.  This was repeated twice for each sample.  Samples were ethanol 
precipitated.  12ul of 5M sodium chloride, 360ul of 100% ethanol and 1ul of glycogen 
were added to each tube.  The solution was then incubated at -20°C for 30 minutes 
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before being centrifuged at 20,000g at 4°C for 10 minutes.  The supernatant was 
removed and the pellet was washed in 70% ethanol.  The tube was centrifuged at 
20,000g at 4°C for 5 minutes, and the ethanol wash was then removed.  The pellet was 
left to dry before the DNA was resuspended in 16µl ddH20.  The concentration was 
measured on the Qubit®, before libraries were prepared. 
 
Libraries were prepared using a DNA SMART™ ChIP-Seq Kit for Illumina (Clontech, 
cat number 634865), according to the manufacturers instructions.  The samples were 
heated to 94°C for 2 minutes to ensure that the DNA was single-stranded.  The samples 
were incubated on ice for at least 2 minutes, and then 3.25µl of DNA SMART buffer 
and 0.75µl were added to each sample.  The tubes were vortexed briefly to mix.  The 
samples were then incubated on a thermal cycler under the following conditions: 
 
37°C for 10 min 
65°C for 5 min 
4°C hold  
 
1µl of DNA SMART T-Tailing Mix and 1µl of Terminal Deoxynucleotidyl Transferase 
were added to each tube, and vortexed.  The samples were then incubated on a thermal 
cycler under the following conditions: 
 
37°C for 20 min 
70°C for 10 min 
4°C hold  
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2µl of DNA SMART Poly(dA) Primer was added to each sample, and heated to 94°C 
for 1 minute before being incubated on ice for at least 2 minutes.  6µl of DNA SMART 
Buffer, 6µl of DNA SMART Oligonucleotide Mix and 4µl of SMARTScribe Reverse 
Transcriptase were added to each sample, and vortexed to mix.  The samples were then 
incubated on a thermal cycler under the following conditions: 
 
42°C for 90 min 
70°C for 15 min 
4°C hold  
 
50µl of SeqAmp PCR Buffer (2x), 2µl of Forward PCR Primer (12.5M), 2µl of Reverse 
PCR Primer (12.5M) and 2µl of SeqAmp DNA Polymerase were added to each sample, 
and vortexed briefly to mix.  Different reverse primers were used for each sample so 
that the samples can be differentiated after sequencing.  The samples were then 
incubated on a thermal cycler under the following conditions: 
 
94°C for 1 min   
98°C for 15 sec 
55°C for 15 sec         15 Cycles 
68°C for 30 sec   
4°C hold 
 
The libraries were sized selected to enrich for sequences between 250 and 500bp.  75µl 
of AMPure XP beads (Beckman Coulter, cat number A62880) were added to each 
library, and mixed by pipetting at least 10 times.  Samples were incubated for 8 minutes 
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at room temperature.  The samples were placed on a Magnetic Separation Device for 
10-20 minutes (or until the solution has cleared).  25µl AMPure XP beads were added 
to new PCR tubes.  The sample tubes were left on the magnetic stand and the 
supernatant was transferred to the new PCR tubes containing the beads, and mixed by 
pipetting at least 10 times.  Samples were incubated for 8 minutes at room temperature.  
The samples were placed on a Magnetic Separation Device for 10-20 minutes (or until 
the solution has cleared).  The sample tubes were left on the magnetic stand and the 
supernatant was removed.  200µl of freshly made 80% ethanol was added to each 
sample, without disturbing the beads.  After 30 seconds the supernatant was carefully 
removed.  This ethanol wash was repeated once.  The samples were incubated for 3-5 
minutes (until the pellet was dry) at room temperature.  Once the pellet was dry the 
tubes were removed from the magnetic stand, and 20µl of Library Elution Buffer was 
added to each tube.  The samples were mixed by pipetting the beads up and down, and 
incubated for 5 minutes at room temperature.  The samples were placed on a Magnetic 
Separation Device for 2 minutes or until the solution had cleared.  The clear supernatant 
was transferred to a new tube and stored at -20°C.      
 
2.3.7. - Quantification of ChIP Library       
The libraries were quantified using qPCR comparing them against a set of standards 
using the KAPA SYBR® FAST ABI Prism qPCR kit (Anachem Ltd, cat number 
KK4835). 
 
2.3.8. - ChIP-Seq Data Analysis 
This was performed by Dr Nikolas Barkas. 
Raw read quality was assessed with FASTQC (online reference available only: 
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http://www.bioinformatics.babraham.ac.uk/projects/fastqc/).  Five base pairs were 
trimmed from the beginning of each read and 20 from the end as low sequence quality 
was observed in the corresponding sequencing cycles. 
 
Sequence reads were aligned to the mouse reference genome (mm10) using Bowtie2 (v. 
2.2.6 [148] [149]).  Duplicates were identified with the Picard Toolkit (v 1.140) 
MarkDuplicates command and subsequently filtered.  MACS2 
(http://liulab.dfci.harvard.edu/MACS/ reference macs1) was used to identify peaks at 
the q < 0.01 significance level.  Peaks that were identified in both replicates were used 
for subsequent analysis. 
 
2.3.9. – Parental Allele-Specific Binding Analysis 
This was performed by Dr Nikolas Barkas. 
Parental allele-specific binding was assessed by binomial testing, using a custom 
bioinformatics pipeline. For performance reasons, only reads of interest, which 
overlapped the previously identified CTCF or RAD21 binding sites, were extracted 
from the SAM files and used for subsequent analysis. 
 
Individual reads were assigned to one of the parental alleles using a custom Perl script, 
using the SAMtools Perl library. Each read was mapped as either derived from the 
reference sequence (Bl6) or from the FIX ME (MOLF_EiJ) allele on the basis of a SNP 
between the parental strains. If more than one SNP was present, the SNP with the best 
quality of read sequence was used. Reads were only considered for subsequent analysis 
if the Phred-scaled alignment mapping quality exceeded 20 and the base call quality at 
the SNP used for mapping of the read exceeded 5.  
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Paired reads were mapped to parental strains separately.  As paired reads are not 
independent data points, when they were in disagreement (<1%) the read pair was 
assigned on the basis of the best SNP in either of the two reads. 
 
Assigned reads were converted to maternally or paternally derived.  Counts of maternal 
and paternal reads were obtained on a per-region basis using MySQL.  Binding regions 
were only tested for parent-of-origin-specific expression if three or more reads could be 
mapped. 
 
Parental allele-specific binding was assessed using a two-sided binomial test 
(implemented in R) of the maternal-versus-paternal allelic read counts.  Regions were 
sorted by P-value score using MySQL.  The genome-wide significance of P-values was 
assessed by means of Bonferroni correction.   
 
2.4. – Chapter 4  
 
2.4.1. - DNA Extraction from ES Cells 
We received frozen cell pellets from our collaborators.  The pellets were resuspended in 
100µl of TE buffer (pH8.0).  1ml of Extraction Buffer was added to each sample, before 
they were incubated at 37°C for 1hr.  7µl of Proteinase K (to a final concentration of 
100µg/ml) was added to each sample and mixed gently.  The samples were then 
incubated at 50°C for 3hours, and swirled periodically.  They were then cooled to room 
temperature.  Phase lock tubes (VWR, cat number 713-2533) were prepared by 
centrifuging them at 13,000g at 4°C for 1 minute.  One volume of phenol:chloroform 
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was added to the DNA in a phase lock tube and inverted to mix the solution.  The 
solution was then centrifuged at 13,000RPM at 4°C for 10 minutes.  The top aqueous 
layer was removed and transferred to a fresh microfuge tube.  0.25 volumes of 7.5M 
ammonium acetate and 2 volumes of 100% ethanol were added to each tube.  The 
samples were centrifuged at 5,000g for 5 minutes.  The supernatant was removed and 
the pellet was washed in 70% ethanol.  The tube was centrifuged at 5,000g for 5 
minutes, and the ethanol wash was then removed.  The pellet was left to dry before the 
DNA was resuspended in 200µl TE buffer pH8.0.  Samples were then placed on a 
rocking platform at room temperature overnight.  Extracted DNA was stored at 4°C. 
 
2.4.2. - Restriction Digest 
9µg of DNA was digested with 3µl of enzyme and 12µl of appropriate buffer in a total 
volume of 114µl, at 37°C for 2hours.  An additional 6µl of enzyme was added to each 
tube before incubating at 37°C overnight.  The following morning the samples were 
heated to 65°C for 20 minutes, for all enzymes except SpeI which required heating to 








Table 2.2 – A summary of the restriction enzymes, and the conditions required for 
digestion.  All restriction enzymes, BSA and buffers used were purchased from New 
England Biolabs®, see appendix 7.3. for details. 
 









H13c probe XbaI 
 
4 + BSA 
(100µg/ml) 
H13c neo probe 
 
SpeI 4 + BSA  
(100µg/ml) 
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The DNA was concentrated into a suitable volume for loading on a gel.  300µl of 100% 
ethanol and 12µl of 3M sodium acetate was added to each sample.  Samples were then 
incubated at 4°C for 30 minutes.  They were then centrifuged at 13,000RPM at 4°C for 
20 minutes.  The supernatant was removed and the pellet was washed in 70% ethanol.  
The samples were centrifuged at 13,000RPM at 4°C for 10 minutes, and the ethanol 
wash was then removed.  The pellet was left to dry before the DNA was resuspended in 
25µl ddH2O.   
 
2.4.3. - Southern Blotting 
Samples were loaded onto a 1% agarose gel and electrophoresed at 110V until the DNA 
migrated from the wells into the gel.  Once this was achieved the voltage was lowered 
to 25V and the gel left to run overnight at room temperature.  The gel was imaged with 
a ruler aligned to the ladder, before being washed in denaturation buffer for 30 minutes, 
shaking gently at room temperature.  This was followed by two 15 minute washes in 
neutralisation buffer, again shaking gently at room temperature.  A capillary blot was 
then set up to transfer the DNA in the agarose gel onto a Hybond-N+ membrane 
(Amersham, cat number RPN 203B), using 20x SSC.  Once assembled this was left 
overnight (2-16hours).  The location of the wells were marked on the membrane with a 
pencil.  The membrane was then washed briefly in 2X SSC, before being left to dry for 
2hours at 80°C.  
 
The membrane was incubated in Church buffer containing 150µl of sheared Salmon 
sperm DNA rotating at 65°C overnight.  The Church buffer was replaced with fresh 
Church buffer plus Salmon sperm DNA.  25ng of the DNA probe was prepared, by 
boiling for 5 minutes before being incubated on ice.  4µl High –prime mix (Sigma 
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Aldrich, cat number 11585592001) and 3µl α32 P – dCTP (at 10µCi/µl) were added to 
the probe.  The labelled probe was incubated at 37°C for 1hr.  2µl of 0.2M EDTA was 
added, and the probe was incubated at 65°C for 10 minutes.  The probe was transferred 
to a spin column and centrifuged at 1,100g for 4 minutes, before being incubated at 
95°C for 10 minutes.  The probe was added to the membrane, and incubated at 65°C 
overnight. 
 
The membrane was washed twice in wash solution 1 at 65°C for 15 minutes.  The 
membrane was monitored for radioactivity.  If the signal was low and specific the 
membrane was then wrapped in saran wrap and placed in a cassette and left to develop.  
If the label was still non specific the membrane was then washed twice in wash solution 
2 at 65°C for 1hour, checking the specificity of the label between washes. 
 
2.4.4. - Long-Range PCR 
 An Expand Long Template PCR System kit was used (Roche, cat number 
11681842001), according to the manufacturers instructions.  1µl DNA from the H13 
knock-out Embryonic Stem cell samples was added to 1.5µl 10µM Forward primer, 
1.5µl 10µM primer Reverse primer, 10mM dNTP, 5µl supplied buffer 1, 0.5µl DNA 
polymerase mix and 40µl H2O.  The reactions were then incubated on a PCR machine 
under the following conditions: 
 
94°C for 2 min   
94°C for 10 sec 
X°C for 30 sec         10 Cycles 
68°C for 4 min   
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94°C for 15 sec 
X°C for 30 sec                                 20 Cycles 
68°C for 4 min + 20sec/cycle   
68°C for 20min 
 
The annealing temperatures and buffers needed for each primer set are summarised in 
table 2.3. 
 
Table 2.3 – The primer name, region amplified, template, buffer and annealing 
temperature for each long range PCR reaction. 
 
2.4.5. – Gel Separation of PCR Products and DNA Extraction 
The products of the PCR reactions were electrophoresed on a 1% agarose gel at 100V 
for about 90minutes.  The gels were then imaged and the appropriate bands extracted.  
The DNA was recovered using a MinElute Gel Extraction Kit (Qiagen™, cat number 
28604) and eluted in 10µl EB buffer, according to the manufacturer’s instructions.  The 
DNA was quantified using a NanoDrop™.   
 
2.4.6. - Ligation 
The ligation reaction was set up on ice.  Insert DNA was added to vector DNA, 1µl of 
10x Rapid ligation buffer, 1µl of T4 DNA ligase (Promega™, cat number M1801) and 
Primers Target Annealing 
Temperature 
(°C) 
Buffer Template Product 
Size 
(Kb) 
H13 Screen F1 
H13 Screen 
neo R1 


















ddH2O to a total of 10µl.  The following equation was used to work out the 
concentration of insert to add.  For most of the ligation reactions 50ng of vector DNA 
was used.  The ligation was incubated at 4°C overnight.   
 
ng of vector X kb size of insert   X  insert:vector molar ratio = ng of insert to add 
kb size of vector 
 
2.4.7. – Transformation into Chemically Competent Cells 
3µl of the ligation reaction was then added to 50µl competent E.coli cells on ice, and 
swirled to mix.  The cells were incubated on ice for 30 minutes before being heat 
shocked at 42°C for 45 seconds.  The cells were then returned to the ice for 2 minutes.  
100µl of S.O.C. medium (Invitrogen, cat number 46-0821) was aseptically added to the 
cells, and they were incubated at 37°C for 1hour shaking.  After 1hour the cells were 
plated out onto Ampicillin (200µl of 50µg/ml in 100mls), IPTG (8.4µl of 1M in 
100mls), X-Gal (100µl of 40mg/ml in 100mls) plates and left overnight at 37°C.  
Colonies were then picked and incubated in 5ml LB and Ampicillin (0.05µg/ml) 
overnight at 37°C shaking. 
 
2.4.8. - DNA Extraction from Bacterial Cultures 
DNA was extracted from a single colony grown overnight in 5mls LB and appropriate 
antibiotic, using a Promega SV Miniprep Wizard Plus Kit (Promega, cat number 





2.4.9. - Sequencing 
To prepare the samples for sequencing 1µl of DNA was added to 2µl of 5x sequencing 
buffer, 0.4µl 10µM primer, 6.1µl H2O and 0.5µl Big Dye Terminator v3.1 (Invitrogen, 
cat number 4337454).  This was added to each well of a 96 well plate.  The plate was 
then run on a PCR machine under the following conditions: 
 
96°C for 1 min 
96°C for 30 sec 
58°C for 15 sec       30 Cycles 
62°C for 1 min 
 
To precipitate the DNA 30µl of 100% ethanol and 1µl of 3M sodium acetate was added 
to each well.  The plate was incubated at 4°C for 20 minutes.  The plate was centrifuged 
at 3060g at 4°C for 20 minutes, before the ethanol was removed and replaced with 70% 
ethanol.  The plate was incubated at 4°C again, this time for 5 minutes, before being 
centrifuged at 3060g at 4°C for 10 minutes.  The ethanol was removed and the plate was 
left to dry at room temperature for 20 minutes.  The pellets were then resuspended in 
10µl Hi-Di formamide (Applied Biosystems, cat number 4311320), and 10µl 1mM 
EDTA was added to empty wells.  The plate was incubated at 94°C for 2 minutes and 
then cooled on ice before being sequenced using a 3730xl Sanger sequencer machine.  
Sequence traces were analysed using Sequencer. 
 
2.4.10. – Generation of Constructs 
There are three constructs to assess transcriptional interference at the H13/Mcts2 locus.  
All of the constructs contain UCOE (ubiquitous chromatin opening element) allowing 
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transcription from the construct regardless of its integration site in the genome.  The 
three constructs each contain different combinations of the introns and exons of H13 
upstream of Mcts2.  In place of Mcts2 the three contain a minimal promoter linked to 
the expression of mCherry.  This promoter will be under the control of a tetracycline 
inducible element.  All three constructs contain the sequence of intron 4 of H13 
immediately downstream of Mcts2 and the complete sequence of exon 5, allowing 
splicing to occur from exon 4 onto exon 5.  All of the constructs also contain eGFP 
located after exon 5, as a readout of transcription through exon 5.  When the construct is 
transfected into cells it will allow us to determine if it is transcription of the internal 
gene that stimulates the use of upstream poly (A) sites, through the readout of either 
mCherry or eGFP.  I would expect to see eGFP expression when the cells aren’t 
exposed to tetracycline, as there should be no transcription from the minimal promoter, 
allowing use of the down-stream poly (A) sites.  In the presence of tetracycline when 
the minimal promoter is stimulated I would expect to see expression of mCherry and a 
decrease in the expression of GFP as some (if not all) transcripts terminate at a poly (A) 








Figure 2.1 – Construct for investigating the affect of an internal promoter on the 
transcription of the host gene.  The star shows the location of the poly (A) site used to 
generate the shorter transcripts in the H13/ Mcts2 locus that this construct is based on. 
x1, x2, x3, x4 and x5 are the corresponding exons from H13.  i1, i2,i3 and i4 are based 
on the corresponding introns in H13.  Due to the large size of i1 and i2 I have used the 
first and last 250bp of each of these introns. 
 
 
UCOE x1 x2 x3 i3 x4 i4 pTRE3G mCherry x5 eGFP i4 Poly(A) 




The constructs were generated through a series of cloning steps (summarised in Figure 
4.8 and section 2.4.10.1 later in the Materials and Methods) requiring a large number of 
unique restriction sites allowing us to control the addition of each fragment to the 
construct, and if necessary, allow its easy removal, without disrupting the rest of the 
construct.  Cloning steps two and three (Figures 4.9 and 4.10 respectively) required the 
replacement of the multiple cloning site (MCS) of two vectors with ‘linker’ sequences 
designed to contain the required restriction sites.  As these steps required the insertion 
of a small (85-150bp) fragment into the vector a large amount of DNA was digested, 
and the digests were electrophoresed through low melting point (LMP) agarose gels to 
maximise the yield of DNA recovered.  These steps were performed in parallel because 
different vectors were being used for these steps. 
 
Steps six (Figure 4.11), eight (Figure 4.12) and nine (Figure 4.13), and assembling the 
H13 sequence (Figure 4.13) required PCR amplification of genomic or cDNA with 
primers containing the required restriction enzyme sites for inserting the products into 
the correct place in the vectors.   
 
Steps four (Figure 4.12), 12 (Figure 4.14) and 14 (Figure 4.15) required the use of only 
one restriction enzyme for the insertion of the fragments into the vector.  This meant 
that in addition to checking that the fragment had been incorporated into the vector, it 
was also necessary to check that the insert was correctly orientated.  To screen for this 
we used a double restriction enzyme digest, with one restriction site located towards one 
end of the insert and another located in the vector.  The different sizes generated by the 




Once all steps were complete the entire construct was sequenced enabling us to verify 
that we had successfully generated both versions of the construct as designed.   
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Figure 2.2 – Summary of the cloning steps required to generate the constructs.  The 
restriction enzymes required for each cloning step are shown.  The antibiotic resistance 
of each plasmid has been included.  UCOE is an Ubiquitously acting Chromatin 
Opening Element.  mCherry is a red fluorescent protein. eGFP is an enhanced Green 
Fluorescent Protein. Green circles: step numbers, representing the order in which 
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2.4.10.1. – Source of Components 
mCherry in pMK-RQ, H13i3 modified sequence in pMA-T, AM linker sequence in 
pMA-T, KP linker sequence in pMA-T, BH linker sequence in pMK-RQ, KS linker 
sequence in pMA-RQ, H13polyA sequence in pMA-T and the x1i3 sequence in pMK-
RQ were generated by GeneArt AG (Life TechnologiesTM).  The pTRE3G promoter 
sequence was supplied in the Tet-On 3G Inducible Expression System (Clontech 
Laboratories Inc, cat number 631168) kit.  An aliquot of pKS+ was generously donated 
by Dr Kirupa Sathasivam, a non-clinical research fellow in the Department of Medical 
and Molecular Genetics.  pCMV-eGFP and pCMV-Tag1 were generated by Dr Mike 
Cowley, a post-doc in the lab.  All the intronic and exonic sequences in the construct 























































1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 
12, 13, 14 
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 
12, 13, 14 
Ethanol precipitation of DNA 3  
Gel electrophoresis 





Transformation into chemically 
competent cells and DNA 




Stages of each cloning step Cloning step requiring each stage 
1, 2, 3, 4, 5, 6, 7, 8, 9, 
10, 11, 12, 13, 14 
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 
12, 13, 14 
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 
12, 13, 14 
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 
12, 13, 14 
Ethanol Precipitation of DNA 2, 4 
6, 8, 9, 10  
12 
12 
Dephosphorylation of plasmid 4, 6, 8, 9, 12, 14 
Removal of 3’ and 5’ extensions 7 
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2.4.10.2. - RNA Extraction 
An RNeasy Mini Kit (Qiagen, cat number 74104) was used according to manufacturers 
instructions.  600µl of buffer RLT was added to 30mg of tissue, and homogenised for 
30 seconds using a rotor-stator homogeniser.  The lysate was centrifuged at full speed 
for 3 minutes.  The supernatant was transferred to a fresh microfuge tube.  1x the 
sample volume of 70% ethanol was added, and pipetted to mix the two well.  Up to 
700µl of the sample was transferred to an RNeasy spin column, placed in a 2ml 
collection tube.  The sample was centrifuged at 10,000 RPM for 15 seconds, and the 
flow-through was discarded.  This was repeated until the entire sample had been passed 
through the column.  350µl of buffer RW1 was added to the column, and the column 
was centrifuged at 10,000 RPM for 15 seconds, and the flow-through discarded.  10µl 
of DNase I stock solution was diluted in 70µl Buffer RDD, and mixed by inverting the 
tube.  The DNase I incubation mix was added to the column membrane and incubated 
on the bench for 15 minutes.  350µl Buffer RW1 was added to the column, and the 
column was centrifuged at 10, 000 RPM for 15 seconds, and the flow-through 
discarded.  500µl Buffer RPE was added to the column, and the column was centrifuged 
at 10, 000 RPM for 15 seconds, and the flow-through discarded.  500µl Buffer RPE was 
added to the column, and the column was centrifuged at 10,000 RPM for 2 minutes.  
The column was moved to a fresh 2ml collection tube, and centrifuged at full speed for 
1 minute.  The column was moved to a fresh 1.5ml microfuge tube.  40µl RNase-free 
water was added directly to the column, and incubated on the bench for 1 minute.  The 
sample was centrifuged at 10,000 RPM for 1 minute.  The RNA was quantified using a 




2.4.10.3. - cDNA Synthesis 
1µg of RNA was added to 1µl 10mM dNTP’s (Life TechnologiesTM, cat number 
R0191), 1µl oligo dT primer (500µg/µl) (Life TechnologiesTM, cat number 18418020), 
and nuclease-free water was added to a total volume of 13µl.  The RNA was heated to 
65°C for 5 minutes.  The RNA was incubated on ice for at least 1 minute while 4µl of 
5x first strand buffer, 1µl of 0.1M DTT and 1µl of nuclease-free water were added.  The 
5 x first strand buffer and 0.1M DTT were supplied with the Superscript II RT.  The 
samples were then incubated at 42°C for 2 minutes.  1µl of Superscript II RT 
(Invitrogen, cat number 18064-014) was added, and the samples incubated at 42°C for 
50 minutes.  The samples were heated to 70°C for 15 minutes, and the cDNA generated 
was stored at -20°C. 
 
2.4.10.4. – DNA Amplification  
2.4.10.4.1. – PCR 
1µl DNA was added to 0.5µl 10µM Forward primer, 0.5µl 10µM Reverse primer, and 
18µl 1.1x Reddy Mix (Thermo Scientific, cat number AB-0608/LD).  The reactions 
were then incubated on a PCR machine under the following conditions: 
 
94°C for 2 min   
94°C for 30 sec 
X°C for 30 sec          X Cycles 
72°C for 1 min   
72°C for 10min 
 
DNA was amplified under the conditions specified in Table 2.4. 
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54 35 Modified 
H13i3 
550 
Table 2.4 - The primer name, region amplified, template, annealing temperature and 
cycle number for each PCR reaction. 
 
 
2.4.10.4.2. – Long-Range PCR  
According to the protocol in section 2.4.4. with the following alterations.   
 
The extension time for the PCR is 2 minutes, instead of 4 minutes.  The cycle number 
for the second round of PCR is 25, instead of 20.  The annealing temperatures and 
buffers needed for each primer set are summarised in table 2.5. 
  
Primers Target Annealing 
Temperature 
(°C) 




i3-i4 56 1 BxC nb Brain 2.4 
SH_i3_F1 
SH_i3_R 
i3 58 3 BxC nb Brain 1.6 
SH_x3-i3_F 
SH_i3_R 
x3-i3 58 1 BxC nb Brain 2.7 
Table 2.5 – The primer name, region amplified, template, buffer and annealing 
temperature for each long range PCR reaction. 
 
2.4.10.5. – DNA Extraction from PCR Products 
DNA was extracted from PCR products using the MinElute PCR Purification Kit 
(Qiagen™, cat number 28004).  5 volumes of buffer PBI were added to 1 volume of the 
PCR reaction, and placed in a MinElute column in a 2ml collection tube.  The column 
was centrifuged at 10,000g for 1 minute, and the flow-through discarded.  750µl of 
buffer PE was added to the column, and the column was centrifuged at 10,000g for 1 
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minute, and the flow-through discarded.  The column was centrifuged at 10,000g for 1 
minute.  The column was moved to a fresh 1.5ml microfuge tube, and 10µl of buffer EB 
was added to the centre of the membrane of the column.  The column was left to stand 
for 1 minute, and then centrifuged at 10,000g for 1 minute.  The DNA was quantified 
using a NanoDrop™. 
 
2.4.10.6. – Restriction Digest 
DNA was digested for 1hour at 37°C, unless otherwise specified.  Samples were 
digested in 1/10 of the total volume of appropriate NEBuffer (with BSA if required), 
using 1µl each of appropriate restriction enzymes, unless otherwise specified.
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  Amount 








 500ng BamHI-HF 
and XhoI 
1µl of each 
4 and BSA 
(100µg/ml) 
1 hr  
 





pTRE3G 1µg BamHI-HF 
and SalI  
1µl of each 
4 1 hr  
 
KS-pMA-RQ 3µg KpnI and 
SacI 
3µl of each 












2µg KpnI and 
SacI 
3µl of each 
1 and BSA 
(100µg/ml) 
Overnight 
AM-pMA-T 500ng AseI and 
MluI 
1µl of each 
3 1 hr  
 
3 –  
Cloning the 
AM linker into 
pCMV-Tag1 pCMV-Tag1 1µg AseI and 
MluI 
1µl of each 






















2µl of each 
4 and BSA 
(100µg/ml) 
1 hr 5 –  
Cloning 
pTRE3GmChe
rry (product of 




pCMV-AM 1µg BamHI-HF 
and XhoI 
2µl of each 
4 and BSA 
(100µg/ml) 
1 hr 
 i4x5 1µg AsiSI and 
FseI 
1µl of each 
4 and BSA 
(100µg/ml) 









1µg AsiSI and 
FseI 
1µl of each 





1µg EcoRI and 
XmaI 
1µl of each 
4 and BSA 
(100µg/ml) 








1µg EcoRV and 
XmaI 
1µl of each 






2µg MluI and 
NotI 
2µl of each 
 






1µg MluI and 
NotI 
2µl of each 
3.1 2 hrs 
i3i4 2µg MluI and 
XhoI 
2µl of each 









1µg MluI and 
XhoI 
2µl of each 
3.1 1 hr 
pMAT-H13 
sequence 
1µg SalI-HF and 
XhoI 
1µl of each 











1µg SalI-HF and 
XhoI 
1µl of each 
3.1 1 hr 
MA892 2µg KpnI 
2µl 
1 and BSA 
(100µg/ml) 


















2µg AgeI and 
PacI 
2µl of each 
1 and BSA 
(100µg/ml) 












2µg AgeI and 
PacI 
2µl of each 























CutSmart 2 hrs 
Table 2.6 – Summary of digest conditions for generating fragments for ligation.  All 
restriction enzymes, BSA and buffers used were purchased from New England 
Biolabs®, see appendix 7.3. for details. 
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Digest Cloning Step 
Amount 





1 –  
Cloning mCherry into the 
pTRE3G plasmid 
 300ng BamHI-HF 
and XhoI 
1µl of each 
4 and BSA 
(100µg/ml) 
1 hr  
 
2 –  
Cloning the KS linker 
sequence into pBluescript 
KS 
300ng KpnI and 
SacI 
1µl of each 




3 –  
Cloning the AM linker into 
pCMV-Tag1 
3µg AseI and 
MluI 
3µl of each 
3 1 hr  
 
 
4 –  
Cloning eGFP into 
pBluescript KS-KS (product 
of step 2) 
1µg BglII 
6µl  
3 1 hr 
5 –  
Cloning pTRE3GmCherry 
(product of step 1) into 




1µl of each 
4 and BSA 
(100µg/ml) 
1 hr 
6 –  
Cloning i4x5 into 
pBluescript KS-eGFP 
(product of step 4) 
500ng AsiSI and 
FseI 
1µl of each 
4 and BSA 
(100µg/ml) 
2 hrs 
8 –  
Cloning modified H13i3 
into pMAT-KP 
500ng NotI and 
MluI  
1µl of each 
3.1 2 hrs 
9 –  
Cloning i3x4i4 into  pMAT-
modi3 (product of step 8) 
500ng MluI and 
XhoI 
1µl of each 
3.1 1 hr 
11 –  
Cloning H13 sequence into 
pCMV-
modi3i3i4pTRE3GmCherry 




3.1 1 hr 
12 –  
Cloning UCOE into pCMV-
H13SeqpTRE3GmCherry 
(product of step 11) 
500ng PacI and 
XbaI 
1µl of each 
CutSmart 1 hr 
13 –  
Cloning i4x5eGFP into 
pCMV-
UCOEH13SeqpTRE3GmCh
erry (product of step 12) 
 
 
500ng AgeI and 
PacI 
1µl of each 




14 –  
Cloning poly(A) into 
pCMV-
UCOEH13SeqpTRE3GmCh
erryi4x5eGFP (product of 
step 13) 
500ng PacI CutSmart 1 hr 
Table 2.7 – Summary of digests to check that the cloning was successful.  All restriction 
enzymes, BSA and buffers used were purchased from New England Biolabs®, see 
appendix 7.3. for details. 
 
2.4.10.7. – Removal of 3’ and 5’ Extensions 
4µl of Mung Bean Nuclease buffer and 1µl of Mung Bean Nuclease (New England 
Biolabs®, cat number M0250) were added to the digested pBluescript i4x5-eGFP, to a 
total of 40µl.  The sample’s were incubated for 30 minutes at 30°C.  To inactivate the 
nuclease the samples were subjected to a phenol:chloroform extraction. 
 
Phase lock tubes (VWR, cat number 713-2533) were prepared by centrifuging them at 
13,000g at 4°C for 1 minute.  One volume of phenol:chloroform (40µl) was added to the 
DNA in a phase lock tube and inverted to mix the solution.  The solution was then 
centrifuged at 13,000RPM at 4°C for 10 minutes.  The top aqueous layer was removed 
and transferred to a fresh 1.5ml microfuge tube.  The DNA was then extracted using an 
ethanol precipitation. 
 
2.4.10.8. – Dephosphorylation of Vector 
To stop the vector self-ligating, the digested sample was treated with Antarctic 
Phosphatase (New England Biolabs®, cat number M0289S).  1/10 of the total volume 
of Antarctic phosphatase buffer and 3µl of Antarctic Phosphatase were added to the 
digested vector.  The sample was incubated for 1 hour at 37°C, before being heated to 
70°C for 5 minutes. 
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2.4.10.9. – Ethanol Precipitation of DNA 
3 times the volume of 100% ethanol and 1/10 volume of 3M sodium acetate was added 
to each sample.  Samples were incubated at 4°C for 30 minutes.  They were then 
centrifuged at 13, 000RPM at 4°C for 20 minutes.  The supernatant was removed and 
the pellet was washed in 70% ethanol.  The samples were centrifuged at 13,000RPM at 
4°C for 10 minutes, and the ethanol wash was removed.  The pellet was left to dry and 
the DNA was resuspended in 15µl ddH2O.   
 
2.4.10.10. – Gel Separation of Digest Products and DNA Extraction 
The digested samples were then loaded on either an agarose gel or a LMP agarose gel 
packed in ice (Life TechnologiesTM, cat number 16520-050), and electrophoresed.  The 
gels were then imaged and the appropriate bands extracted.  The DNA was recovered 
using a MinElute Gel Extraction Kit (Qiagen™, cat number 28604) or, for the last 
cloning step, a QIAEX II Gel Extraction Kit (Qiagen™, cat number 20021) and eluted 
in 10µl EB buffer, according to the manufacturer’s instructions.  The DNA was 
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Table 2.8 – Summary of type of gel and conditions used to separate out the fragments of 
interest from the digestion reaction. 
 
 
2.4.10.11. – Ligation 
According to the protocol in section 2.4.6.  
 
2.4.10.12. – Transformation into Chemically Competent Cells 
According to the protocol in section 2.4.3.7. with the following alterations. 
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For cloning step eight 10µl of the ligation reaction was added to 150µl competent E.coli 
cells, which were then added to 300µl of S.O.C. medium (Invitrogen, cat number 
15544-034), following the protocol above.  For cloning step 14 One Shot® Top10 















Table 2.9 – Table of antibiotic resistance for plasmids used to generate the constructs, 
and the concentrations the antibiotics were used at. 
 
2.4.10.13. - DNA Extraction from Bacterial Cultures 
According to the protocol in section 2.4.8. 
  
2.4.10.14. – Sequencing  
According to the protocol in section 2.4.9.  For primer details see appendix 7.2. 
 
2.4.10.15. – Generating Glycerol Stocks 
3µl of a positive sample was then transformed into competent E.coli cells (as above), 





2.4.11. – Generation of Tetracycline-responsive Cell Lines 
Using the Tet-On 3G Inducible Expression System (Clontech Laboratories Inc, cat 
number 631168). 
 
2.4.11.1. – Transfection 
200,000 3T3 or HEK 293 cells were seeded into 1 well of a 6 well plate in complete 
growth medium, and left overnight.  Xfect polymer was thawed and vortexed.  For each 
well 2µg pCMV-Tet3G was added to Xfect reaction buffer, to a total of 100µl, and 
vortexed for 5 seconds.  0.6µl Xfect polymer was added to the diluted DNA, and 
vortexed for 10 seconds, before being incubated at room temperature for 10 minutes.  
The entire 100.6µl mixture was added drop by drop to the well.  The plate was rocked 
gently to mix, before being incubated at 37°C for 4hrs.  The medium was then removed 
from the well and replaced with 2mls of complete growth medium.   
 
48hrs later each well was split into four 10cm dishes.  48hrs later G418 sulphate 
(Geneticin® Selective Antibiotic; Life technologies, cat number 11811-023) was added 
to the medium at a concentration of 50µg/ml to select for cells that had taken up the 
pCMV-Tet3G plasmid.  The medium was changed every four days, until G418 resistant 
colonies appeared, and were visible to the naked eye. 
 
Cloning discs (Sigma Aldrich, cat number Z374431-100EA) were soaked in trypsin.  
The medium was removed from the 10cm dish.  Sterile tweezers were used to place 
individual cloning discs over each discrete colony.  The dish was incubated at 37oC for 
a few minutes, until cells had detached from the plate and attached onto the disc.  Sterile 
tweezers were used to move each cloning disc to a well of a 24 well plate, already 
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containing medium containing G418.  Once cells had migrated off the cloning disc into 
the well, the disc was removed.  When the well was confluent the cells were split and 
transferred into 3 wells of a 6 well plate for screening for their response to doxycycline 
using the Dual- luciferase reporter assay.  
 
2.4.11.2. – Dual-luciferase Reporter Assay 
Transfect as in the first paragraph of 2.4.11.1, but use 5µg of pTRE3G-Luc and 0.5µg 
Renilla, and 1.5µl Xfect Polymer per well.  4hrs after the DNA:Xfect polymer mix has 
been added to the cells, the medium is removed and replaced with 2mls of complete 
growth medium, either with or without 1µg/ml doxycycline.  After 24hrs the cells are 
washed once in 1xPLB (Passive Lysis Buffer).  500µl of 1xPLB is added to each well, 
and the plates were rocked gently at room temperature for 15 minutes.  The cells were 
transferred to 1.5ml microfuge tubes and stored at -80oC for at least 24 hrs.  Once the 
lysates were thawed 20µl was added to three wells of a 96 well plate.  The plate was 
loaded onto a single injector luminometer.  50µl of LARII (luciferase assay substrate re-
suspended in luciferase assay buffer) was added to each well and the firefly luciferase 
activity was measured.  50µl of Stop and Glo reagent (50x Stop and Glo substrate 
diluted in Stop and Glo buffer) was added to each well, and the Renilla luciferase 
activity was measured.  The Dual-luciferase reporter assay was performed using the kit 
from Promega, cat no. E1910. 
 
2.4.11.3. – Transfection of pCMV-A and pCMV-B into HEK 293 Cells 
Transfect as in the first paragraph of 2.4.11.1, but use 2µg of pCMV-A or pCMV-B, 
and 0.6µl Xfect Polymer per well.  4hrs after the DNA:Xfect polymer mix has been 
added to the cells, the medium is removed and replaced with 2mls of complete growth 
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medium, either with or without 1µg/ml doxycycline.  After 24hrs the cells are washed 
once in PBS and collected for RNA and DNA extraction. 
 
2.4.11.4. – DNA Extraction from Transfected Cells 
A DNeasy Blood and Tissue Kit (Qiagen, cat number 69504) was used according to 
manufacturers instructions.  The cells were washed in PBS.  The pellet was resuspended 
in 200µl of PBS.  20µl of proteinase K and 4µl of RNase A were added to the sample, 
vortexed to mix, and then incubated at room temperature for 2 minutes.  200µl of Buffer 
AL was added to the sample, vortexed to mix, and then incubated at 56oC for 10 
minutes.  200µl of ethanol was added to the sample, and vortexed to mix, before the 
entire sample was transferred into a DNeasy Mini spin column.  The sample was 
centrifuged at 6,000g for 1 minute, and the flow-through was discarded.  500µl of 
Buffer AW1 was added to the sample.  The sample was centrifuged at 6000g for 1 
minute, and the flow-through was discarded.  500µl of Buffer AW2 was added to the 
sample.  The sample was centrifuged at 6,000g for 3 minutes, and the flow-through was 
discarded.  The DNeasy Mini spin column was transferred to a fresh 1.5ml microfuge 
tube.  200µl of Buffer AE was added directly to the membrane of the column, and 
incubated at room temperature for 1 minute.  The sample was centrifuged at 6,000g for 
1 minute to elute the DNA.  The DNA was quantified using a NanoDrop™ and stored at 
-20oC. 
 
2.4.11.5. – Quantitative Real-time PCR  
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Genomewide Identification of Co-localisation Sites for CTCF, cohesin, 
ATRX and MeCP2 
 
3.1. - Introduction  
Previous studies from Professor Oakey’s laboratory have used a ChIP-Seq (chromatin 
immunoprecipitation followed by high-throughput sequencing) approach to map 
genomewide the occupancy of protein binding sites by the insulator protein CTCF, and 
by cohesin, the protein complex associated with both cell division and transcriptional 
regulation [22].  ChIP-Seq was performed on postnatal day 21 BxC and CxB mouse 
brain tissue, using antibodies specific for CTCF and the Rad21 subunit of cohesin.  
CTCF and cohesin were shown to bind together at around 27,000 sites across the 
genome, as well as independently at just over 22,000 sites for CTCF and 25,000 sites 
for cohesin.  This is consistent with previous studies showing both independent and co-
ordinated roles for these two factors.  We found that the majority of DMR’s are bound 
by CTCF, or cohesin, or both CTCF and cohesin, and that CTCF only binds in an allele-
specific manner at or near imprinted loci, but not at all imprinted loci.  No allele-
specific binding was detected for cohesin, although when cohesin was bound with 
CTCF when CTCF was bound in an allele-specific manner cohesin tended to bind on 






















Table 3.1 – Summary of the binding of CTCF and cohesin to gDMR’s in the mouse.  M 
= maternal, P = paternal, Bi = biallelic.  Adapted from Prickett et al, 2013 [22].  
 
It has been shown that ATRX (a chromatin remodeler) and MeCP2 (a methylation-
sensitive DNA binding protein) bind with CTCF and cohesin at many loci across the 
genome, including at the H19 ICR and the Gtl2/Dlk1 imprinted regions [147].  It is 
currently unknown whether these ‘super complexes’ provide a general mechanism for 
gDMR Information (WAMIDEX) CTCF and cohesin Binding Determined 
by ChIP-Seq 
gDMR gDMR Position Methylated Allele CTCF Cohesin 
Binds Allele Binds Allele 
Bound by CTCF and cohesin precisely colocalised at gDMR 
GRB10 Chr11: 12, 025, 482 – 12, 025, 787 M Yes - Yes - 
H19/IGF2 Chr7: 142, 580, 263 – 142, 582, 519 P Yes M Yes M 
INPP5F_V2 Chr7: 128, 688, 274 – 128, 688, 642 M Yes Bi Yes Bi 
Mcts2 Chr2:152, 686, 755 -152, 687, 275 M Yes - Yes - 
MEST Chr6: 30, 736, 488 – 30, 739, 335 M Yes P Yes P 
NNAT Chr2: 157, 560, 050 – 157, 561, 662 M Yes - Yes - 
PEG13 Chr15: 72, 806, 335 – 72, 811, 649 M Yes P Yes P 
Plagl1 (Zac1) Chr10: 13, 090, 470 – 13, 090, 798 M Yes Bi Yes Bi 
Bound by CTCF and cohesin colocalised at gDMR 
Cdh15 Chr8: 125, 387, 861 – 125, 390, 344 M Yes P Yes - 
NESPAS Chr2: 174, 295, 707 – 174, 300, 981 M Yes - Yes - 
Zrsr1 Chr11: 22, 971, 842 – 22, 972, 319 M Yes - Yes Bi 
ZIM2 (Peg3) Chr7: 6, 727, 576 – 6, 732, 116 M Yes P Yes P 
Bound by CTCF only 
PEG10 Chr6: 4, 747, 209 – 4, 747, 507 M Yes - No - 
Meg3/Dlk1 Chr12: 109, 523, 353 – 109, 530, 779 P Yes - No - 
IMPACT Chr18: 12, 972, 197 – 12, 973, 741 M Yes - No - 
Bound by cohesin only 
IGF2R/AIR Chr17: 12, 741,297 – 12, 742, 707 M No - Yes - 
GNAS-EXON1A Chr2: 174, 326, 930 – 174, 329, 007 M No - Yes - 
KCNQ1OT1 Chr7: 143, 295, 155 – 143, 295, 492 M No - Yes - 
SNURF/SNRPN Chr7: 60, 004, 992 – 60, 005, 415 M No - Yes - 
No binding 
Nap1l5 Chr6: 58, 906, 696 – 58, 907, 062 M No - No - 
Rasgrf1 Chr9: 89, 879, 568 – 89, 879, 853 P No - No - 
Slc38a4? Chr15: 96, 885, 270 – 96, 886, 284 M No - No - 
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the regulation of gene expression, or whether they play a role specific to the regulation 
of gene expression from imprinted loci.  By investigating the co-occupancy and 
potential interaction of these four proteins genomewide we hope to provide evidence 
that will lend support to one of these hypotheses, improving our understanding of the 
mechanisms underlying this type of regulatory process. 
 
At least two alternative models have been proposed to explain how the interaction of 
ATRX, MeCP2, CTCF and cohesin at a single genomic location can regulate 
transcription.  These are illustrated in Figure 3.1, using the H19 DMR as an example.  
This locus has been studied in depth for CTCF binding [24] and gene expression [23] 
and so provides an excellent model to draw from.  In both proposed models, CTCF is 
bound to the un-methylated maternal allele, and interacts directly with cohesin through 
the SCC3 subunit [150].  In the ‘Imprinting super-complex’ model (Figure 3.1) ATRX 
and MeCP2 interact with this complex on the maternal un-methylated allele.  It is 
proposed that ATRX interacts with the SMC1 subunit of cohesin [147].  The position of 
MeCP2 is as yet unclear in the literature, although it is likely to interact with ATRX, 
since these proteins have been shown to interact in other studies [71].  In the 
‘Differential binding’ model (Figure 3.1) ATRX and MeCP2 localise to the methylated 
paternal allele, away from the CTCF-cohesin complex on the maternal allele.  This 
model takes into account MeCP2’s preference for binding to methylated regions of 
DNA [98]; this arguably gives credence to the ‘Differential binding’ model since this 
preference is ignored by the ‘Imprinting Super-Complex’ model (which has MeCP2 





















Figure 3.1 – Potential models of interaction between CTCF, cohesin, ATRX and 
MeCP2, shown at the H19 DMR.  The paternal allele is methylated (black circles) and 
the maternal allele is un-methylated (white circles).  The arrows show the direction of 
transcription (reproduced from McCole, 2010 [151]).  
 
We are therefore interested in clarifying how MeCP2 and/or ATRX interact with CTCF 
and cohesin.  It is known that the four proteins form complexes at some imprinted loci 
[147], and by surveying genomewide we aim to determine whether this is a more widely 
adopted mode of gene regulation that occurs at other imprinted loci.  We would also 
like to assay co-occupancy of these four proteins to find out if their interaction is 
limited to imprinted gene loci or if it occurs more widely across the genome.  To 
determine this we undertook ChIP-Seq experiments using antibodies specific for ATRX 
and MeCP2, in order to locate these proteins on the genome.  We then compared these 
results with those generated from ChIP-Seq experiments performed on CTCF and 










‘Imprinting super-complex’ ‘Differential binding’ 
ATRX Cohesin CTCF MeCP2 
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are genomic regions where sequencing reads for the protein of interest pile up on top of 
one another, implying a binding site for the protein. 
 
To allow us to determine the interactions of ATRX, MeCP2, CTCF and cohesin in the 
context of imprinted genes we used tissues from intercross mice.  These are the 
offspring of parents from different inbred sub-species of mice; genomic sequence 
differences between the two sub-species thus make it possible to determine the parent of 
origin of each allele of an imprinted gene (Figure 3.2).  In this work we utilised mice 
generated from crosses between Mus musculus castaneus and C57BL/6 (both with Mus 
musculus castaneus as the mother and C57BL/6 as the father, and the reciprocal cross).  
Single nucleotide polymorphisms (SNPs) (a difference in the base present at a particular 
location in the sequence between two samples) occur roughly every 200-300bp between 
these two sub-species, enabling us to determine the parental inheritance of each allele of 
an imprinted gene.  We were therefore able to investigate differential binding patterns 
for our proteins of interest between the maternal and paternal alleles of imprinted genes 





























Figure 3.2 - Summary of the assignment of parental inheritance using SNPs.  The SNP 
in the sequence is in green.  In the C57BL/6 genome this is a G, in the Mus musculus 
castaneus genome this is a C.  By comparing the sequence generated in the sequencing 
experiments to both parental genomes, parental inheritance of this region of sequence 
can be determined.     
 
 
We used brain tissue as most imprinted genes are expressed in the brain.  The CTCF 
and cohesin ChIP-Seq libraries were generated from intercross brain tissue and so using 
this for the ATRX and MeCP2 ChIP-Seq will allow us to compare between all four 
datasets easily. 
 
3.2. – Results  
 
3.2.1. - Optimisation of Chromatin Immunoprecipitation 
 
ChIP-Seq was previously performed in Professor Oakey’s laboratory for CTCF and 
cohesin (using antibodies to the Rad21 subunit).  Our initial approach to ChIP-Seq 
using ATRX and MeCP2 antibodies therefore followed the same protocol [22] (protocol 
1; see Materials and Methods).  As our aim is to compare binding sites for all four 
proteins, this approach has the advantage that all four datasets would be generated using 
the same tissue type.  In protocol 1, ChIP-Seq is performed using CTCF, ATRX and 








castaneus G = Maternal allele 
C = Paternal allele 
C57BL/6  Mus musculus castaneus C = Maternal allele 
G = Paternal allele 
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attempted 20 times using a range of concentrations of the ATRX and MeCP2 
antibodies, and both protein A and G agarose beads.  In each case we were unable to 
extract sufficient chromatin to generate sequencing libraries.  The library preparation kit 
that we used for the CTCF and cohesin ChIP-Seq (NEBNext ChIP-Seq Library Prep 
Master Mix Set for Illumina (NEB, cat no E6240)) requires 10ng of ChIP DNA for each 
library.  Performing ChIP on multiple samples for both ATRX and MeCP2 and pooling 
them didn’t yield enough DNA to take forward for library preparation.  Previous work 
in the laboratory had shown that to generate the optimal quality libraries ChIP DNA 
needs to be processed within two weeks of its generation, making it difficult to pool 
samples from consecutive ChIP experiments, check the efficiency using qPCR and 
check the fragment size and re-sonicate if necessary all within this time frame.  
 
The generation of sequencing libraries is a multi-step process, where chromatin can be 
lost at every step.  Sufficient chromatin needs to be extracted from the ChIP for qPCR 
validation, the quantification of the DNA concentration, the analysis of fragment sizes 
and qPCR quantification of the libraries produced.  In the literature it is clear that most 
successful applications of ChIP-Seq have been performed in cell lines, rather than 
tissues.  As such there are relatively few published or commercially available tissue-
based ChIP-Seq protocols. 
 
One commercially available protocol optimised for use in cell lines is EZ-ChIPTM kit 
(ChIP protocol 2; see Materials and Methods).  Although our experiments are tissue-
based, we were encouraged to employ this kit due to its successful use for ATRX and 
MeCP2 ChIP by Kernohan et al [147], albeit in cell lines.  However after four trials we 
were unable again to extract enough chromatin for the preparation of libraries.  This is 
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most likely due to the fact that we performed the experiments in whole tissue samples.  
In particular, possible reasons for the failure of this protocol could include: 
incompatibility of one of the buffers or reagents we used for chromatin extraction with 
those used in the kit (which supplies its own reagents for chromatin extraction in cell 
lines); incomplete dissociation of tissue samples into individual cells due to tissue 
structure (thus inhibiting chromatin extraction or reducing the efficiency of chromatin 
extraction); or incompatibility of one of our antibodies with the reagents in the kit.  
Note that we were unable to perform this experiment in a cell line because the in-house 
BxC/CxB mouse intercross system that allows parental inheritance of alleles to be 
determined is tissue-based.  One option could have been to breed intercross mice and 
derive cell lines, however by the time these problems came to light, our Mus musculus 
castaneus mice were having fertility problems in the animal facility and by the time 
these were resolved, there was not sufficient time to generate the lines and do the ChIP-
Seq.   
 
Finally, ChIP protocol 3 was designed after consultation with Professor Adrian Bird 
(Wellcome Trust Centre for Cell Biology, University of Edinburgh) and Professor 
Richard Gibbons (Weatherall Institute of Molecular Medicine, University of Oxford) 
whose laboratory groups have performed ChIP on MeCP2 and ATRX respectively.  
Professor Bird advised us that since MeCP2 binds to numerous CpG rich regions in the 
genome, it is typical to see high background levels of MeCP2 binding in ChIP-Seq 
experiments making the interpretation of this data at regions of interest extremely 
challenging.  For this reason optimisation of the ATRX ChIP-Seq experiments was 
prioritised.  ChIP protocol 3 was thus based on a protocol provided by Dr Hsiao Voon 
in Professor Gibbons’ laboratory group for ChIP-Seq on ATRX (see Materials and 
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Methods section).  Dr Voon’s protocol is optimised for use with ES cells, and attempts 
to implement this protocol in tissue were unsuccessful.   
 
Having been unable to successfully perform ChIP for our proteins of interest using 
protocols 1-3 in tissue, we considered performing ChIP in cultured cells as an 
alternative.  This has the disadvantage that consistency with the existing CTCF and 
cohesin ChIP-Seq data sets, which were generated using BxC/CxB intercross tissue, is 
reduced; on the other hand we found that ChIP using cell lines could reliably generate 
sufficient DNA for sequencing library preparation.  ChIP protocol 3 was performed in 
two cell lines.  Firstly, Neuro2a cells, which are a Mus musculus neuroblast cell line 
were chosen because being a neural cell line they should be expected to be comparable 
with the CTCF and cohesin ChIP-Seq data sets that were generated in neural tissue.  
Secondly, we obtained reciprocal intercross embryonic stem (ES) cell lines from Dr 
Robert Feil (Institute Genetique Moleculaire Montpellier) [152].  His laboratory group 
use Japanese Fancy Mice (a species of Mus musculus molossinus) and C57BL/6 (a 
strain of Mus musculus domesticus), and have generated ES cells from the reciprocal 
crosses between these two inbred sub-species (JxB and BxJ).  Like the Mus musculus 
castaneus and C57BL/6 reciprocal crosses, there are frequent SNPs between these 
strains of mice, which allow the parent of origin of each allele to be determined.  In 
addition, the JF1 mouse genome has been sequenced, allowing us to perform 
sequencing experiments and compare the sequence to the reference genome.  Since 
ChIP protocol 3 was successful in both cell lines, we decided to use the reciprocal 
intercross ES cells for subsequent analysis as they would allow the determination of 




Table 3.2 – Summary of ChIP protocols and conditions tried. 
 
 
3.2.2. – Library Preparation for Sequencing 
 
We generated libraries for an input sample (chromatin extracted and processed in the 
same way as the other chromatin samples, but not subject to ChIP), two ATRX samples 
for the JxB ES cells and a MeCP2 sample for both BxJ and JxB ES cells.  We were 
unable to collect sufficient chromatin from the ATRX ChIP on the BxJ ES cells for 
generating sequencing libraries.  Two libraries were included for ATRX for the JxB ES 
cells to ensure there was sufficient chromatin for sequencing, as the chromatin yields 
from these ChIP experiments were lower than for the MeCP2 ChIP experiments.  This 
Protocol 
 







Incubation time with 
antibodies 
qPCR primers 
Little or no 
enrichment of 
MeCP2 and ATRX 











Incubation time with 
antibodies 
qPCR primers 
Little or no 
enrichment of 
MeCP2 and ATRX 









Incubation time with 
antibodies 
No enrichment of 
MeCP2 and ATRX 





Dynabeads Concentration of 
antibodies 
Some enrichment of 
MeCP2 and ATRX 
samples over the 
IgG control, but 





Dynabeads Concentration of 
antibodies 
Cell number 
Good enrichment of 
MeCP2 and ATRX 







Dynabeads Concentration of 
antibodies 
Cell number 
Good enrichment of 
MeCP2 and ATRX 
samples over the 
IgG control 
 128 
was done using the DNA SMART™ ChIP-Seq Kit for Illumina.  We used the Agilent 
2200 Tapestation to assess the size of the fragments in each library generated (Figure 
3.3).  The average fragment length for each library is shown in table 3.3.  A qPCR kit 





Figure 3.3 – Trace representation of fragment size analysis from the Agilent 2200 
Tapestation for all six of the ChIP libraries prepared.  All six of the libraries contain a 
peak between about 200 and 500bps, showing that the majority of fragments in these 












Table 3.3 – Index used to label each library and the average fragment size of each 
library. 
Index no. Sample Average 
fragment 
size (bp) 
2 JxB Input 339 
3 JxB ATRX 1 336 
4 JxB ATRX 2 332 
5 JxB MeCP2 326 
6 BxJ Input 338 
7 BxJ MeCP2 321 
JxB Input JxB ATRX 1 
JxB ATRX 2 JxB MeCP2 
BxJ Input BxJ MeCP2 
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3.2.3. – Quality Control of ChIP-Seq Datasets and Read Statistics 
 
The ChIP-Seq data for the JxB and BxJ MeCP2 experiments showed low-level binding 
across the genome, making it impossible to call specific peaks, even with the most 
lenient cutoffs.  For this reason I have chosen to perform further analysis only on the 
two JxB ATRX datasets.   
 
MACS2 was used to call peaks in the ATRX 1 and ATRX 2 ChIP-Seq datasets.  Peaks 
are regions of the genome where multiple reads (sequences generated from the ChIP-
Seq) align.  As more reads are aligned to the genome, they start to stack on top of each 
other in regions where a large number of reads align.  This is called a peak, and implies 
that the protein being investigated in the ChIP-Seq experiment, in this case ATRX, 
binds to this region. 
Figure 3.4 – Screenshot from Galaxy of the ATRX 1 and ATRX 2 reads aligning to 
form peaks along chromosome 7.  The scale and genomic location at the top of the 
figure are from the UCSC mouse build mm10.  The red dots are the JxB ATRX 2 reads, 
and the blue dots are the JxB ATRX 1 reads.  
 
The quality of the reads generated was assessed in two ways.  Phred scaled quality 
scores were generated for each base in the read.  This is a measure of the accuracy of 
the assignment of each base in the read, and operates on a logarithmic scale.  A score of 
10 indicates a base call accuracy of 90%, whereas a score of 40 indicates a higher base 
call accuracy of 99.99% [153].  For JxB ATRX 1 the majority of bases have Phred 
scores of above 30 (see Figure 3.5 A), showing that the reads are of a good quality.  JxB 
Chromosome 7 
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ATRX 2 on the other hand, has Phred scores between 10 and 20 for the majority of 
bases in its reads, implying that this sequencing is of a poorer quality (see Figure 3.5 B). 
 
The percentage of each base incorporated along the reads was also assessed.  The four 
bases should be incorporated in similar proportions (roughly about 25% for each).  
Preferential inclusion of one base over the others can be an indicator of a problem with 
the sequencing reaction, the ChIP experiment itself or reading the sequence into the 
adaptors used to prepare the sequencing libraries.  Identifying the presence of 
preferential inclusion of bases allows the reads to be trimmed to remove these portions 
of the sequences, improving the quality of the reads.  For JxB ATRX 1 the base 
incorporation is as expected, except for the first couple of bases, this indicates that the 
reads are of a good quality (Figure 3.5 C).  For JxB ATRX 2 the base incorporation is 
also as expected, except for the first 14-16 bases (Figure 3.5 D), indicating that the 
reads are of a good quality after this point.  The reads for both ATRX 1 and 2 were 








Figure 3.5 – Quality plots for the forward reads of the JxB ATRX 1 and 2 ChIP-Seq 
libraries.  A and B - Phred scaled quality score box plot as a function of read position.  
This suggests a good quality for ATRX 1 (A), but a poor read quality for ATRX 2 (B).  
Both graphs show the expected drop in quality towards the 3’ end.  C and D  - Base 
incorporation percentage as a function of read position.  The uneven base incorporation 
in the first couple of bps for ATRX 1 (C) and the first 14-16 bps for ATRX 2 (D) shows 
that there has been a problem with the sequencing.  The relatively flat lines for each of 
the bases beyond these points shows there has been little cycle-to-cycle variation.  In C 
increasing C and T percentages at the 3’ end could suggest reading into the adaptors.       
 
 
37, 439, 989 reads were found in the JxB ATRX 1 dataset, whereas 62, 567, 501 reads 
were identified in the JxB ATRX 2 dataset.  Of these reads 65.07% and 65.46% aligned 
to repetitive regions, in the JxB ATRX 1 and JxB ATRX 2 replicates respectively.  
About 15% of the reads generated (14.78% of the ATRX 1 reads, and 15.08% of the 
ATRX 2 reads) didn’t align to the genome.  There were an average of 248 and 383 
reads in each peak in the JxB ATRX 1 and JxB ATRX 2 libraries respectively.  The 
difference in the number of ATRX reads between the two replicates is likely due to the 
difference in the quality of the samples.  It is possible that the inaccuracies in assigning 
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bases in the ATRX 2 reads may have caused them to align to other regions of the 
genome, as well as regions where ATRX binds, artificially increasing the read count. 
 
The cluster density for the libraries was 763 +/- 75 k/mm2.  The libraries were barcoded 
and run on the same cell of a flow cell.  This was a little low compared to other cells on 
the same flow cell, with six of the seven other cells having a cluster density of over 800 
k/mm2 and two being over 1000 k/mm2.  We generated libraries containing long reads 
as we wanted to be able to align the reads to the parental genomes, using SNP’s 
between the two, to allow us to assign parental inheritance and look for strain specific 
differences.        
 
ATRX ChIP-Seq data generated by Dr Gibbons’ laboratory on mouse ES cells (a 
published dataset in the public domain) contained 11,638,285 reads after the removal of 
duplicate reads [154].  Our read counts are much higher than this.  Neither of our ATRX 
sequencing libraries is of as high a quality as we would like, and this could explain why 
we appear to have gained reads.   
 
3.2.4. – ATRX Binding Genomewide 
 
ATRX binds at many different locations across the mouse genome.  We identified 
12,925 peaks across the genome where ATRX binds.  Peaks were defined as those 
significant where q<0.01.  This is a much higher number than that identified in the 
ATRX ChIP-Seq data from Dr Gibbons’ laboratory, which identified 1,305 binding 
sites [154].  This discrepancy is probably due to the inaccuracies in assigning bases in 
our reads causing them to align to other regions of the genome, as well as regions where 
ATRX binds, artificially increasing the number of binding sites identified. 
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3.2.5. – Validation of ATRX and MeCP2 Chromatin Immunoprecipitation 
 
To validate the results obtained via ChIP-Seq we performed qPCR on the chromatin 
generated from both the ATRX and MeCP2 ChIP experiments, and their matched inputs 
(chromatin which was processed through the ChIP protocol but which wasn't exposed to 
an antibody).  A standard curve consisting of five different concentrations of DNA was 
also run for each primer set, allowing the ChIP qPCR results to be quantified.  The 
results of the ATRX and MeCP2 qPCR's are shown as a percentage of the qPCR results 
of the input for the same primer set.  This analysis strategy was used by Kernohan et al 
[147], and is more appropriate than running an endogenous control, which could be 
bound to different extents by the antibodies used.  We confirmed that ATRX binds 
within the ICR of H19 and to Nap1l5, but not within the promoter of GAPDH or MNT 
(Figure 3.6 A and B), in JxB ES cells (one Figure per ATRX input sample).  qPCR for 
MeCP2 confirmed binding within the ICR of H19 and Gtlk-GD3 (part of the Gtl2/Dlk1 
imprinted region defined by Kernohan et al [147]), but not a CpG negative region 
downstream of GAPDH on chromosome 14 (labelled here as CpG negative), in both 
JxB (Figure 3.6 C) and BxJ (Figure 3.6 D) ES cells.  The difference in binding at Gtlk-
GD3 between the JxB MeCP2 ChIP compared to the BxJ MeCP2 ChIP could be due to 
the presence of a SNP between the C57BL/6 and Japanese Fancy Mouse genomes 
causing a difference in the affinity of MeCP2 to one parental genome over the over at 
this locus.  The locations of the regions amplified in the qPCR experiments are shown 
in Figure 3.7.   
 
ChIP was performed on BxC p21 mouse brain using the CTCF antibody as a positive 
control for the ChIP protocols.  Previous work in the laboratory has shown that CTCF 
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reliably binds to intron 10 of H13 and doesn’t bind at intron 3 of H13.  I saw the same 



























Figure 3.6 – qPCR validation of ChIP.  The error bars are the standard deviation of the 
sample.  For A and B GAPDH and MNT were regions where ATRX doesn’t bind, and 
H19 and Nap1l5 were regions where ATRX does bind.  For C and D a CpG negative 
region, just downstream of GAPDH on chromosome 14, is one region where MeCP2 
doesn’t bind, and H19 and GTLK-GD3 were regions where MeCP2 does bind.  For E 
part of intron 3 of H13 acts a negative control region for CTCF, and part of intron 10 of 
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Figure 3.7 – The genomic locations of the regions amplified by qPCR.  A and B show 
the locations of regions where ATRX does not bind (at the promoter of GAPDH and 
within intron 1 of MNT respectively).  C and D show the location of regions where 
ATRX does bind (within the ICR of H19 and Nap1l5 respectively).  E shows the 
location of a CpG negative region where MeCP2 does not bind.  C and F show the 
locations of regions where MeCP2 does bind (within the ICR of H19 and within an 
intron of Meg3, part of the Gtl2/Dlk1 imprinted region, respectively).  G shows the 
locations of a region not bound by CTCF (within intron 3 of H13), and a region bound 
by CTCF (within intron 10 of H13).  Taken from the UCSC genome browser [155], 

















3.2.6. –Allele-specific Binding of ATRX at Imprinted Regions 
 
ATRX was shown to bind at three of the 22 imprinted gDMR’s studied.  Interestingly 
the only gDMR that is bound by ATRX, CTCF and cohesin is Mcts2, which is the 
imprinted retrogene in our model imprinted locus studied in Chapter 4.  ATRX binds to 
the paternal allele of Mcts2, but allele-specific binding could not be determined for 
CTCF and cohesin (Figure 3.8 A).  In Mcts2 the paternal allele is un-methylated.  The 
binding of ATRX to the un-methylated allele supports the ‘Imprinting super-complex’ 
model, in which ATRX, MeCP2, CTCF and cohesin all bind to the same un-methylated 
allele.  The allele-specific binding of MeCP2, CTCF and cohesin needs to be 
determined at this locus to inform on which model more accurately represents the 
interaction of these four proteins.    
 
ATRX is shown to bind at the GTL2/DLK1 iDMR (on chromosome 12; 109, 523, 353 – 
109, 530, 779) (Figure 3.8 B), along with CTCF, and at IGF2R/AIR (on chromosome 7; 
142, 580, 263 – 142, 582, 519) (Figure 3.8 C) with cohesin.  It is likely that ATRX 
binds to more imprinted regions, for example PCR on ATRX ChIP (using murine brain) 
has shown that ATRX binds to the DMR of H19 [147], which we are unable to see in 





Table 3.4 – Summary of the binding of ATRX, CTCF and cohesin to gDMR’s in the 




















gDMR Information (WAMIDEX) ATRX, CTCF and cohesin Binding Determined by ChIP-Seq 
gDMR gDMR Position Methylated Allele ATRX CTCF Cohesin 
Binds Allele Binds Allele Binds Allele 
Bound by ATRX, CTCF and cohesin 
Mcts2 Chr2:152, 686, 755 -152, 687, 275 M Yes P Yes - Yes - 
Bound by ATRX and CTCF 
GTL2/DLK1 Chr12: 109, 523, 353 – 109, 530, 779 P Yes - Yes - No - 
Bound by ATRX and cohesin 
IGF2R/AIR Chr17: 12, 741,297 – 12, 742, 707 M Yes - No - Yes - 
Bound by CTCF and cohesin 
GRB10 Chr11: 12, 025, 482 – 12, 025, 787 M No - Yes - Yes - 
H19/IGF2 Chr7: 142, 580, 263 – 142, 582, 519 P No - Yes M Yes M 
INPP5F_V2 Chr7: 128, 688, 274 – 128, 688, 642 M No - Yes Bi Yes Bi 
MEST Chr6: 30, 736, 488 – 30, 739, 335 M No - Yes P Yes P 
NESPAS Chr2: 174, 295, 707 – 174, 300, 981 M No - Yes - Yes - 
NNAT Chr2: 157, 560, 050 – 157, 561, 662 M No - Yes - Yes - 
PEG13 Chr15: 72, 806, 335 – 72, 811, 649 M No - Yes P Yes P 
U2AF1-RS1 Chr11: 22, 971, 842 – 22, 972, 319 M No - Yes - Yes Bi 
ZAC1 Chr10: 13, 090, 470 – 13, 090, 798 M No - Yes Bi Yes Bi 
ZIM2 Chr7: 6, 727, 576 – 6, 732, 116 M No - Yes P Yes P 
Bound by CTCF 
IMPACT Chr18: 12, 972, 197 – 12, 973, 741 M No - Yes - No - 
PEG10 Chr6: 4, 747, 209 – 4, 747, 507 M No - Yes - No - 
Bound by cohesin 
GNAS-EXON1A Chr2: 174, 326, 930 – 174, 329, 007 M No - No - Yes - 
KCNQ1OT1 Chr7: 143, 295, 155 – 143, 295, 492 M No - No - Yes - 
SNURF/SNRPN Chr7: 60, 004, 992 – 60, 005, 415 M No - No - Yes - 
 138 
Figure 3.8 – Peaks of ATRX binding over Mcts2 (panel A), GTL2/DLK1 (panel B) and 
IGF2R/AIR (panel C).  CpG islands are shown in green.  Imprinted DMR’s are shown 
in red (maternally methylated) and blue (paternally methylated).  Taken from the UCSC 
genome browser [155], using the mouse GRCm38/mm10 reference genome (published 
in 2011.) 
 
3.3. – Discussion 
In this chapter we have discussed the optimisation of ChIP with ATRX and MeCP2 
antibodies, the analysis of the data generated and comparison of this data with ChIP-Seq 
datasets generated previously in Professor Oakey’s laboratory.       
 
The ATRX and MeCP2 ChIP experiments required a lot of optimisation.  It was 
difficult to find antibodies that had been previously used in ChIP-Seq experiments on 
tissue samples, rather than cell lines.  There are more ATRX antibodies available now, 





work with as they require the structure of the tissue to be dissembled completely to 
release individual cells in the final sample.  If clumps of cells remain in the sample it 
can make it difficult for the antibody to bind properly causing binding sites to be 
missed, as access is blocked by the presence of other cells.  It might be worth 
considering generating antibodies for ATRX and MeCP2 ourselves, or over-expressing 
a tagged version of the proteins and using an antibody specific for the tag.    
 
There were several issues associated with the bioinformatics analysis of the ATRX and 
MeCP2 datasets, which need to be considered.  About 15% of the reads in the ATRX 1 
and 2 replicates didn’t align to the genome.  We didn’t investigate these reads any 
further.  The forward and reverse reads in all the datasets were considered 
independently, rather than being analysed as one complete set of reads, which may have 
affected the alignment of the reads to the genome.  The SNP annotation used did not 
exactly match the mouse strain.  A difference between the SNPs present in the SNP 
annotation used and the mouse strain may have stopped reads aligning properly to the 
genome, causing this information to be lost from the analysis.  Another important point 
to consider is that we only had data from one cross, and not the reciprocal.  Without the 
reciprocal cross we cannot rule out the possibility that the allele-specific peaks we 
found are due to a bias in the alignment of sequences to one genome over the other, 
rather than an actual preference for one parental allele over the other.         
 
The apparent lack of overlap between the binding of ATRX, CTCF and cohesin at 
imprinted regions could be due to differential binding in the samples used.  The CTCF 
and cohesin ChIP-Seq experiments used murine brain tissue, whereas the ATRX ChIP-
Seq experiment utilised ES cells.  It is possible that ATRX does co-localise to regions 
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where CTCF and cohesin bind but that these regions vary across tissue types.  Ideally 
these three datasets would all have been generated from the same mouse tissue, using 
reciprocal crosses of the same two mouse strains, so that we could capture these 
interactions and interrogate them in an allele-specific manner.   
 
Another possible explanation for the apparent lack of overlap in the binding sites of 
ATRX, CTCF and cohesin could be due to the quality of the sequences generated from 
the ATRX ChIP-Seq experiments.  This data was not of an ideal quality, and we know 
from other published ATRX ChIP-Seq datasets that we are missing some ATRX 
binding sites.  It is possible that by chance the binding sites we are missing are in the 
regions where CTCF and cohesin bind.  If I had more time I would compare these 
published ATRX ChIP-Seq datasets to our CTCF and cohesin ChIP-Seq datasets to 
allow me to determine if this is the case.  The published ATRX ChIP-Seq datasets are 
not generated from the same tissue types, and in some cases the same species, as our 
CTCF and cohesin ChIP-Seq datasets, but this would still give us an indication if the 
three proteins do bind to the same regions of the genome.   
 
MeCP2 is a difficult protein to work with given its propensity to bind to methylated 
CpG’s, of which there are many throughout the genome.  This leads to low-levels of 
MeCP2 binding genomewide, making it very difficult to determine defined peaks at 
regions where it binds.  A better way to investigate the importance of MeCP2 binding in 
collaboration with ATRX, CTCF and cohesin, and at imprinted regions might be to look 
at these on an individual basis.  Once the regions where ATRX, CTCF and cohesin co-
localise have been determined these can then be checked by ChIP and qPCR for binding 
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by MeCP2.  This would reduce the background noise seen when investigating MeCP2 
binding using high-throughput sequencing techniques.  
 
The ATRX and MeCP2 ChIP-Seq data that we have generated from this project can not 
provide the data that we need determine the role of ‘super-complexes’ in the regulation 
of gene expression. We do not have allele-specific binding information for ATRX and 
MeCP2 so we are unable to discriminate between the two proposed models for ‘super-
complexes’: the ‘Imprinting Super-Complex’ and the ‘Differential binding’ model.  
More work is needed before we can inform on these models.  However, we have made a 
start, and more ChIP-Seq experiments in additional reciprocal crosses and deeper 




Examining the Mechanisms of Gene Regulation in the Context of a 
Well Studied Imprinted Gene Pair 
 
4.1. – Introduction 
We have investigated the mechanisms of gene regulation in the context of the 
H13/Mcts2 imprinted locus.  This locus was chosen because the presence of the 
imprinted retrogene (Mcts2) in one of the introns of the ‘host’ gene (H13) alters 
transcription through the host, imposing an allele-specific expression onto it, despite the 
fact that the promoter of the host gene itself is not imprinted (Figure 4.1).  Imprinted 
retrogenes are a good model for examining mechanisms of gene regulation because 
even though the two alleles share an identical environment and are subject to the same 
influences, the gene is only expressed from one allele and not the other.  Therefore this 
must be due to epigenetic factors operating in cis.  Two approaches were used to 
investigate regulatory mechanisms at H13/Mcts2.  Both approaches use purpose-built 

























Figure 4.1 - Transcription of Mcts2, an imprinted retrogene, affects transcription of 
H13, the host gene.  When Mcts2 is not expressed, at the maternal allele (M), 
transcription occurs through H13 to one of three downstream poly (A) sites.  When 
Mcts2 is expressed from the paternal allele (P), this causes premature termination of 
transcription of H13, and use of one of two upstream poly (A) sites.  Transcripts are 
indicated by the horizontal arrows.  The black circles show methylated CpG’s and the 
white circles show un-methylated CpG’s.  The downward pointing arrows show the 
approximate locations of the two poly (A) sites located upstream of Mcts2.  The other 
three poly (A) sites are located much further downstream of Mcts2, and are not shown 
in this diagram. 
 
The first approach, the generation of Mcts2 knock-in and knock-out mice, is part of a 
long-term project in Professor Oakey’s laboratory, which aims to generate transgenic 
mice containing our constructs of interest, allowing transcription through the 
H13/Mcts2 locus to be altered.  The use of mice allows for the correct setting of 
methylation marks through meiosis at the site of the construct, which could be 
important for regulation of transcription at this site.  During embryonic development, 
methylation is removed from the genome, thus removing any acquired epigenetic 
modifications.  The genome is then re-methylated to reset essential methylation patterns 
[50].  
 
Two constructs had previously been generated by Dr Mike Cowley, a post-doctoral 
researcher in the laboratory: one targeted to H13 to knock out endogenous expression of 
Mcts2 and the other targeted to Fam13c to insert Mcts2 into one of its introns.  Fam13c 








of multiple poly (A) sites to generate transcripts of different sizes (Figure 4.2).  
However, Fam13c does not exhibit imprinted expression and its introns harbour no 
retrogenes.  Fam13c is transcribed in oocytes and during early development.  This could 
be important for the correct methylation of Mcts2 in our knock-in construct, as 
transcription through the gene during embryonic development is thought to be 
important for the correct methylation of maternally imprinted genes.  This has been 
shown at the imprinted Gnas [156] and Snrpn loci in mice [157].  Inserting Mcts2 into 
Fam13c will allow us to test whether the use of alternative poly (A) sites is altered by 
the presence of Mcts2; that is, whether the introduction of Mcts2 induces a different 










Figure 4.2 – Comparison of the H13 and Fam13c gene structure.  A – The gene 
structure of H13 and Mcts2.  B – The gene structure of Fam13c.  Taken from the UCSC 
genome browser [155], using the mouse NCB137/mm9 reference genome (published in 
2007.) 
 
Both of these constructs contain homologous arms, which allow the vector to be 
targeted to the correct region of the genome (Figure 4.3).  They also contain the gene 
for neomycin resistance and HSV thymidine kinase allowing for selection, and lox P 
sites allowing for Cre/lox P recombination [158]. Neomycin is used as a positive 
selection agent on the ES cells, as only the ES cells containing the construct are 
resistant to neomycin, while the ES cells that didn’t integrate the construct are killed by 





is used as a negative selection agent on the ES cells, as HSV thymidine kinase can 
convert gancyclovir to a toxic product killing the ES cells that have integrated the 
construct randomly rather than through homologous recombination at the target site.  
The lox P sites flank the promoter-associated CpG island of Mcts2, allowing it to be 
removed to prevent the expression of Mcts2.  The Flp/FRT recombination system works 
in a similar way to the Cre/lox P system.  The Flippase enzyme recognises the Flippase 
recognition target (FRT) sites, which in these constructs surround the neomycin 





Figure 4.3 – Schematic of the knock-in/knock-out construct.  For the knock-in construct 
the sequence in the region of the 5’ and 3’ arms is taken from the intron of Fam13c in 
which the construct is to be integrated.  For the knock-out construct the sequence in the 
region of the 5’ and 3’ arms will be taken from the sequence of intron four of H13 
which surrounds Mcts2. Lox P sites allow for the removal of the CpG island of Mcts2 
when crossed with a Cre mouse.  Frt sites allow for the removal of the neomycin 
resistance gene (labelled as neo) when crossed with a Flp mouse. PGK-pro-tk can 
convert gancyclovir to a toxic product, allowing for negative selection of cells that have 
integrated the construct randomly, rather than through homologous recombination at the 
target site.  
 
Both constructs have been generated and electroporated into ES cells from a murine 
strain derived from 129.  The cells generated were subjected to negative selection with 
HSV- thymidine kinase, which is toxic and due to its location in the construct would 
only be expressed in clones where insertion into the genome had been random rather 
than targeted.  The surviving cells were subjected to positive selection through 
treatment with neomycin.  Only the cells that had incorporated the correct part of the 
construct including the neomycin resistance gene would survive.  The ES cells were 
generated by Xiangang Zou, a collaborator based at Cancer Research UK.  My role in 
Region of 3’ arm Region of 5’ arm Neo Mcts2 PGK-pro-tk 




the implementation of generation of Mcts2 knock-in and knock-out mice was to check 
the ES cells for the correct integration of the two constructs, using Southern Blotting 
and long range PCR. 
 
The second approach, the dose-responsive control of expression, uses two constructs 
based on the H13/Mcts2 locus in a system that allows expression through these 
constructs to be controlled.  Both of these constructs were designed and generated by 
myself.  Due to the large size of H13, the DNA sequence utilised was limited to the first 
five exons (including the poly (A) sequence associated with exon five), and the first 
four introns.  In place of Mcts2 these constructs contain a reporter gene, mCherry, under 
the control of a tetracycline-responsive promoter.  These constructs were transfected 
into tetracycline-responsive cell lines (also generated as part of this work).  We 
hypothesised that varying transcription through mCherry should cause transcription 
through the rest of the construct to be altered.  The constructs are described in greater 
detail in section 4.2.2.  These experiments compliment those performed in the 
generation of Mcts2 knock-in and knock-out mice.  
 
Both of these approaches test the hypothesis that it is transcription from an internal 
promoter that causes premature polyadenylation of transcription through the host gene 
in a host/retrogene pair. 
 
4.2. – Results 
 
4.2.1. – Screening the ES Cells for Incorporation of the Constructs 
The goals of generating Mcts2 knock-in and knock-out mice were to demonstrate that 
intragenic promoters affect host gene transcript polyadenylation in vitro and in vivo, and 
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to demonstrate that relocating an intragenic promoter from its original position into an 
intron of a new host gene is sufficient to influence poly (A) site selection in the new 
host in vitro.  To examine this property of intragenic promoters, we generated two 
constructs, one to knock-out Mcts2 and one to knock-in Mcts2 into another endogenous 
locus in the mouse genome.  The new host gene was selected using the following 
criteria: the gene should be intronic, the intron structure should be similar to that of 
H13, and there should be no other intronic genes present in the new host gene.  Based 
on these criteria Fam13c was chosen as the new host gene.  The results presented here 
were generated by myself and reflect my contribution to this work.  The design and 
generation of these constructs were undertaken by a post-doctoral fellow in the 
laboratory, Dr Mike Cowley.   
 
Two Southern blots were performed to check for the insertion of the Mcts2 knock-in 
construct into Fam13c via homologous recombination; one each to check that the 5’ and 
3’ ends of the construct had been correctly integrated into the ES cell genome.  To 
check that the 5’ end of the construct had been correctly integrated into the ES cell 
genome DNA preparations from clones were digested with HindIII.  The construct had 
been engineered to contain a HindIII site at its 5’ end so that the fragment generated by 
digestion with this enzyme should be shorter than that obtained from the wild type 
Fam13c sequence.  The digested DNA samples were electrophoresed through an 
agarose gel, followed by Southern blot transfer onto a nylon membrane and the 
fragments were detected using a radioactive probe that hybridises to a sequence present 
in both the construct and the mouse genome (Figure 4.4 A).  Of the 14 clones screened, 
all apart from clone 96 had correctly integrated the 5’ end of the construct, via 
homologous recombination, into the genome.  The presence of double bands (Figure 4.4 
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B) shows that the construct had only been integrated into one of the two Fam13c alleles.  
To check that the 3’ end of the construct had been correctly integrated into the ES cell 
genome, a second Southern blot was performed.  For this test the clones were digested 
with StuI, which due to the presence of another StuI site in the construct should result in 
a larger fragment if the 3’ end of the construct has been correctly integrated.  A probe 
that hybridises to the neomycin resistance gene was used to detect the fragments (Figure 
4.4 C).  Of the 14 clones screened, all apart from clone 96 have correctly integrated the 












Figure 4.4 – Southern blot experiment to check for insertion of the Mcts2 knock-in 
construct into Fam13c.  A – Diagram to show the location of the HindIII restriction 
sites of interest and of the probe (red bar).  B – Southern blot of clones digested with 
HindIII and hybridised with a probe to a sequence present both in the construct and in 
the mouse genome.  C - Diagram to show the location of the StuI restriction sites of 
interest and the probe used (red bar).  D – Southern blot of clones digested with StuI and 
incubated with a probe hybridising to the neomycin resistance gene.  The numbers at the 
top of each column correlate to the clone it contains.  gDNAx4 is a sample of genomic 
DNA loaded at 4 times the concentration of the test clones, acting as a control sample.  
 
 



















































































































To check for the correct integration of the Mcts2 knock-out construct into the ES cell 
genome, we used long-range PCR to screen the clones.  Although theoretically we could 
use the same neomycin probe that had been used to check correct integration of the 
knock-in construct, we were unable to produce any Southern blot results using the probe 
targeted to the 5’ end of the knock-out construct.  I tried this several times with a range 
of probes specific for the 5’ end of the construct, without any success.  The reason for 
this remains unclear, although the successful hybridisation of other probes to different 
parts of the construct confirms that the DNA samples were of a good quality.  We 
therefore decided to adopt an alternative approach based on PCR.  Due to the large size 
of the construct two overlapping primer sets were used, both using a primer located in 
the genome close to the construct’s integration site (Figure 4.5 A; see Appendix 7.2 for 
primer sequences).  Of the six clones tested, we found just one clone (clone 272) had 
successfully integrated the Mcts2 knock-out construct (Figure 4.5 B and C).  This was 































Figure 4.5 – Long range PCR to check for the insertion of the Mcts2 knock-out 
construct into H13.  A – Diagram of the Mcts2 knock-out construct showing the 
location of the primers used for long range PCR.  B – Gel of long range PCR using the 
H13 Screen F1 and H13 Screen neo R1 primers.  The presence of a band at 4.9Kb in 
lanes containing clones 18 and 272 shows that these clones have incorporated the 5’ end 
of the construct, from the sequence of the 5’ arm to the neomycin resistance gene.  C – 
Gel of long range PCR using the Conseq F10 and H13 Screen R1 primers.  The 
presence of a band at 4.1Kb in the lane containing clone 272 shows that this is the only 
clone to have incorporated the 3’ end of the construct, from the neomycin resistance 
gene to the sequence of the 3’ arm.  Primer sequences are in appendix 7.2.  
 
 
Six of the clones which had successfully incorporated the Mcts2 knock-in construct into 
Fam13c (clones 12, 31, 85, 89, 101, 164) and clone 272, which had successfully 
incorporated the Mcts2 knock-out construct were chosen to be used in the generation of 
targeted transgenic mice.  Several male animals containing each of these constructs 
were generated at the Transgenic Core Facility, CRUK Cambridge Research Institute.  
However, chimerism in these animals reached 65% as measured by coat colour, failing 
to reach the required minimum for founder mice at this facility of 70%.  A second 
attempt to generate live animal models containing these constructs will be therefore be 
made after the completion of this thesis.  However, we are able to work with the ES 
cells from the knock-in and knock-out lines screened by myself.  This is currently the 
focus of work being performed by Samuele Amante (in Professor Oakey’s laboratory); 
5’ arm 3’ arm Neo Mcts2 
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Samuele is aiming to demonstrate that intragenic promoters affect host gene transcript 
polyadenylation in vitro.  Together these experiments are expected to validate our 
existing correlative evidence by showing that intragenic promoters can control host 
gene polyadenylation, and that this occurs at endogenous loci in ES cells.  This part of 
my thesis work therefore makes an important contribution to a larger ongoing team 
effort to understand these promoters. 
 
4.2.2. – Design of a Construct to Test the Hypothesis that Alternative poly (A) Site 
Usage at the H13/Mcts2 Locus is a Result of Transcriptional Interference 
 
In the work described previously in this chapter, the constructs used allowed for the 
selection of ES cells through the addition of antibiotics to the medium.  The antibiotic 
resistance genes the constructs contain are then removed through the crossing of the 
mice generated with Flp mice.  However, as the approach we are using to test our 
hypothesis that alternative poly (A) site usage at the H13/Mcts2 locus is a result of 
transcriptional interference will be performed in cell lines, the removal of these 
elements is not possible.  We therefore took an alternative approach: we designed and 
engineered two expression vectors to modulate intragenic promoter activity and 
quantitatively measure the impacts on host gene polyadenylation. 
 
We designed two versions of the construct (A and B), containing different complements 
of the H13 exons and introns surrounding Mcts2 (Figure 4.6).  At the 5’ end of both 
versions of the construct is a Ubiquitously acting Chromatin Opening Element (UCOE) 
[160], which is used to drive expression of the construct.  It will also act to ensure that 
regardless of where the construct integrates in the genome it will be expressed, as 
UCOE acts to ‘open up’ the chromatin making it accessible to the DNA binding factors 
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needed for transcription.  Downstream of this is the sequence of H13 that surrounds 
Mcts2 in its endogenous context.  Both versions of the construct contain exons three and 
four, and introns three and four.  Intron three has been included as this is retained in 
some H13 transcripts.  Intron four is the intron in which Mcts2 is located, and it may 
contain sequences that are important for splicing or transcription of both H13 and 
Mcts2.  The portions of this intron which occur either side of the Mcts2 sequence are 
therefore included in full.  Exon five has also been included in both versions of the 
construct, and is fused to eGFP, allowing this to be used as a readout for expression 
from the H13 sequence.  In addition to exons three to five of H13, construct A also 
contains exons one and two, while construct B does not.  This makes construct B much 
smaller than construct A and we expected that this would make it easier to generate.  In 
place of Mcts2 both versions of the construct contain the sequence for the red 
fluorescent protein mCherry under the control of an inducible promoter, pTRE3G.  
pTRE3G consists of seven repeats of a 19bp tet operator sequence upstream of a 
Cytomegalovirus (CMV) promoter [161], and can be activated by the presence of 
tetracycline.  This allows the expression of mCherry to be regulated through the 






Figure 4.6 – Diagram of the constructs for investigating the effect of an internal 
promoter on the transcription of the host gene.  x1, x2, x3, x4 and x5 are the 
corresponding exons from H13. i3 and i4 are based on the corresponding introns in 
H13. 
 
We designed the constructs for transfection into HEK 293 cells that are tetracycline-
responsive.  A synthetic tetracycline derivative, doxycycline, was used to activate the 
UCOE x1 x2 x3 i3 x4 i4 pTRE3G mCherry x5 eGFP i4 Poly(A) 




pTRE3G promoter.  Specifically, the addition of doxycycline to the cells causes a 
conformational change to the Tet-On 3G transactivator protein, allowing it to bind to 
the tet sequences in the pTRE3G promoter and activate expression of mCherry. 
 
The constructs were designed such that transfection into tetracycline-responsive cell 
lines would allow us to determine the effect of transcription of the internal gene on poly 
(A) site usage of the host gene, through the expression of either mCherry or eGFP.  If 
we are correct in our hypothesis that poly (A) site usage is fully determined by whether 
transcription of the internal gene occurs, we would expect to see eGFP expression when 
the cells are not exposed to tetracycline, because there should be no transcription from 
the pTRE3G promoter, allowing use of the downstream poly (A) sites; conversely in the 
presence of tetracycline, when the internal promoter is stimulated, we would expect to 
see expression of mCherry and a decrease in the expression of eGFP as some (if not all) 
transcripts terminate at a poly (A) site upstream of the minimal promoter in exon four 




























Figure 4.7 – A summary of expected outcomes when tet-responsive cell lines are treated 
with and without doxycycline for 24hrs.  When cells are grown without doxycycline 
only the UCOE promoter should be active and so most transcripts should terminate at 
the poly (A) site at x5 (eGFP).  When cells are grown in the presence of doxycycline for 
24hrs both the UCOE and the pTRE3G promoters are active and so transcripts 
terminating with both the poly (A) site at x5 (eGFP) and mCherry are produced.  x1, x2, 
x3, x4 and x5 are the corresponding exons from H13. i3 and i4 are based on the 
corresponding introns in H13. 
 
 
4.2.3. – Generation of Tetracycline-responsive Cell Lines 
 
Tetracycline-responsive cell lines were generated using the Tet-On 3G Inducible 
Expression System.  HEK 293 cells were chosen because these are a human cell line: 
sequence differences between mouse and human therefore facilitate the differentiation 
UCOE x1 x2 x3 i3 x4 i4 pTRE3G mCherry x5 eGFP i4 Poly(A) 
UCOE x3 i3 x4 i4 pTRE3G mCherry x5 eGFP i4 Poly(A) 
Transfect into Tet-responsive cell lines 
- Doxycycline + Doxycycline 
UCOE H13 exons/introns x5 eGFP i4 UCOE H13 exons/introns x5 eGFP i4 
pTRE3G mCherry 
+ / - Doxycycline for 24hrs 
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of endogenously expressed transcripts from those generated by our construct (which is 
derived from mouse sequence).  The HEK 293 cells were transfected with pCMV-
Tet3G and then selected for uptake with G418 (Life Technologies, cat number 
11811023).  To generate lines, the transfected cells were seeded onto plates at very low 
densities allowing individual colonies to form (taking anything from 1-4 weeks).  These 
colonies were transferred into individual vessels and cultured, at 37oC in 5% CO2, until 
there were sufficient numbers (approximately 5 million cells) to test for expression of 
the Tet-On 3G transactivator and a high level of induction from pTRE3G. 
 
To test the response of the cell lines to doxycycline, they were transfected with 
pTRE3G-Luc and TAL-Renilla, both with and without doxycycline.  We then assayed 
the expression of firefly and Renilla luciferases using a Dual Luciferase Reporter Assay.  
Of the 12 HEK 293 lines tested only HEK 293-11 and HEK 293-14 showed a response 
to doxycycline (Figure 4.8).  As doxycycline is added to the medium the expression of 
luciferase is stimulated in HEK 293-11 and HEK 293-14 compared to the parental HEK 
293 line.  This shows that these lines express the Tet-On 3G transactivator protein.      
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Figure 4.8 – The response of cell lines HEK 293, HEK 293-11 and HEK 293-14 to 
doxycycline.  As doxycycline is added to the medium the expression of luciferase is 
stimulated in HEK 293-11 and HEK 293-14 compared to the parental HEK 293 line.  
This shows that these lines express the Tet-On 3G transactivator protein.  Dox = 
doxycycline.  n=3.  The bars show +/- the standard error.  
 
 
4.2.4. – Transfection of the Construct into Tetracycline-responsive Cell Lines 
The two constructs were transiently transfected into the HEK 293-11 and HEK 293-14 
lines, because these showed the best response to treatment with doxycycline (see section 
2.4.11.3. in the Materials and Methods for more detail). 
 
4.2.5. – Quantitative PCR to Assess Activity of Constructs 
Quantitative PCR was used to assay expression of transcripts from the two constructs in 
both of the tetracycline-responsive cell lines generated, as shown in figure 4.9.  We saw 
no difference in the expression levels of the transcripts generated from the constructs in 
either cell line in response to 24 hour treatment with doxycycline. We were expecting to 
see an increase in the transcripts detected by the mCherry assay and a decrease in the 
transcripts detected by the x5 and eGFP assays in the presence of doxycycline compared 
























to generate a difference in expression.  Possible modifications to the procedure which 
we anticipate could produce the expected response include treatment with doxycycline 
over a longer time period [162] [163], or at a different concentration (for example at 24, 
48, 72 and 96 hours at a concentration of 1, 2, 4, 6 and 10 µg/ml doxycycline); work to 











Figure 4.9 – qPCR showing expression of the different transcripts generated from 
constructs A and B.  x2 is the region of H13 exon two, x3 is the region of H13 exon 
three, i3 is the region of H13 intron three and x5 is the region of H13 exon five in the 
constructs.  x2 and x3 show the transcripts initiating from construct A and B 
respectively.  i3 is in the transcripts that terminate upstream of mCherry.  x5 and eGFP 
are in the transcripts that splice over mCherry. For A, B, C and D n=3.           
 
Commercial fetal bovine serum added to the media used to generate and grow the cell 
lines can contain low levels of tetracycline, which can affect the results of these 
experiments.  For this reason I used a tetracycline-free serum (available from Clontech) 
for the generation of these cell lines, and during the subsequent experiments.   
 
Once the constructs were completed, and before they were used in any experiments, I 
























































































sequences of the constructs generated to the planned sequences for each, and checked 
that each component was in the correct reading frame, and present in full.  I also 
checked for mutations in the promoters and that the junctions between components were 
as planned.  Therefore I feel confident to say that it is unlikely the unexpected results 
generated are due to a problem with the constructs themselves.   
 
4.3. – Discussion 
This chapter has described two complementary approaches designed to study imprinted 
gene expression at the H13/Mcts2 locus: generation of Mcts2 knock-in and knout-out 
mice, and the dose-responsive control of expression, in which two alternative constructs 
replicate the host/retrogene structure of H13/Mcts2 and allow the expression of 
alternative transcripts of the host to be measured under controlled expression of the 
retrogene. 
 
We have shown that good progress has been made towards the generation of Mcts2 
knock-in and knock-out mice.  In section 4.2.1. I showed that several ES cell lines have 
successfully integrated the constructs, and work to culture these cells is ongoing in 
Professor Oakey’s laboratory.  These ES cells will be electroporated to allow for the 
uptake of flippase recombinase to remove the neomycin resistance gene from the 
construct.  Experiments will be performed on these cells, as well as on cells that have 
been electroporated with Cre recombinase to remove the CpG island of Mcts2: 
comparison of these results should enable the effect of the CpG island on alternative 
poly (A) site usage on H13 (in the knock-out model) or Fam13c (in the knock-in model) 















Figure 4.10 – Summary of the expected effect of active or inactive Mcts2 on alternative 
poly (A) site usage in both H13 and Fam13c.  A – A diagram of the H13 locus showing 
the location of Mcts2 in intron four.  Below this are the transcripts produced by using 
the different poly (A) sites present in the gene, in response to active or inactive Mcts2.  
B - A diagram of the Fam13c locus, showing the insertion of Mcts2 in intron eleven.  
Below this are the transcripts produced by using the different poly (A) sites present in 
the gene, in response to active or inactive Mcts2. 
 
 
For the knock-out construct (in which the endogenous Mcts2 sequence is replaced by 
one where the CpG island is bound by lox P sites), if our hypothesis is correct we would 
expect to see an increase in the number of transcripts that terminate downstream of 
Mcts2 when the CpG island of Mcts2 is removed, inactivating the gene (see Figure 4.10 
A).  For the knock-in construct we are expecting that insertion of the active Mcts2 will 
induce a preference for the use of the poly (A) sites upstream of the insertion site in 
Fam13c, and a reduction in the use of the downstream sites: when the CpG island of 
Mcts2 is removed we are expecting the usage of poly (A) sites to reflect the usage seen 




 =Mcts2  =Mcts2 with the CpG islands removed 
B 
Shorter transcripts produced 
when Mcts2 is active  
Longer transcripts produced 
when the CgG island of Mcts2 is 
removed 
Shorter transcripts produced 
when Mcts2 is active  
Longer transcripts produced 
when the CgG island of Mcts2 is 
removed 
 = location of poly(A) sites  = exons 
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These experiments complement the dose-responsive control of expression, which uses 
two constructs in tet-responsive cell lines.  Both approaches investigate the effect of an 
internal promoter on the expression of the gene in which it is located, but in slightly 
different ways.  The ES cell experiments of mice experiments will generate results in a 
more biologically relevant system (as they are in a live animal model) whereas the dose-
responsive control of expression experiments in tet-responsive cell lines allow us a 
more controlled environment in which to manipulate expression from the internal 
promoter and measure its influence on transcription.  
 
I showed in section 2.4.10. of the Materials and Methods that we have successfully 
generated the construct, which should allow us to identify the effects of an internal 
promoter on the expression of the gene within which it is located.  Two different 
versions of the construct were generated, differing in the region of H13 (our host gene 
of interest) that they contain.  The generation of these constructs was technically 
challenging, involving multiple cloning steps and the sourcing or generation of all the 
subunits.  It was important to use unique restriction sites where possible to allow for the 
correct insertion (or removal if needed) of the individual subunits into the construct.  
Due to the number of cloning steps required this involved the use of some restriction 
enzymes requiring special conditions for their activity.  We also successfully generated 
tetracycline-responsive cell lines, and demonstrated this by testing a subset for their 
response to doxycycline treatment (see section 4.2.3.).  Of the twelve HEK 293 cell 
lines generated, only two showed a response to doxycycline.  Unfortunately, the 
timescale of this thesis did not allow the next steps of this work to be taken, but there 
are several ways in which this work can be taken forward.  Firstly, it could be 
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advantageous to test additional HEK 293 cell lines (and choose those that showed the 
best response to doxycycline, instead of using the only two that showed some response 
to doxycycline).  It would also be beneficial to repeat the process of generating these 
cell lines again, and to generate an additional set of tetracycline-responsive cell lines, 
based on the 3T3 cell line.  
      
The original goal of this part of the project was to generate cell lines that stably express 
our constructs in response to doxycycline treatment.  Unfortunately, the numerous 
challenges that we encountered during the execution of the work prevented this goal 
from being fully achieved during the timescale of this thesis.  However, I was able to 
perform some preliminary experiments in which the constructs were transiently 
transfected into the tetracycline-responsive cell lines that we did generate.  Transiently 
transfected cells express the construct but it is not integrated into the genome, and so is 
not passed on during cell division.  This means that transient transfections only express 
the construct for a short period of time (approximately 2-3 days), whereas in stable 
transfections the construct is expressed in the cells and is passed on to the progeny 
during cell division.  Stable transfection therefore makes it possible to generate a cell 
line that stably expresses the construct, meaning that a single transfection is sufficient to 
produce a cell line that can be used for multiple experiments; conversely a transient 
transfection requires a separate transfection each time the experiment is repeated.  
Transient transfections are generally used when looking at short-term changes in gene 
expression or protein production.  Stable transfections are useful for looking at longer-
term changes, and at genetic regulation of the transfected DNA.  Both systems will 
inform on our theory.  The transient transfections will allow us to study expression 
through the construct and how this changes in response to doxycycline.  When stable 
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transfections have been established, so that the construct is integrated into the genome, 
these should be informative regarding the mechanisms of gene regulation involved in 
alternative poly (A). 
 
We observed no difference in expression across the construct in transfected cells treated 
with doxycycline (to activate expression through part of the construct) compared to 
untreated transfected cells (see section 4.2.5.).  This was observed for both constructs in 
both of the tetracycline-responsive cells lines.  There could be a number of reasons for 
this.  Firstly, it is possible that additional work to optimise the transient transfection 
protocol would enable us to maximise expression from the constructs.  It is possible that 
24 hour’s treatment with doxycycline is not long enough to have an effect on 
expression, or that the dose used needs to be higher.  For example, human ES cells have 
been shown to respond to 2µg/ml of dox after 48 hours [162].  Alternatively, our 
experiments were designed with the aim of producing tetracycline-responsive cell lines 
that stably express the constructs: since the kit used to generate the cell lines was 
designed to generate stable cell lines, we may be unable to produce the results we 
expect with transient transfections.  Therefore, these experiments need to be repeated in 
stable cell lines before any conclusions can be drawn.       
 
There is previous work to support our hypothesis that the presence of an internal 
promoter can cause premature termination of its host gene [164].  A similar effect has 
been reported at another gene locus, where the imprinted Nap1l5 causes premature 
termination of the Herc3 gene in which it is located [143], which suggests that this 
mechanism could occur at other locations across the genome.  Histone modifications 
and DNA methylation at intron/exon boundaries have also been shown to play a role in 
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alternative splicing [165], and it is possible that since we only used part of the 
H13/Mcts2 locus these important marks were lost.  It could be that the presence of an 

























5.1. - Overview 
The work in this thesis aimed to investigate the mechanisms controlling gene 
expression, with particular emphasis on those acting on imprinted genes.  We have 
focused on imprinted genes because even though the two alleles share an identical 
environment and are subject to the same influences, the gene is only expressed from one 
allele and not the other.  Many imprinted genes are only expressed in an imprinted 
manner in certain tissues [166], and so the more we understand about the mechanisms 
regulating their gene expression the better we are able to understand tissue-specific 
regulation of genes.  Two main approaches were used: one a genomewide approach 
using ChIP-Seq on a set of four DNA binding proteins, which have previously been 
shown to be associated with imprinted genes and their regulation, and a locus specific 
approach using a series of constructs to alter the expression of a model imprinted gene 
and its host, the H13/Mcts2 locus.  These two approaches were designed to be 
complimentary, with the ChIP-Seq investigating the interactions of these four proteins 
across the entire genome to look for trends, and the construct work using our well-
studied model locus providing a mechanistic component to this research project, 
informing on the role of intragenic promoters in tissue-specific gene expression in 
mammals. 
 
5.2. - Original Hypothesis  
Chromosome looping plays an important role in the regulation of gene expression, by 
aiding the interactions between regulatory elements and gene promoters.  Early 
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experiments at the H19 imprinting control locus showed the importance of looping in 
cis regulation to control imprinted gene expression [167].  The development of more 
genomewide techniques detected novel trans interactions, widening the scope of known 
contacts with the H19 DMD [168].  Both imprinted and non-imprinted gene interactions 
were detected, demonstrating that complex transcriptional networks were involved in 
the regulation of these genes and this has been further developed to reveal the co-
regulation of imprinted genes in imprinted gene networks [169].     
 
In the H19 model these loops themselves serve to bring the regulatory elements into 
close enough proximity to the promoter of the gene so that they can affect transcription 
through it.  Chromosome looping in general can occur in two main ways, through the 
interaction of two bound CTCF proteins with each other stabilised by the cohesin 
complex, and through interactions between cohesin and the Mediator Complex.  
Cohesin plays a key role in stabilising these chromosome loops.  CTCF and cohesin are 
therefore intimately associated with the regulation of gene expression.  ATRX and 
MeCP2 have been shown to co-localise with CTCF and cohesin at many loci across the 
genome, including at the H19 ICR and the Gtl2/Dlk1 imprinted regions [147].  As 
CTCF and cohesin ChIP-Seq datasets had already been generated in Professor Oakey’s 
laboratory [22] it made sense to perform ChIP-Seq with ATRX and MeCP2 to 
investigate the interactions of these four proteins and their role in gene expression both 
genomewide and at all imprinted regions.   
 
5.3. –Regulating Gene Expression 
We have made some progress with elucidating the mechanisms responsible for 
regulating the expression of genes.  In regards to imprinted genes it is clear from 
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published evidence that ATRX, MeCP2, CTCF and cohesin form a super complex over 
the DMR of the gene [170], but the details of how they interact to regulate gene 
expression once in place remains to be determined.  Intronic promoters can influence 
alternative poly (A) site selection of their host gene, but more work needs to be done to 
determine whether their presence alone is enough to alter poly (A) site usage.   
 
The ATRX and MeCP2 ChIP experiments required a great deal of optimisation to 
determine which antibodies, types of beads and samples worked together.  It is clear to 
me now that I should have made the switch to using cell lines and ES cells much sooner 
than I did, but at the time I wanted to ensure a good match with the CTCF and cohesin 
ChIP-Seq datasets, which utilised murine brain.  Switching to cell lines and ES cells 
sooner would have allowed me to repeat the CTCF and cohesin ChIP-Seq on these 
samples as well, ensuring that a match was maintained across the four datasets.  It 
would have been beneficial to test a wider range of ATRX and MeCP2 antibodies, or to 
generate our own for the ChIP.  The generation of the tet-responsive constructs was also 
time consuming, but went according to plan.  The use of a new cloning kit, the Gibson 
Assembly Kit, was problematic, and in retrospect I spent too much time trying to 
optimise this approach, which ultimately resulted in the re-design of the cloning strategy 
to make use of more traditional cloning techniques, which worked well despite the large 
number of steps required.  This extensive protocol development period left us with less 
time to optimise the expression of these constructs in cell lines in response to 





5.4. – Complimentary and Related Approaches To Investigate The Regulation of 
Gene Expression 
Active intragenic promoters influence alternative poly (A) site usage.  Mcts2 is a good 
model for studying this as it is an imprinted gene and so we have an active and an 
inactive promoter in the same cell type, and because the relationship between active 
Mcts2 and alternative poly (A) site use by H13 has already been established [146].  
Several approaches are being used together to investigate the mechanisms of gene 
regulation at imprinted regions, including those described in this thesis investigating the 
influence of intragenic promoters on host poly (A) site usage, using H13/Mcts2 locus as 
a model.  We hypothesised that H3K36me3 is involved in poly (A) site selection.  
H3K36me3 affects the rate of transcription and one model for alternative poly (A) site 
selection that could be relevant is a competition based model, in which distal poly (A) 
sites are favoured, unless the relevant machinery can be bought to a proximal site before 
the polymerase reaches the distal site, in which case the proximal site will be used.  By 
ablating the histone mark using siRNAs targeted to Setd2, which catalyses H3K36me3, 
we are altering histone methylation marks and can investigate if this mark is relevant to 
the mechanism of poly (A) site selection at the H13/Mcts2 locus.  To explore whether 
this is also relevant at other loci genomewide, and could indeed be a mechanism 
relevant to tissue-specific genes elsewhere, we have assayed the total transcriptome in 
ES cells using RNA-Seq.  RNA-Seq allows the quantification of transcripts and the 
identification of structural elements, like intron-exon boundaries, as well as the ability 
to distinguish expression between specific alleles and alternate isoforms generated from 
the same gene [171].  By defining the expression pattern seen over the H13/Mcts2 
locus, we can search for this pattern of expression across the genome, allowing us to 
identify other regions where a gene located within an intron of a larger gene can alter its 
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transcription.  Preliminary results from these data suggest that there are multiple sites 
across the genome that behave similarly and further interrogation of these data is 
ongoing in the laboratory. 
 
5.5. - Future Work 
In order to elucidate the mechanisms controlling imprinted gene expression, using the 
H13/Mcts2 locus as a model, the work in this thesis needs to be extended, and 
considered with respect to the results of the other approaches being used by the Oakey 
laboratory.  The ES cell work needs to be continued, and ideally Mcts2 knock-in and 
knock-out mice need to be generated allowing for the correct setting of methylation 
marks through meiosis at the site of the construct, which could be important for 
regulation of transcription at this site.  Stable tet-responsive cell lines need to be 
generated and the experiments described in chapter four repeated with the constructs 
that I generated.  These will allow us to control expression through the constructs in a 
dose responsive manner.  We expect these experiments to show that the presence of an 
internal promoter within a gene is enough to influence the use of alternative poly (A) 
sites on the host gene.  
 
The ATRX ChIP-Seq data need to be analysed further in respect to ATRX binding 
allele-specifically at imprinted loci, and genomewide, to inform on its binding at these 
sites with CTCF and cohesin.  This would inform on which of the two proposed models 
of interaction for these proteins (and MeCP2), if either, is more likely to be occurring, 
and if this alters depending on whether the gene is imprinted or not.  The binding of 
MeCP2 at imprinted regions needs to be investigated, using an alternative method, since 
the ChIP-Seq approach has been unsuccessful.  One option would to be to use data in 
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the public domain in related cell types.  It would also be beneficial to look for the 
binding motifs of CTCF and cohesin within the peaks identified in the ATRX ChIP-Seq 
data, to see if they are binding at the same sites, or binding separately at the same 
regions.  
 
Ultimately the ATRX ChIP needs to be optimised further to generate sequencing data of 
a high quality, which will aid its analysis, and allow us to form more confident 
conclusions on the binding of ATRX and its interactions with CTCF and cohesin.  It is 
possible that the CTCF and cohesin ChIP-Seq experiments may need to be repeated to 
match the tissue type used for the ATRX ChIP-Seq.  This will aid our comparisons of 
these datasets and ensure that we aren’t missing interactions due to their transient nature 
in certain tissue types.        
 
5.6. - Conclusions 
The mechanisms controlling gene expression are complicated and dynamic.  CTCF and 
cohesin have been shown to play a role in regulating gene expression through the 
establishment and maintenance of chromosome loops bringing regulatory regions into 
close proximity with gene promoters.  ATRX and MeCP2 have been shown to co-
localise with CTCF and cohesin at several sites across the genome.  Due to the 
methylation specific binding of CTCF and MeCP2 (CTCF preferentially binds to un-
methylated regions and MeCP2 binds to methylated regions) it is likely that these four 
proteins play a role in the regulation of imprinted gene expression.  We have made a 
good start in investigating mechanisms controlling gene expression at imprinted 
regions, and those occurring more generally throughout the genome, but further work is 
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7.1. - Buffers and Reagents 
2.3.2. - Chromatin Immunoprecipitation – Method 1 
Dilution Buffer (250ml) Volume (ml)  
1M Tris-HCl pH8 4.175 
5M NaCl 8.250 
20% Triton X-100 13.750 
0.5M EDTA 0.600 
H2O 223.125 
 
Wash Buffer 1 (500ml) Volume (ml) (final concentration) 
1M Tris-HCl pH8 10.0 (20mM) 
5M NaCl 15.0 (150mM) 
10% SDS 5.0 (0.1%) 
20% Triton X-100 25.0 (1%) 
0.5M EDTA 2.0 (2mM) 
0.1M PMSF (in 100% Ethanol) 0.2 
H2O 442.8 
 
Wash Buffer 2 (500ml) Volume (ml) (final concentration) 
1M Tris-HCl pH8 10.0 (20mM) 
5M NaCl 50.0 (500mM) 
10% SDS 5.0 (0.1%) 
20% Triton X-100 25.0 (1%) 
0.5M EDTA 2.0 (2mM) 
0.1M PMSF (in 100% Ethanol) 0.2 
H2O 407.8 
 
Wash Buffer 3 (500ml) Volume (ml) (final concentration) 
1M Tris-HCl pH8 5.0 (10mM) 
1M lithium chloride 125.0 (250mM) 
20% IpeGal 360 25.0 (1%) 
20% sodium deoxycholate 25.0 (2g) 
0.5M EDTA 1.0 (1mM) 
0.1M PMSF (in 100% Ethanol) 0.2 
H2O 318.8 
 
EDTA-free protease inhibitor (Roche, cat number 04693132001) was added to the wash 





2.3.4. - Chromatin Immunoprecipitation – Method 3 
 
PBS/BSA (50ml) Volume (ml) (final concentration) 
BSA 0.25g (5mg/ml) 
PBS 50.00 
 
This should be made up fresh each time and kept cold. 
 
Lysis Buffer 1 (100ml) Volume (ml) (final concentration) 
1M HEPES-KOH, pKa 7.5 10.00 (100mM) 
5M NaCl 2.80 (140mM) 
0.5M EDTA 0.20 (1mM) 
Glycerol 10.00 (10%) 
100% NP-40 0.50 (0.5%) 
Triton X-100 0.25 (0.25%) 
 
Lysis Buffer 2 (100ml) Volume (ml) (final concentration) 
5M NaCl 4.0 (200mM) 
0.5M EDTA 0.2 (1mM) 
125mM EGTA 0.4 (0.5mM) 
500mM Tris pH8 2.0 (1mM) 
 
Lysis Buffer 3 (100ml) Volume (ml) (final concentration) 
0.5M EDTA 0.2 (1mM) 
125mM EGTA 0.4 (0.5mM) 
500mM Tris pH8 2.0 (1mM) 
5M NaCl 2.0 (100mM) 
Na-Deoxycholate 0.1g (0.1%) 
N-lauroyl sarcosine 0.5g (0.5%) 
 
Wash Buffer (RIPA) (100ml) Volume (ml) (final concentration) 
500mM HEPES, pKa 7.4 10.00 (50mM, pH7.6) 
8M LiCl 6.25 (500mM) 
0.5M EDTA 0.20 (1mM) 
1% NP-40 1.00 
0.7% Na-Deoxycholate 0.70g 
 
Elution Buffer (50ml) Volume (ml) 
1M NaHCO3 5.00 (100mM) 
20% SDS 1.25 (0.5%) 
This should be made up fresh each time. 
 
EDTA-free protease inhibitor (Roche, cat number 04693132001) was added to all 






2.4.1. – DNA Extraction from ES cells 
 
TE Buffer (pH8.0) Volume (ml) 
1M Tris HCl (pH8.0) 1 
0.5M EDTA  0.2 
H2O To 100 
 
Extraction Buffer Volume (ml) 
1M Tris HCl (pH8.0) 200µl (10mM) 
0.5M EDTA  4 (0.1M) 
RNase A (10µg/ml 
stock) 
40µl (20µg/ml) 
10% SDS 1 (0.5%) 
H2O To 20 
 
 
2.4.3. - Southern Blotting 
 
Denaturation Buffer Volume (ml) 
NaCl 58.44g (1M) 
NaOH 20g (0.5M) 
H2O To 1L 
 
Neutralisation Buffer Volume (ml) 
NaCl 87.66g (1.5M) 
Tris 6.057g (50mM) 
0.5M EDTA  2ml (1mM) 
H2O To 1L 
 
20x SSC Volume (ml) 
NaCl 175.3g 
Trisodium citrate 88.2g 
H2O To 800mls, adjust to 
pH7 (using 1M HCl) 
H2O To 1L 
 
 
Salmon sperm DNA 
• Add 25ml H20 to 250mg DNA to give 10mg/ml 
• Pass through G18 needle several times to shear 
 
 
Church Buffer Volume (ml) 
1M PB 15 
0.5M EDTA 60µl 
SDS 2.1g 
BSA 0.3g 
H20 To 30 
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1M PB Volume (ml) 
Na2HP04 pH8.0 67g 
Phosphoric acid 2 (in fume hood) 
H20 To 500 
 
Wash Solution 1 Volume (ml) 
BSA (coarse) 2.5g 
SDS 25g 
1M PB 20 
0.5M EDTA 1 
H20 To 500 
 
Wash Solution 2 Volume (ml) 
SDS 10g 
01M PB 40 
0.5M EDTA 2 
H20 To 1L 
 
7.2. - Primers and Probes  
 
2.3.5. - Quantitative Real-Time PCR 
Custom Plus TaqMan assay   
 
 Based on primers from 
GAPDH Kernohan, 2010 
Gtlk_GD3 Kernohan, 2010 
H19 Kernohan, 2010 
 
Chen 2 Sequence 
Forward Primer CCAGGAATAAGCTTAGAGGCCTTTT 
Reverse Primer GGAATGTCTACCGGCCTACTC 
FAM conjugated probe CCGCTCTCAACCCTCC 
 
H13e Sequence 
Forward Primer GATCACTCAGCCCATTTCTGTCT 
Reverse Primer CTTTTCCTAGCCATTCCTCAGTCT 
FAM conjugated probe CCTGTTTGCAGTAGTCCAC 
 
Using the Roche Universal Probe library 
 
CpG negative region Sequence 
Forward Primer CTCTGGTCCAGGGATTTGAA 
Reverse Primer AAAGCAACACACATCCACCA 




Forward Primer CTGGGTCGCACGTCTAGC 
Reverse Primer AGCAGTCCGGGTAACCAAC 
Probe Number 102 
 
Nap1l5 Sequence 
Forward Primer TGGGCAAGCTCTCCATAAAG 
Reverse Primer CAGCTGAGCCGAGCAGTAG 
Probe Number 32 
 
2.4.3. - Southern Blotting 
Fam13c Sequence 
Forward Primer GAGACGACCCCACACATCAT 














Fam13c neo Sequence 
Forward Primer CAACAGACAATCGGCTGCTCTG 






















2.4.4. – Long-Range PCR 
 
Primer Name  Sequence 
H13 Screen F1 


















































2.4.9 – Sequencing 
 
Primer name Sequence 
Conseq F3 CCCGTCAAAATAGTGAGATGCC 
Conseq F4 CTTCTACTCCTCCCCTAGTCAG 
Conseq F5 GCAGCAAGAAGCCACGGAAG 
Conseq F7 CGTGTTTGCCTGGGCTTTGG 
Conseq F8 CCCCAGCAGGCAGAAGTATG 
Conseq F9 GGTGCCCTGAATGAACTCCA 
Conseq F10 CCGCTTTTCTGGATTCATCG 
Conseq F11 TCTTCTGAGCGGGACTCTGG 
H13 3’ seq F1 CTAGCTTCAGGTGGCAGGGC 
H13 3’ seq F2 GCAGGATGGGACACAGCGAG 
H13 3’ seq F3 GGTAAATGAGTTGAGGCTCAGG 
H13 3’ seq F4 GTGTCTTAGTGGGATGGAAGC 
H13 3’ seq F5 CATCATTGGTGTCAGGGACTC 
H13 3’ seq F6 CAGGTCTGCACAGAGAAACCC 
H13 3’ seq F7 CCACAGTTCTAGGGTTGACTCC 
H13 3’ seq F8 CATGCAGGCAAAACACCAATG 
H13 3’ seq R1 CAGCAAGGTAGATGGAGAGCG 
H13 3’ seq R2 GGGGACCTGGATTCGATCTC 
H13 3’ seq R3 CTCTCATCCTGCTGCTTCCGC 
H13 3’ seq R4 CACTACATCACGCTGGGATTC 
H13 3’ seq R5 TACTGCATCTAGAAGCCTAGGGG 
H13 3’ seq R6 TGGTAGTAGTGGTGGTAGTGTCC 
H13 3’ seq R7 CATGATGTCCAGCTCTGAGGG 
H13 3’ seq R8 CCTCCTTCAGGCGCTGACAG 
H13 3’ seq R9 CCAGGCACTGTGCTGAGGGCA 
H13 5’ seq F1 CCACTGCCTGCCTCAGACCAG 
H13 5’ seq F2 CTCCAGTTCACAGATTCACACC 
H13 5’ seq F3 GAGGCAGGTCTGAGCTGTAGAG 
H13 5’ seq F4 CTCTATGCCTTGTACCCGTCT 
H13 5’ seq F5 GGCTATCACTAATGTAACCCCC 
H13 5’ seq F6 GCAACAGAGACTTCATAGCAGGC 
H13 5’ seq F7 CAGTGCTGCCCATGTCCCCT 
H13 5’ seq F8 CGATGCCTTGGACTAAGTGG 
H13 5’ seq R1 GGAAGCAATCAGCACAGTGCC 
H13 5’ seq R2 GCAACAGAGACTTCATAGCAGGC 
H13 5’ seq R3 GCAACAGAGACTTCATAGCAGGC 
H13 5’ seq R4 GATGTTTCCAGACCTACCTTG 
H13 5’ seq R5 GGCAGAGATGGGACTTGAACC 
H13 5’ seq R6 CCTGAGCAACTGAGTGAAACTC 






2.4.10.4.1. – PCR 











2.4.10.4.2. – Long-Range PCR  















2.4.10.14. – Sequencing  


















SH_UCOE_F4 GGAAAAGACATTGGTCCCCT   






2.4.11.5. – Quantitative Real-time PCR  
Using the Roche Universal Probe library 
 
i3 Sequence 
Forward Primer aaaatgcccgctaaagactg 
Reverse Primer gagggatttgggtgtggtc 









Forward Primer tgggaacatggtcttttgtg 
Reverse Primer gggaagattcccttggattt 
Probe Number 21 
 
x5eGFP Sequence 
Forward Primer tcgtgaccaccctgacctac 
Reverse Primer aagtcgtgctgcttcatgtg 
Probe Number 41 
 
mCherry Sequence 
Forward Primer gaagggcgagatcaagca 
Reverse Primer ttgacctcagcgtcgtagtg 






















Forward Primer acatgccagaaaccatcacc 
Reverse Primer aagaggtagagccccaggag 
Probe Number 60 
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7.3. - Restriction Enzymes 
 







Method used in 
AgeI R0552S 2.4.10.6. 
AseI R0526S 2.4.10.6. 
AsiSI R0630S 2.4.10.6. 
BamHI-HF R3136S 2.4.10.6. 
BglII R0144S 2.4.10.6. 
EcoRI R3101S 2.4.10.6. 
EcoRV R0195S 2.4.10.6. 
FseI R0588S 2.4.10.6. 
HindIII R0104S 2.4.2. 
KpnI R0142S 2.4.10.6. 
MluI R0198S 2.4.10.6. 
NotI R0189S 2.4.10.6. 
PciI R0655S 2.4.10.6. 
PacI R0547S 2.4.10.6. 
SacI R0156S 2.4.10.6. 
SalI R0138S 2.4.10.6. 
SalI-HF R3138S 2.4.10.6. 
SpeI R0133S 2.4.2. 
StuI R0187S 2.4.2. 
XbaI R0145S 2.4.2. 
XmaI R0180S 2.4.10.6.  
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